Search Notes						

Application No.	Applicant(s)
09/843,221	KOSTENUIK ET AL.
Examin r	Art Unit
Christopher Nichols Ph.D.	1647

SEARCHED					
Class	Subclass	Date	Examiner		
·					
	_				
		H			
		-			
-	_				

INTERFERENCE SEARCHED							
Class	Subclass	Date	Examiner				
	L						

SEARCH NOTES (INCLUDING SEARCH STRATEGY)					
	DATE	EXMR			
SEQ ID NO: 2	1/16/2004	CJN			
·					
÷					

## GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 16, 2004, 09:36:27; Search time 42 Seconds

(without alignments)

861.659 Million cell updates/sec

Title: US-09-843-221A-2

Perfect score: 1238

Sequence: 1 MDKTHTCPPCPAPELLGGPS.....MHEALHNHYTQKSLSLSPGK 228

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A Geneseq 19Jun03:\*

1: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:\*

2: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:\*

3: /SIDS1/gcgdata/geneseq/geneseqp-emb1/AA1982.DAT:\*

4: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:\*

5: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:\*

6: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:\*

7: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:\*

8: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:\*

9: /SIDS1/gcgdata/geneseq/geneseqp-emb1/AA1988.DAT:\*

10: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:\*

11: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:\*

12: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:\*

13: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:\*

14: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:\*

15: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:\*

16: /SIDS1/gcgdata/geneseg/genesegp-embl/AA1995.DAT:\*

17: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:\*

18: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:\*

19: /SIDS1/gcgdata/geneseq/geneseqp-emb1/AA1998.DAT:\*

20: /SIDS1/gcgdata/geneseq/geneseqp-emb1/AA1999.DAT:\*

21: /SIDS1/gcgdata/geneseq/geneseqp-emb1/AA2000.DAT:\*

22: /SIDS1/gcgdata/geneseq/geneseqp-emb1/AA2001.DAT:\*

23: /SIDS1/gcgdata/geneseq/geneseqp-emb1/AA2002.DAT:\*

24: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2003.DAT:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed,

# SUMMARIES

		%			501	
Result		Query				
No.	Score		Length	DB	ID	Description
						Description
1	1238	100.0	228	21	AAB16955	Human IgG1 Fc prot
2	1238	100.0	228	21	AAY96529	Human IgG1 Fc chai
3	1238	100.0	228	22	AAB98953	Human IgG1 Fc regi
4	1238	100.0	228	23	AAU81074	Human IgG1 Fc. Ho
5	1238	100.0	228	23	ABB73410	Human immunoglobul
6	1238	100.0	228	23	AAE14310	Human immunoglobul
7	1238	100.0	228	23	AAU73018	Human immunoglobul
8	1238	100.0	228	23	AAG66012	Human immunoglobul
9	1238	100.0	228	23	ABB04279	Human IgG1 Fc doma
10	1238	100.0	228	24	ABJ38267	Human IgG1 Fc prot
11	1238	100.0	243	21	AAB17957	Fc-MMP inhibitor f
12	1238	100.0	243	23	ABB73425	Fc-MMP inhibitor f
13	1238	100.0	247	21	AAB16958	Fc-TMP protein seq
14	1238	100.0	247	23	ABB73411	Fc-TPO mimetic pep
15	1238	100.0	248	21	AAB17951	Fc-TNF-alpha inhib
16	1238	100.0	248	21	AAB17953	Fc-IL-1 antagonist
17	1238	100.0	248	23	ABB73419	Fc-TNF-alpha inhib
18	1238	100.0	248	23	ABB73421	Fc-interleukin 1 (
19	1238	100.0	252	21	AAB17955	Fc-VEGF antagonist
20	1238	100.0	252	23	ABB73423	Fc-VEGF antagonist
21	1238	100.0	253	21	AAB16964	Fc-EMP protein seq
22	1238	100.0	253	23	ABB73415	Fc-EPO mimetic pep
23	1238	100.0	268	21	AAB16959	Fc-TMP-TMP protein
24	1238	100.0	268	23	ABB73412	Fc-TMP-TMP amino a
25	1238	100.0	269	21	AAY96531	Human IgG1 Fc TMP
26	1238	100.0	277	21	AAB16967	Fc-EMP-EMP protein
27	1238	100.0	277	23	ABB73418	Fc-EMP-EMP nucleic
28	1238	100.0	282	23	AAU81169	Echistatin/IgG Fc
29	1238	100.0	374	19	AAW83963	Recombinant human
30	1238	100.0	374	19	AAW49075	Recombinant human
31	1238	100.0	401	22	AAY72922	Human met-Fc (lack
32	1238	100.0	401	22	AAB80904	Human metFcdeltaC-
33	1234	99.7	229	24	ABU07950	Human IgG Fc fragm
34	1234	99.7	235	20	AAY01372	Amino acid sequenc
35	1234	99.7	248	24	ABJ38332	TALL-1 inhibitory
36	1234	99.7	248	24	ABJ38333	TALL-1 inhibitory
37	1234	99.7	248	24	ABJ38334	TALL-1 inhibitory
38	1234	99.7	252	24	ABJ38335	TALL-1 inhibitory
39	1234	99.7	252	24	ABJ38336	TALL-1 inhibitory
40	1234	99.7	252	24	ABJ38337	TALL-1 inhibitory
41	1234	99.7	252	24	ABJ38338	TALL-1 inhibitory
42	1234	99.7	252	24	ABJ38339	TALL-1 inhibitory
43	1234	99.7	252	24	ABJ38340	TALL-1 inhibitory
44	1234	99.7	252	24	ABJ38341	TALL-1 inhibitory
45	1234	99.7	252	24	ABJ38342	TALL-1 inhibitory

```
RESULT 1
AAB16955
ΙD
     AAB16955 standard; Protein; 228 AA.
XX
AC
     AAB16955;
XX
DT
     31-OCT-2000 (first entry)
XX
DE
     Human IgG1 Fc protein sequence SEQ ID NO:2.
XX
     Modified peptide; therapeutic agent; fusion; Fc domain; cancer;
KW
KW
     autoimmune disease; cytostatic; antiasthmatic; thrombolytic; VEGF;
KW
     immunosuppressive; EPO; TPO; CTLA4; mimetic; IL-1; TNF; antagonist;
KW
     MMP; inhibitor; erythropoietin; thrombopoietin; interleukin 1;
KW
     cytotoxic T cell lymphocyte antigen 4; tumour necrosis factor;
KW
     vascular endothelial growth factor; matrix metalloproteinase;
KW
     asthma; thrombosis; pharmaceutical.
XX
OS
     Homo sapiens.
XX
PN
     WO200024782-A2.
XX
PD
     04-MAY-2000.
XX
PF
     25-OCT-1999;
                    99WO-US25044.
XX
PR
     23-OCT-1998;
                    98US-0105371.
PR
     22-OCT-1999;
                    99US-0428082.
XX
PA
     (AMGE-) AMGEN INC.
XX
ΡI
     Feige U, Liu C, Cheetham J, Boone TC;
XX
DR
     WPI; 2000-350702/30.
DR
     N-PSDB; AAA69443.
XX
PT
     Novel composition of matter comprising an Fc domain and
PT
     pharmacologically active peptides, useful for treating cancer and
PT
     autoimmune diseases -
XX
PS
     Claim 7; Page 176-177; 608pp; English.
XX
CC
     The present invention describes composition of matter (I) comprising an
CC
     Fc domain, pharmacologically active peptides, and linkers. Where (I) is:
CC
     (X1)a-F1-(X2)b, where: F1 = an Fc domain; X1 and X2 = are each
CC
     independently selected from -(L1)c-P1, -(L1)c-P1-(L2)d-P2,
CC
     -(L1)c-P1-(L2)d-P2-(L3)e-P^3, or -(L1)c-P1-(L2)d-P2-(L3)e-P3-(L4)f-P4
CC
     where P1, P2, P3, and P4 = are each independently sequences of
CC
     pharmacologically active peptides; L1, L2, L3, and L4 = are each
CC
     independently linkers; and a, b, c, d, e, and f = are each independently
     0 or 1, provided that at least 1 of a and b is 1. The composition can
CC
     have cytostatic, antiasthmatic, thrombolytic and immunosuppressive
CC
CC
     activities. DNAs, vectors and host cells from the present invention can
CC
    be used for producing pharmaceutical compositions. The compositions are
CC
     useful for treating cancer, asthma, thrombosis, or autoimmune diseases.
CC
    The use of an Fc domain (rather than a Fab domain) can provide a longer
CC
    half-life or incorporate functions such as Fc receptor binding, protein
```

```
to AAA69526 and AAB16955 to AAB18003 represent nucleotide and amino acid
CC
CC
    sequences used in the exemplification of the present invention.
XX
SO
    Sequence
              228 AA;
  Query Match
                       100.0%; Score 1238; DB 21; Length 228;
  Best Local Similarity
                       100.0%; Pred. No. 1.2e-91;
 Matches 228; Conservative
                          0; Mismatches
                                             0;
                                                Indels
                                                         0;
                                                            Gaps
                                                                    0;
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Qу
            Db
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
             61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Db
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Οv
            Db
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLD 180
Qу
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
            181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Dh
RESULT 2
AAY96529
    AAY96529 standard; Protein; 228 AA.
XX
AC
    AAY96529;
XX
    04-SEP-2000 (first entry)
DT
XX
DΕ
    Human IgG1 Fc chain.
XX
KW
    Immunoglobulin; IgG1; Fc; thrombopoietin; mimetic; TMP; TPO; platelet;
    megakaryocyte; production; anti-human immunodeficiency virus; anti-HIV;
KW
    anti-anaemic; dermatological; immunosuppressive; anti-inflammatory.
KW
XX
OS
    Homo sapiens.
XX
PN
    WO200024770-A2.
XX
PD
    04-MAY-2000.
XX
PF
    22-OCT-1999;
                 99WO-US24834.
XX
PR
    23-OCT-1998;
                 98US-0105348.
XX
PΑ
    (AMGE-) AMGEN INC.
XX
PΙ
    Liu C, Feige U, Cheetham J;
XX
DR
    WPI; 2000-365108/31.
    N-PSDB; AAA29220.
DR
```

A binding, complement fixation, and possibly placental transfer. AAA69443

CC

```
PT
    Thrombopoietic peptides which activate mpl receptors and increase the
PT
    production of platelets or platelet precursors, useful for treatment of
PT
    diseases which involve thombocytopenia
XX
PS
    Disclosure; Page 76-77; 91pp; English.
XX
CC
    A compound which binds to an mpl receptor comprising a thrombopoietin
CC
    mimetic peptide (TMP) dimer joined by a linker [TMP 1-(L 1) nTMP 2],
CC
    is new. TMP_1 and TMP 2 are amino acid sequences varying from at least
CC
    10 to 14 residues in length comprising X 2-X 1 0, X 2-X 1 1, X 2-X 1 2,
    X_2-X_1_3, X_2-X_1_4, X_1-X_1_0, X_1-X_1_1, X_1-X_1_2, X_1-X_1_3, and
CC
CC
    X_1-X_1_4. X_1=I, A, V, L, S or R; X_2=E, D, K or V; X_3=G or A;
    X_4 = P; X_5 = T \text{ or } S; X_6 = L, I, V, A \text{ or } F; X_7 = R \text{ or } K; X_8 = Q, N,
CC
CC
    or E; X_9 = W, Y or F; X_1_0 = L, I, V, A, F, M, or K; X_1_1 = A, I, V,
    L, F, S, T, K, H, or E; X_1^2 = A, I, V, L, F, G, S, or Q; X_1^3 = R, K,
CC
CC
    T, V, N, Q or G; X_1_4 = A, I, V, L, F, T, R, E, or G; L 1 = linker
CC
    comprising 1 to 20 amino acids; and n = 0 or 1. The compounds bind to and
CC
    activate the c-Mpl receptor which mediates the activity of endogenous
    thrombopoietin. The TMPs are useful for increasing the production of
CC
CC
    platelets or platelet precursors (e.g. megakaryocytes) in a mammal, which
CC
    is useful for treatment of diseases which involve thombocytopenia, e.g.
CC
    aplastic anaemia, immune thrombocytopenia (ITP), human immunodeficiency
CC
    virus associated ITP, and systemic lupus erythematosus.
XX
SO
    Sequence
              228 AA;
 Query Match
                        100.0%; Score 1238; DB 21; Length 228;
 Best Local Similarity 100.0%; Pred. No. 1.2e-91;
 Matches 228; Conservative 0; Mismatches
                                             0; Indels
                                                            0; Gaps
                                                                       0;
Qу
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
             Db
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
             61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Db
Qу
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
             Db
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qy .
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
             Db
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKSLSLSPGK 228
RESULT 3
AAB98953
ID
    AAB98953 standard; Protein; 228 AA.
XX
AC
   AAB98953;
XX
DΤ
    14-AUG-2001 (first entry)
XX
DE
    Human IgG1 Fc region.
```

XX

```
ХX
KW
    Human; IgG1; immunoglobulin; Fc region; Fc fusion protein;
KW
    misfolding; therapy; cancer; osteoarthritis; AIDS; obesity;
KW
    inflammation; transplant rejection.
XX
    Homo sapiens.
OS
XX
PN
    WO200134638-A1.
XX
PD
    17-MAY-2001.
XX
    10-NOV-2000; 2000WO-US30798.
PF
XX
PR
    12-NOV-1999;
                  99US-0165188.
    09-NOV-2000; 2000US-0709704.
PR
XX
PA
    (AMGE-) AMGEN INC.
XX
PΙ
    Treuheit MJ, O'Conner SR, Kosky AA;
XX
DR
    WPI; 2001-335908/35.
    N-PSDB; AAH25762.
DR
XX
PT
    Correcting disulfide bond misfolds in Fc-containing proteins,
PT
    particularly therapeutic Fc-containing fusion proteins or antibodies,
PT
    by treatment with copper halide -
XX
PS
    Claim 30; Fig 5; 59pp; English.
XX
CC
    The present invention describes a process for preparing a
CC
    pharmacologically active compound, involving preparing a compound
    comprising an immunoglobulin Fc domain fused to a protein of interest,
CC
CC
    treating the compound with a copper(II) halide and isolating the treated
CC.
    molecule. This can be used to correct misfolding of Fc domain containing
CC
    proteins, for use in therapeutic agents which may be used in the
CC
    treatment of cancer, inflammation, transplant rejection, AIDS,
CC
    osteoarthritis and obesity. The present sequence is the IgG1 Fc domain.
XX
SO
    Sequence
              228 AA;
 Query Match
                        100.0%; Score 1238; DB 22; Length 228;
 Best Local Similarity
                       100.0%; Pred. No. 1.2e-91;
 Matches 228; Conservative 0; Mismatches
                                             0; Indels
                                                            0;
                                                               Gaps
                                                                       0;
Qу
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
             Db
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Qу
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
             Db
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qy (
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
             Db
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
```

CC

```
RESULT 4
AAU81074
     AAU81074 standard; Protein; 228 AA.
ХХ
AC
     AAU81074;
XX
DT
     09-APR-2002 (first entry)
XX
DE
     Human IqG1 Fc.
XX
KW
     Human; IgG Fc; anticoagulant; thrombolytic; cytostatic;
     antiinflammatory; immunosuppressive; osteopathic; antagonist;
KW
KW
     laminin; saw-scaled viper; echistatin; integrin; selectin; vinculin;
KW
     platelet aggregation; angiogenesis; tumour; inflammation;
     autoimmune disease; rheumatoid arthritis; osteoporosis.
KW
XX
OS
     Homo sapiens.
XX
PN
     WO200181377-A2.
XX
PD
     01-NOV-2001.
XX
PF
     23-APR-2001; 2001WO-US13069.
XX
PR
     21-APR-2000; 2000US-198919P.
     03-MAY-2000; 2000US-201394P.
PR
XX
PA
     (AMGE-) AMGEN INC.
XX
PΙ
     Feige U, Kohno T, Lacey DL, Boone TC:
XX
DR
     WPI; 2002-062025/08.
DR
    N-PSDB; ABK24097.
XX
     Composition comprising integrin or adhesion antagonistic peptide and
PT
PT
     vehicle, useful for treating or preventing platelet aggregation, has a
     longer half-life than free peptide
PT
XX
PS
     Claim 9; Fig 3; 68pp; English.
XX
CC
    The invention relates to a composition comprising an integrin/adhesion
CC
     antagonistic peptide (I) and a vehicle e.g. IgG Fc. The peptides
CC
     are based on laminin or saw-scaled viper echistatin and target integrin,
CC
    selectin or vinculin. Also included are compounds of formula (Ia) and
     their multimers (X^1)_a-F^1-(X^2)_b where;
CC
CC
     F^1 = Fc domain;
CC
    X^1 and X^2 = -(L^1)_C - P^1, (L^1)_C - P^1 - (L^2)_C - P^2,
     (L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3 or
CC
CC
     (L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3-(L^4)_f-P^4;
CC
    P^1-P^4 = same or different (I);
CC
    L^1-L^4 = same or different linkers;
CC
    a-f = 0 or 1, provided at least one of a and b = 1,
```

a nucleic acid that encodes (Ia), an expression vector containing the

```
CC
     nucleic acid, host cells containing the vector, producing a
CC
     pharmaceutically active compound (B) by covalently linking at least one
CC
     Fc domain to at least one amino acid sequence of a selected randomized
CC
     (I) and any of six laminin-related peptides (Ib). The compositions are
     used prophylactically and therapeutically in the same way as (I), e.g. to
CC
     inhibit platelet aggregation or angiogenesis (tumours), or to treat
CC
CC
     inflammation and autoimmune diseases (e.g. rheumatoid arthritis) and many
CC
     different forms of osteoporosis, also for diagnosis. Attaching the
CC
     vehicle (especially Fc domain) to (I) increases the half-life (free (I)
CC
     are normally degraded very quickly in vivo). The present sequence
CC
     is human IgG1 Fc which is used as a vehicle for the antagonists of
CC
     the invention.
XX
SO
     Sequence
               228 AA;
  Query Match
                        100.0%; Score 1238; DB 23; Length 228;
  Best Local Similarity
                        100.0%; Pred. No. 1.2e-91;
  Matches 228; Conservative 0; Mismatches
                                               0; Indels
                                                            0; Gaps
                                                                        0;
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Qу
             1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Db
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
             Db
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
             Db
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Qу
             Db
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
RESULT 5
ABB73410
ID
    ABB73410 standard; Protein; 228 AA.
XX
AC
    ABB73410;
XX
\mathsf{DT}
    05-APR-2002 (first entry)
XX
DE
    Human immunoglobulin G1 Fc (IgG1 Fc) amino acid SEQ ID NO:2.
XX
KW
    Modified peptide; mimetic; Fc domain; fusion; immunoglobulin G; IgG;
KW
    EPO; erythropoietin; TPO; tumour necrosis factor alpha inhibitor;
KW
    TNF-alpha inhibitor; interleukin 1 antagonist; IL-1 antagonist; TMP;
    TPO mimetic peptide; EPO mimetic peptide; EMP; VEGF antagonist;
KW
KW
    MMP inhibitor; antiinflammatory; antitumour; immunosuppressive;
KW
    cytostatic; antirheumatic; antiarthritic; antidiabetic; ophthalmological;
    antianaemic; anorectic; antiinfertility; haemostatic; dermatological;
KW
KW
    neuroprotective; inflammatory disease; autoimmune disease; tumour growth;
KW
    cancer; rheumatoid arthritis; diabetic retinopathy; infertility; obesity;
KW
    sleep disorder; neurological degenerative disease; anaemia;
KW
    thrombocytopaenia; metastatic tumour; systemic lupus erythematosus;
```

```
KW
     Fanconi's syndrome.
XX
OS
     Homo sapiens.
XX
PN
     WO200183525-A2.
XX
PD
     08-NOV-2001.
XX
PF
     02-MAY-2001; 2001WO-US14310.
XX
PR
     03-MAY-2000; 2000US-0563286.
XX
PA
     (AMGE-) AMGEN INC.
XX
     Feige U, Liu C, Cheetham JC, Boone TC, Gudas JM;
PΙ
XX
DR
     WPI; 2002-130313/17.
     N-PSDB; ABL35760.
DR
XX
PT
     Novel vehicle-peptide molecule or its multimers useful for treating
PT
     inflammatory and autoimmune diseases, cancer, rheumatoid arthritis.
PT
     diabetic retinopathy, obesity, sleep disorders and infertility -
XX
PS
     Claim 7; Fig 4; 176pp; English.
XX
CC
     The present invention describes a vehicle-peptide molecule (I) or its
CC
     multimers. (I) can have antiinflammatory, antitumour, immunosuppressive,
CC
     cytostatic, antirheumatic, antiarthritic, antidiabetic, ophthalmological,
     antianaemic, anorectic, antiinfertility, haemostatic, dermatological and
CC
CC
     neuroprotective activities. (I) can be used as a therapeutic or
CC
     prophylactic agent as well as for screening purposes. (I) is useful for
CC
     diagnosing diseases characterised by dysfunction of their associated
CC
     protein of interest, for identifying normal or abnormal proteins of
CC
     interest, as a part of diagnostic kit to detect the presence of their
CC
     proteins of interest in a biological sample. Additionally, (I) is useful
CC
     for treating inflammatory and autoimmune diseases, tumour growth, cancer,
CC
     rheumatoid arthritis, diabetic retinopathy, obesity, sleep disorders,
CC
     infertility, and neurological degenerative diseases. (I), comprising
CC
     EPO-mimetic compounds are useful for treating disorders characterised by
CC
     low red blood cell levels such as anaemia. The TPO-mimetic comprising
CC
     compounds are useful for treating conditions that involve an existing
CC
     megakaryocyte/platelet deficiency or an expected megakaryocyte/platelet
CC
     deficiency, such as thrombocytopaenia, aplastic anaemia, metastatic
CC
     tumour which result in thrombocytopaenia, systemic lupus erythematosus,
CC
     and Fanconi's syndrome. ABB72403 to ABB73426 and ABL35695 to ABL35777
CC
     represent amino acid and nucleic acid sequences used in the
CC
     exemplification of the present invention.
XX
SQ
               228 AA;
     Sequence
  Query Match
                         100.0%; Score 1238; DB 23;
                                                       Length 228;
  Best Local Similarity
                         100.0%; Pred. No. 1.2e-91;
 Matches 228; Conservative
                               0; Mismatches
                                                  0;
                                                      Indels
Qу
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
              Db
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
```

```
Оv
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
             Db
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
         121 \ \mathsf{KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD} \ 180
QУ
             Db
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLD 180
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Qу
             Db
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
RESULT 6
AAE14310
    AAE14310 standard; Protein; 228 AA.
XX
AC
    AAE14310;
XX
DT
    07-MAR-2002 (first entry)
XX
    Human immunoglobulin G (IgG1) Fc.
DE
XX
KW
    Human; calcitonin; CT; CT receptor; Fc domain; therapy; osteoporosis;
KW
    immunoglobulin G; IgG; osteopathic.
XX
OS
    Homo sapiens.
XX
PN
    WO200183526-A2.
XX
PD
    08-NOV-2001.
XX
PF
    03-MAY-2001; 2001WO-US14320.
XX
PR
    03-MAY-2000; 2000US-201511P.
PR
    02-MAY-2001; 2001US-0847712.
XX
PA
    (AMGE-) AMGEN INC.
XX
    Liu C, Marshall WS, Reynolds A;
PΙ
XX
DR
    WPI; 2002-034503/04.
DR
    N-PSDB; AAD23840.
XX
PT
    Compositions comprising Calcitonin receptor modulator domains, useful
PT
    for treating osteoporosis -
XX
PS
    Claim 8; Fig 3; 64pp; English.
XX
CC
    The invention relates to therapeutic agents that modulate the
CC
    activity of calcitonin (CT) receptor. Modulators of CT receptor
    comprise a CT receptor modulating domain and a vehicle such as a
CC
    polymer or an Fc domain, where the vehicle is covalently attached
CC
CC
    to the CT receptor modulating domain. The compositions comprising
    CT receptor modulating domains are used to treat osteoporosis.
CC
CC
    The present sequence is human immunoglobulin G (IqG1) Fc protein
```

```
CC
    used in the invention.
XX
SO
    Sequence
              228 AA:
 Query Match
                       100.0%; Score 1238; DB 23; Length 228;
 Best Local Similarity
                       100.0%; Pred. No. 1.2e-91;
 Matches 228; Conservative 0; Mismatches
                                             0;
                                                 Indels
                                                              Gaps
                                                                     0;
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Qу
             Db
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Qу
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
             Db
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLD 180
Qу
             Db
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKSLSLSPGK 228
             Db
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
RESULT 7
AAU73018
ID
    AAU73018 standard; Protein; 228 AA.
XX
AC
    AAU73018;
XX
DT
    12-MAR-2002 (first entry)
XX
DE
    Human immunoglobulin G (IgG) Fc region.
XX
KW
    Human; parathyroid hormone; PTH; parathyroid hormone-related protein;
    PTHrP; bone resorption inhibitor; osteoprotegrin; OPG; OPG-L antibody;
KW
KW
    calcitonin; bisphosphonate; oestrogen; oestrogen receptor; tibolone;
    osteopenia; hyperthyroidism; hypercalcaemia; tumour metastasis; bone;
KW
KW
    breast cancer; prostate cancer; cachexia; anorexia; osteoporosis;
KW
    Paget's disease; osteomyelitis; osteonecrosis; bone cell death;
KW
    Gaucher's disease; sickle cell anaemia; systemic lupus erythematosus;
KW
    rheumatoid arthritis; periodontal disease; alopecia; fracture repair;
KW
    immunoglobulin G; IgG.
XX
OS
    Homo sapiens.
XX
ΡN
    WO200181415-A2.
XX
PD
    01-NOV-2001.
XX
PF
    27-APR-2001; 2001WO-US13528.
XX
PR
    27-APR-2000; 2000US-200053P.
    28-JUN-2000; 2000US-214860P.
PR
    06-FEB-2001; 2001US-266673P.
PR
PR
    26-APR-2001; 2001US-0843221.
```

```
XX
PΑ
     (AMGE-) AMGEN INC.
XX
PΙ
    Kostenuik P, Liu C, Lacey DL;
XX
    WPI; 2002-066435/09.
DR
    N-PSDB; AAS97392.
DR
XX
    Composition, useful for treating osteopenia, comprises parathyroid
PT
РΤ
    hormone and parathyroid hormone-related protein receptor modulators -
XX
PS
    Claim 6; Figure 3; 107pp; English.
XX
CC
    The invention relates to a composition (I) comprising modulators of
CC
    parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP)
CC
    which comprise a PTH/PTHrP modulating domain and a vehicle. (I)
CC
    comprising PTH agonist optionally with a bone resorption inhibitor, such
    as osteoprotegrin (OPG), OPG-L antibody, calcitonin, bisphosphonates,
CC
CC
    oestrogens, oestrogen receptor modulators and tibolone is useful for
CC
    treating osteopenia. (I) is useful for therapeutic and prophylactic
CC
    purposes. Antagonists of PTH receptor are useful in treating primary and
    secondary hyperthyroidism, hypercalcaemia, tumour metastases,
CC
CC
    particularly breast and prostate cancer, cachexia and anorexia,
CC
    osteopenia, including various forms of osteoporosis, Paget's disease of
    bone, osteomyelitis, osteonecrosis or bone cell death, associated with
CC
CC
    traumatic injury or nontraumatic necrosis associated with Gaucher's
CC
    disease, sickle cell anaemia, systemic lupus erythematosus, rheumatoid
CC
    arthritis, periodontal disease and alopecia. PTH receptor agonists are
CC
    useful as therapeutic agents in conditions including fracture repair
CC
    (including healing of non-union fractures), osteopenia, including various
CC
    forms of osteoporosis. AAU73018-AAU73181 represent parathyroid hormone
CC
    and parathyroid hormone related protein (PTH/PTHrP) modulators and
CC
    related amino acid sequences of the invention.
XX
SO
    Sequence
              228 AA;
 Query Match
                        100.0%; Score 1238; DB 23; Length 228;
 Best Local Similarity
                        100.0%; Pred. No. 1.2e-91;
 Matches 228; Conservative
                            0; Mismatches
                                               0;
                                                 Indels
                                                            0;
                                                               Gaps
                                                                       0;
Qу
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
             Db
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
             Db
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qy
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLD 180
             Db
       121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
             Dh
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
```

```
RESULT 8
AAG66012
ID
     AAG66012 standard; Protein; 228 AA.
XX
AC
     AAG66012;
XX
DT
     27-FEB-2002 (first entry)
XX
DE
     Human immunoglobulin (Ig) G1 Fc region sequence.
XX
     Apo-AI; amphipathic; pharmaceutical; peptide mimic; antilipemic;
KW
     anti-HIV; virucide; immunoglobulin; IgG1.
KW
XX
OS
     Homo sapiens.
XX
PN
     WO200181376-A2.
XX
PD
     01-NOV-2001.
XX
PF
     23-APR-2001; 2001WO-US13068.
XX
PR
     21-APR-2000; 2000US-198920P.
XX
PA
     (AMGE-) AMGEN INC.
XX
PΙ
     Kohno T;
XX
DR
     WPI; 2002-049262/06.
DR
     N-PSDB; AAI67658.
XX
PT
     Recombinant or modified therapeutic agents having Apo-AI amphipathic
PT
     helix peptide activity useful in treatment of hypercholesterolemia and
PT
     viral infections such as herpes simplex virus, human immunodeficiency
PT
     virus
XX
PS
     Claim 8; Fig 3A-B; 49pp; English.
XX
CC
     The invention provides a composition comprising a therapeutic agent that
CC
     has activity similar to Apo-AI amphipathic helix peptide, but with better
     pharmaceutical characteristics attached to a vehicle through the
CC
     peptide's N-terminus or C-terminus having a specified formula. The
CC
CC
     peptide mimic has greater half-life compared to conventional Apo-AI
CC
     amphipathic helix peptide. The compositions are useful for treating
     hypercholesterolemia and viral infection such as HIV, HSV. The present
CC
CC
     sequence represents the human immunoglobulin (Ig) G1 Fc region which acts
CC
    as a vehicle.
XX
SO
    Sequence
               228 AA;
 Query Match
                         100.0%; Score 1238; DB 23;
                                                      Length 228:
 Best Local Similarity
                         100.0%; Pred. No. 1.2e-91;
 Matches 228; Conservative 0; Mismatches
                                                     Indels
                                                               0; Gaps
                                                                           0;
Ov
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
              Db
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
```

```
61 DGVEVHNAKTKPREEOYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKA 120
QУ
             Db
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLD 180
Ov
             121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Db
Qу
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
             Db
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
RESULT 9
ABB04279
ID
    ABB04279 standard; Protein; 228 AA.
XX
AC
    ABB04279;
XX
DT
    13-FEB-2002 (first entry)
XX
DE
    Human IgG1 Fc domain.
XX
KW
    Glucagon antagonist; antidiabetic; anti-hormonal; Fc domain;
KW
    non-insulin dependent diabetes mellitus; human; immunoglobulin G; IqG.
XX
OS
    Homo sapiens.
XX
PN
    WO200183527-A2.
XX
PD
    08-NOV-2001.
XX
PF
    03-MAY-2001; 2001WO-US14321.
XX
PR
    03-MAY-2000; 2000US-201436P.
PR
    02-MAY-2001; 2001US-0847249.
ХX
PA
     (AMGE-) AMGEN INC.
XX
PΙ
    Marshall WS, Stark KL;
XX
DR
    WPI; 2002-017738/02.
    N-PSDB; ABA03672.
DR
XX
PT
    Compositions comprising glucagon antagonist domains, useful for
PT
    treating diabetes mellitus -
XX
PS
    Claim 8; Fig 2; 54pp; English.
XX
CC
    The invention relates to compositions comprising a glucagon antagonist
CC
    domain and a vehicle, such as a polymer (e.g. PEG or dextran) or,
    preferably, an Fc domain. The vehicle is covalently attached to the
CC
CC
    glucagon antagonist domain. The compositions are administered to
CC
    treat non-insulin dependent diabetes mellitus. The present sequence
CC
    is the human IgG Fc domain, which may be used as the vehicle
CC
    in the compositions of the invention.
XX
```

```
Ouery Match
                       100.0%; Score 1238; DB 23; Length 228;
 Best Local Similarity
                       100.0%; Pred. No. 1.2e-91;
 Matches 228; Conservative 0; Mismatches
                                            0; Indels
                                                                    0:
Qу
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
            Db
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
QУ
            61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Db
Qу
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLD 180
            Db
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLD 180
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Οv
            Db
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
RESULT 10
ABJ38267
ID
    ABJ38267 standard; Protein; 228 AA.
XX
AC
    ABJ38267;
XX
DT
    12-JUN-2003 (first entry)
XX
DE
    Human IgG1 Fc protein SEQ ID No 2.
XX
KW
    TALL-1-binding protein; TALL-1; B-cell-mediated autoimmune disease;
KW
    systemic lupus erythematosus; B-cell-mediated cancer; lymphoma;
    inflammation; rheumatoid arthritis; acute pancreatitis; atherosclerosis;
KW
KW
    Alzheimer's disease; asthma; cachexia; cirrhosis; diabetes; osteoporosis;
KW
    glomerulonephritis; Hashimoto's thyroiditis; ischaemic injury; psoriasis;
    multiple myeloma; multiple sclerosis; Parkinson's disease; vasculitis;
KW
KW
    gene therapy; human IgG1Fc; human.
ХX
OS
    Homo sapiens.
XX
PN
    WO200292620-A2.
XX
PD
    21-NOV-2002.
XX
PF
    13-MAY-2002; 2002WO-US15273.
XX
PR
    11-MAY-2001; 2001US-290196P.
XX
PΑ
    (AMGE-) AMGEN INC.
XX
PΙ
    Min H, Hsu H;
XX
DR
    WPI; 2003-156719/15.
```

SQ

DR

N-PSDB; ABT33856.

Sequence

228 AA;

```
XX
PΤ
    New TALL-1-binding polypeptide, useful for modulating the activity of
PT
    TALL-1 and in treating, preventing or diagnosing a B-cell-mediated
PT
    autoimmune diseases, cancers or lymphomas -
XX
PS
    Claim 36; Fig 3; 236pp; English.
XX
CC
    The invention relates to a novel TALL-1-binding polypeptide comprising a
CC
    defined sequence in the specification. The composition is useful in
CC
    modulating the activity of TALL-1, and in treating, preventing,
CC
    ameliorating, diagnosing or prognosing a B-cell-mediated autoimmune
CC
    disease (e.g. systemic lupus erythematosus) or B-cell-mediated cancer or
CC
    lymphoma. The composition may also be used in treating inflammations
CC
     (e.g. rheumatoid arthritis), acute pancreatitis, Alzheimer's disease,
    asthma, atherosclerosis, cachexia, cirrhosis, diabetes,
CC
    glomerulonephritis, Hashimoto's thyroiditis, ischaemic injury, multiple
CC
    myeloma, multiple sclerosis, osteoporosis, Parkinson's disease, psoriasis
CC
CC
    and vasculitis. Disorders may be treated with the novel composition using
CC
    gene therapy. This sequence represents a human IqG1Fc protein relating to
CC
    the TALL-1 sequence of the invention.
XX
SO
    Sequence
              228 AA;
 Query Match
                        100.0%; Score 1238; DB 24; Length 228;
 Best Local Similarity
                       100.0%; Pred. No. 1.2e-91;
 Matches 228; Conservative
                             0; Mismatches
                                              0; Indels
                                                           0;
                                                               Gaps
                                                                      0;
Qу
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
             Db
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
QУ
             61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Db
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Оy
             Db
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKSLSLSPGK 228
             Db
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
RESULT 11
    AAB17957 standard; Protein; 243 AA.
XX
AC
    AAB17957;
XX
DT
    31-OCT-2000 (first entry)
XX
    Fc-MMP inhibitor fusion protein sequence SEQ ID NO:1068.
DE
XX
KW
    Modified peptide; therapeutic agent; fusion; Fc domain; cancer;
    autoimmune disease; cytostatic; antiasthmatic; thrombolytic; VEGF;
KW
    immunosuppressive; EPO; TPO; CTLA4; mimetic; IL-1; TNF; antagonist;
KW
```

```
KW
     MMP; inhibitor; erythropoietin; thrombopoietin; interleukin 1;
KW
     cytotoxic T cell lymphocyte antigen 4; tumour necrosis factor;
KW
     vascular endothelial growth factor; matrix metalloproteinase;
KW
     asthma; thrombosis; pharmaceutical.
XX
OS
     Synthetic.
XX
PN
     WO200024782-A2.
XX
PD
     04-MAY-2000.
XX
PF
     25-OCT-1999;
                   99WO-US25044.
XX
PR
     23-OCT-1998;
                    98US-0105371.
PR
     22-OCT-1999;
                   99US-0428082.
XX
PA
     (AMGE-) AMGEN INC.
XX
PΙ
     Feige U, Liu C, Cheetham J, Boone TC;
XX
DR
     WPI; 2000-350702/30.
DR
     N-PSDB; AAA69507.
XX
PΤ
     Novel composition of matter comprising an Fc domain and
PT
     pharmacologically active peptides, useful for treating cancer and
PT
     autoimmune diseases -
XX
PS
     Example 7; Page 585-586; 608pp; English.
XX
CC
     The present invention describes composition of matter (I) comprising an
CC
     Fc domain, pharmacologically active peptides, and linkers. Where (I) is:
CC
     (X1)a-F1-(X2)b, where: F1 = an Fc domain; X1 and X2 = are each
CC
     independently selected from -(L1)c-P1, -(L1)c-P1-(L2)d-P2,
CC
     -(L1)c-P1-(L2)d-P2-(L3)e-P^3, or -(L1)c-P1-(L2)d-P2-(L3)e-P3-(L4)f-P4
CC
     where P1, P2, P3, and P4 = are each independently sequences of
CC
     pharmacologically active peptides; L1, L2, L3, and L4 = are each
CC
     independently linkers; and a, b, c, d, e, and f = are each independently
CC
     0 or 1, provided that at least 1 of a and b is 1. The composition can
CC
     have cytostatic, antiasthmatic, thrombolytic and immunosuppressive
CC
     activities. DNAs, vectors and host cells from the present invention can
CC
     be used for producing pharmaceutical compositions. The compositions are
CC
     useful for treating cancer, asthma, thrombosis, or autoimmune diseases.
CC
     The use of an Fc domain (rather than a Fab domain) can provide a longer
CC
     half-life or incorporate functions such as Fc receptor binding, protein
CC
     A binding, complement fixation, and possibly placental transfer. AAA69443
CC
     to AAA69526 and AAB16955 to AAB18003 represent nucleotide and amino acid
CC
     sequences used in the exemplification of the present invention.
XX
SQ
    Sequence
               243 AA;
                         100.0%; Score 1238; DB 21;
 Query Match
                                                       Length 243;
                         100.0%; Pred. No. 1.3e-91;
 Best Local Similarity
 Matches 228; Conservative
                               0; Mismatches
                                                  0;
                                                      Indels
                                                                0; Gaps
                                                                            0;
Qу
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
              Db
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
```

```
Οv
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKA 120
             61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Db
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
             Db
         121 KGQPREPQVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLD 180
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
QУ
             Db
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
RESULT 12
ABB73425
ID
    ABB73425 standard; Protein; 243 AA.
XX
AC
    ABB73425;
XX
DT
    05-APR-2002 (first entry)
XX
DE
    Fc-MMP inhibitor fusion nucleic acid SEQ ID NO:1067.
XX
    Modified peptide; mimetic; Fc domain; fusion; immunoglobulin G; IgG;
KW
KW
    EPO; erythropoietin; TPO; tumour necrosis factor alpha inhibitor;
    TNF-alpha inhibitor; interleukin 1 antagonist; IL-1 antagonist; TMP;
KW
KW
    TPO mimetic peptide; EPO mimetic peptide; EMP; VEGF antagonist;
KW
    MMP inhibitor; antiinflammatory; antitumour; immunosuppressive;
    cytostatic; antirheumatic; antiarthritic; antidiabetic; ophthalmological;
KW
KW
    antianaemic; anorectic; antiinfertility; haemostatic; dermatological;
KW
    neuroprotective; inflammatory disease; autoimmune disease; tumour growth;
KW
    cancer; rheumatoid arthritis; diabetic retinopathy; infertility; obesity;
KW
    sleep disorder; neurological degenerative disease; anaemia;
KW
    thrombocytopaenia; metastatic tumour; systemic lupus erythematosus;
KW
    Fanconi's syndrome.
XX
OS
    Homo sapiens.
OS
    Synthetic.
XX
PN
    WO200183525-A2.
XX
PD
    08-NOV-2001.
XX
    02-MAY-2001; 2001WO-US14310.
PF
XX
PR
    03-MAY-2000; 2000US-0563286.
XX
PA
     (AMGE-) AMGEN INC.
XX
PΙ
    Feige U, Liu C, Cheetham JC, Boone TC, Gudas JM;
XX
DR
    WPI; 2002-130313/17.
DR
    N-PSDB; ABL35775.
XX
PT
    Novel vehicle-peptide molecule or its multimers useful for treating
PT
    inflammatory and autoimmune diseases, cancer, rheumatoid arthritis,
```

```
PT
    diabetic retinopathy, obesity, sleep disorders and infertility -
XX
PS
    Example 7; Fig 25A-B; 176pp; English.
XX
CC
    The present invention describes a vehicle-peptide molecule (I) or its
CC
    multimers. (I) can have antiinflammatory, antitumour, immunosuppressive,
CC
    cytostatic, antirheumatic, antiarthritic, antidiabetic, ophthalmological,
CC
    antianaemic, anorectic, antiinfertility, haemostatic, dermatological and
CC
    neuroprotective activities. (I) can be used as a therapeutic or
CC
    prophylactic agent as well as for screening purposes. (I) is useful for
CC
    diagnosing diseases characterised by dysfunction of their associated
CC
    protein of interest, for identifying normal or abnormal proteins of
CC
    interest, as a part of diagnostic kit to detect the presence of their
CC
    proteins of interest in a biological sample. Additionally, (I) is useful
CC
    for treating inflammatory and autoimmune diseases, tumour growth, cancer,
CC
    rheumatoid arthritis, diabetic retinopathy, obesity, sleep disorders,
CC
     infertility, and neurological degenerative diseases. (I), comprising
CC
    EPO-mimetic compounds are useful for treating disorders characterised by
    low red blood cell levels such as anaemia. The TPO-mimetic comprising
CC
    compounds are useful for treating conditions that involve an existing
CC
CC
    megakaryocyte/platelet deficiency or an expected megakaryocyte/platelet
CC
    deficiency, such as thrombocytopaenia, aplastic anaemia, metastatic
    tumour which result in thrombocytopaenia, systemic lupus erythematosus,
CC
CC
    and Fanconi's syndrome. ABB72403 to ABB73426 and ABL35695 to ABL35777
CC
    represent amino acid and nucleic acid sequences used in the
CC
    exemplification of the present invention.
ХX
SQ
    Sequence
              243 AA;
 Query Match
                        100.0%; Score 1238; DB 23; Length 243;
  Best Local Similarity 100.0%; Pred. No. 1.3e-91;
 Matches 228; Conservative 0; Mismatches
                                              0; Indels
                                                            0; Gaps
                                                                       0;
Qу
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
             1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Db
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
QУ
             Db
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLD 180
             Db
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLD 180
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Qу
             Db
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
RESULT 13
AAB16958
ID
    AAB16958 standard; Protein; 247 AA.
XX
AC
    AAB16958;
XX
DT
    31-OCT-2000 (first entry)
```

```
XX
DE
     Fc-TMP protein sequence SEO ID NO:6.
XX
KW
     Modified peptide; therapeutic agent; fusion; Fc domain; cancer;
     autoimmune disease; cytostatic; antiasthmatic; thrombolytic; VEGF;
KW
KW
     immunosuppressive; EPO; TPO; CTLA4; mimetic; IL-1; TNF; antagonist;
KW
     MMP; inhibitor; erythropoietin; thrombopoietin; interleukin 1;
     cytotoxic T cell lymphocyte antigen 4; tumour necrosis factor;
KW
     vascular endothelial growth factor; matrix metalloproteinase;
KW
KW
     asthma; thrombosis; pharmaceutical.
XX
OS
     Homo sapiens.
OS
     Synthetic.
XX
PN
     WO200024782-A2.
XX
PD
     04-MAY-2000.
XX
PF
     25-OCT-1999;
                    99WO-US25044.
XX
PR
     23-OCT-1998;
                    98US-0105371.
PR
     22-OCT-1999;
                    99US-0428082.
XX
PΑ
     (AMGE-) AMGEN INC.
XX
PΙ
     Feige U, Liu C, Cheetham J, Boone TC;
XX
DR
     WPI; 2000-350702/30.
DR
     N-PSDB; AAA69444.
XX
PT
     Novel composition of matter comprising an Fc domain and
PT
     pharmacologically active peptides, useful for treating cancer and
PT
     autoimmune diseases -
XX
PS
     Claim 21; Page 179-180; 608pp; English.
XX
CC
     The present invention describes composition of matter (I) comprising an
CC
     Fc domain, pharmacologically active peptides, and linkers. Where (I) is:
CC
     (X1)a-F1-(X2)b, where: F1 = an Fc domain; X1 and X2 = are each
CC
     independently selected from -(L1)c-P1, -(L1)c-P1-(L2)d-P2,
CC
     -(L1)c-P1-(L2)d-P2-(L3)e-P^3, or -(L1)c-P1-(L2)d-P2-(L3)e-P3-(L4)f-P4
CC
     where P1, P2, P3, and P4 = are each independently sequences of
CC
     pharmacologically active peptides; L1, L2, L3, and L4 = are each
CC
     independently linkers; and a, b, c, d, e, and f = are each independently
CC
     0 or 1, provided that at least 1 of a and b is 1. The composition can
CC
     have cytostatic, antiasthmatic, thrombolytic and immunosuppressive
CC
     activities. DNAs, vectors and host cells from the present invention can
CC
     be used for producing pharmaceutical compositions. The compositions are
CC
     useful for treating cancer, asthma, thrombosis, or autoimmune diseases.
CC
     The use of an Fc domain (rather than a Fab domain) can provide a longer
CC
     half-life or incorporate functions such as Fc receptor binding, protein
CC
     A binding, complement fixation, and possibly placental transfer. AAA69443
CC
     to AAA69526 and AAB16955 to AAB18003 represent nucleotide and amino acid
CC
     sequences used in the exemplification of the present invention.
XX
SO
     Sequence
                247 AA;
```

```
Query Match
                       100.0%; Score 1238; DB 21; Length 247;
                       100.0%; Pred. No. 1.3e-91;
  Best Local Similarity
  Matches 228; Conservative 0; Mismatches
                                             0: Indels
                                                                     0:
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Ov
             Db
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
             61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Db
Qу
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
             121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Db
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKSLSLSPGK 228
QУ
             Db
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
RESULT 14
ABB73411
TD
    ABB73411 standard; Protein; 247 AA.
XX
AC
    ABB73411;
XX
DT
    05-APR-2002 (first entry)
XX
DE
    Fc-TPO mimetic peptide (Fc-TMP) amino acid SEO ID NO:6.
XX
KW
    Modified peptide; mimetic; Fc domain; fusion; immunoglobulin G; IgG;
KW
    EPO; erythropoietin; TPO; tumour necrosis factor alpha inhibitor;
KW
    TNF-alpha inhibitor; interleukin 1 antagonist; IL-1 antagonist; TMP;
    TPO mimetic peptide; EPO mimetic peptide; EMP; VEGF antagonist;
KW
KW
    MMP inhibitor; antiinflammatory; antitumour; immunosuppressive;
KW
    cytostatic; antirheumatic; antiarthritic; antidiabetic; ophthalmological;
KW
    antianaemic; anorectic; antiinfertility; haemostatic; dermatological;
KW
    neuroprotective; inflammatory disease; autoimmune disease; tumour growth;
KW
    cancer; rheumatoid arthritis; diabetic retinopathy; infertility; obesity;
KW
    sleep disorder; neurological degenerative disease; anaemia;
KW
    thrombocytopaenia; metastatic tumour; systemic lupus erythematosus;
KW
    Fanconi's syndrome.
XX
OS
    Homo sapiens.
OS
    Synthetic.
XX
PN
    WO200183525-A2.
XX
PD
    08-NOV-2001.
XX
PF
    02-MAY-2001; 2001WO-US14310.
XX
PR
    03-MAY-2000; 2000US-0563286.
XX
PΑ
    (AMGE-) AMGEN INC.
XX
```

```
XX
DR
     WPI; 2002-130313/17.
DR
     N-PSDB; ABL35761.
XX
PT
     Novel vehicle-peptide molecule or its multimers useful for treating
PT
     inflammatory and autoimmune diseases, cancer, rheumatoid arthritis,
PT
     diabetic retinopathy, obesity, sleep disorders and infertility -
XX
PS
     Claim 21; Fig 7; 176pp; English.
XX
CC
     The present invention describes a vehicle-peptide molecule (I) or its
CC
     multimers. (I) can have antiinflammatory, antitumour, immunosuppressive,
CC
     cytostatic, antirheumatic, antiarthritic, antidiabetic, ophthalmological,
CC
     antianaemic, anorectic, antiinfertility, haemostatic, dermatological and
CC
     neuroprotective activities. (I) can be used as a therapeutic or
CC
     prophylactic agent as well as for screening purposes. (I) is useful for
CC
     diagnosing diseases characterised by dysfunction of their associated
CC
    protein of interest, for identifying normal or abnormal proteins of
CC
     interest, as a part of diagnostic kit to detect the presence of their
CC
    proteins of interest in a biological sample. Additionally, (I) is useful
CC
     for treating inflammatory and autoimmune diseases, tumour growth, cancer,
     rheumatoid arthritis, diabetic retinopathy, obesity, sleep disorders,
CC
CC
     infertility, and neurological degenerative diseases. (I), comprising
     EPO-mimetic compounds are useful for treating disorders characterised by
CC
CC
     low red blood cell levels such as anaemia. The TPO-mimetic comprising
CC
     compounds are useful for treating conditions that involve an existing
CC
    megakaryocyte/platelet deficiency or an expected megakaryocyte/platelet
CC
    deficiency, such as thrombocytopaenia, aplastic anaemia, metastatic
CC
     tumour which result in thrombocytopaenia, systemic lupus erythematosus,
CC
    and Fanconi's syndrome. ABB72403 to ABB73426 and ABL35695 to ABL35777
CC
    represent amino acid and nucleic acid sequences used in the
    exemplification of the present invention.
CC
XX
SQ
    Sequence
               247 AA;
 Ouery Match
                        100.0%; Score 1238; DB 23; Length 247;
 Best Local Similarity
                        100.0%; Pred. No. 1.3e-91;
 Matches 228; Conservative
                             0; Mismatches
                                               0;
                                                  Indels
                                                            0; Gaps
                                                                       0;
Qу
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
             Db
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
             Db
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
             Db
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Ov
             181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Db
```

Feige U, Liu C, Cheetham JC, Boone TC, Gudas JM:

PΙ

```
RESULT 15
AAB17951
ID
     AAB17951 standard; Protein; 248 AA.
XX
AC
     AAB17951;
XX
DT
     31-OCT-2000 (first entry)
XX
     Fc-TNF-alpha inhibitor fusion protein sequence SEQ ID NO:1056.
DE
XX
KW
     Modified peptide; therapeutic agent; fusion; Fc domain; cancer;
KW
     autoimmune disease; cytostatic; antiasthmatic; thrombolytic; VEGF;
KW
     immunosuppressive; EPO; TPO; CTLA4; mimetic; IL-1; TNF; antagonist;
KW
     MMP; inhibitor; erythropoietin; thrombopoietin; interleukin 1;
KW
     cytotoxic T cell lymphocyte antigen 4; tumour necrosis factor;
KW
     vascular endothelial growth factor; matrix metalloproteinase;
KW
     asthma; thrombosis; pharmaceutical.
XX
OS
     Synthetic.
XX
PN
     WO200024782-A2.
XX
PD
     04-MAY-2000.
XX
PF
     25-OCT-1999;
                    99WO-US25044.
XX
PR
     23-OCT-1998;
                    98US-0105371.
     22-OCT-1999;
PR
                    99US-0428082.
XX
PΑ
     (AMGE-) AMGEN INC.
XX
PΙ
     Feige U, Liu C, Cheetham J, Boone TC:
XX
DR
     WPI; 2000-350702/30.
DR
     N-PSDB; AAA69501.
XX
PT
     Novel composition of matter comprising an Fc domain and
PT
     pharmacologically active peptides, useful for treating cancer and
PT
     autoimmune diseases -
XX
PS
     Example 4; Page 568-569; 608pp; English.
XX
     The present invention describes composition of matter (I) comprising an
CC
CC
     Fc domain, pharmacologically active peptides, and linkers. Where (I) is:
CC
     (X1)a-F1-(X2)b, where: F1 = an Fc domain; X1 and X2 = are each
     independently selected from -(L1)c-P1, -(L1)c-P1-(L2)d-P2,
CC
CC
     -(L1)c-P1-(L2)d-P2-(L3)e-P^3, or -(L1)c-P1-(L2)d-P2-(L3)e-P3-(L4)f-P4
CC
    where P1, P2, P3, and P4 = are each independently sequences of
CC
    pharmacologically active peptides; L1, L2, L3, and L4 = are each
CC
     independently linkers; and a, b, c, d, e, and f = are each independently
CC
     0 or 1, provided that at least 1 of a and b is 1. The composition can
CC
    have cytostatic, antiasthmatic, thrombolytic and immunosuppressive
CC
    activities. DNAs, vectors and host cells from the present invention can
CC
    be used for producing pharmaceutical compositions. The compositions are
CC
    useful for treating cancer, asthma, thrombosis, or autoimmune diseases.
CC
    The use of an Fc domain (rather than a Fab domain) can provide a longer
CC
    half-life or incorporate functions such as Fc receptor binding, protein
```

CC CC XX	A binding, complement fixation, and possibly placental transfer. AAA69443 to AAA69526 and AAB16955 to AAB18003 represent nucleotide and amino acid sequences used in the exemplification of the present invention.							
SQ	Sequence	248 AA;						
Ве	Query Match 100.0%; Score 1238; DB 21; Length 248; Best Local Similarity 100.0%; Pred. No. 1.3e-91;							
Ма	tches 22	8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;						
Qy	1	MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60						
Db	1	MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60						
Qу	61	DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120						
Db	61	DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120						
Qу	121	KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180						
Db	121							
Qу	181	SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228						
Db	181							

Search completed: January 16, 2004, 09:37:55

Job time : 43 secs

## GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 16, 2004, 09:36:27; Search time 21 Seconds

(without alignments)

459.375 Million cell updates/sec

Title: US-09-843-221A-2

Perfect score: 1238

Sequence: 1 MDKTHTCPPCPAPELLGGPS.....MHEALHNHYTQKSLSLSPGK 228

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 328717 seqs, 42310858 residues

Total number of hits satisfying chosen parameters: 328717

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued\_Patents AA:\*

1: /cgn2\_6/ptodata/1/iaa/5A\_COMB.pep:\*
2: /cgn2\_6/ptodata/1/iaa/5B\_COMB.pep:\*
3: /cgn2\_6/ptodata/1/iaa/6A\_COMB.pep:\*
4: /cgn2\_6/ptodata/1/iaa/6B\_COMB.pep:\*

5: /cgn2\_6/ptodata/1/iaa/PCTUS\_COMB.pep:\*
6: /cgn2\_6/ptodata/1/iaa/backfiles1.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

### SUMMARIES

		ક				
Result		Query				
No.	Score	Match	Length	DB	ID	Description
1	1234	99.7	229	4	US-09-122-144-2	Sequence 2, Appli
2	1234	99.7	347	1	US-07-940-861-43	Sequence 43, Appl
3	1234	99.7	347	1	US-08-459-512-43	Sequence 43, Appl
4	1234	99.7	347	2	US-08-459-657-43	Sequence 43, Appl
5	1234	99.7	347	2	US-08-460-132-43	Sequence 43, Appl
6	1234	99.7	347	3	US-08-466-465 <b>-</b> 8	Sequence 8, Appli
7	1234	99.7	347	5	PCT-US92-02050-43	Sequence 43, Appl
8	1234	99.7	446	4	US-09-157-452B-12	Sequence 12, Appl
9	1234	99.7	482	4	US-09-189-129-2	Sequence 2, Appli
10	1233	99.6	232	2	US-08-595-043A-50	Sequence 50, Appl
11	1233	99.6	235	3	US-09-131-247-6	Sequence 6, Appli

```
12
     1233
           99.6
                  331 3 US-09-178-869-2
                                                  Sequence 2, Appli
13
     1233
           99.6
                  331 4 US-09-761-413-2
                                                  Sequence 2, Appli
14
     1233 99.6
                  360 4 US-09-180-100-11
                                                  Sequence 11, Appl
                  371 1 US-08-236-311-7
15
     1233 99.6
                                                  Sequence 7, Appli
                 371 3 US-08-457-918-7
16
     1233 99.6
                                                  Sequence 7, Appli
                 376 4 US-09-180-100-22
17
     1233 99.6
                                                  Sequence 22, Appl
                  387 1 US-08-470-299-4
18
     1233 99.6
                                                  Sequence 4, Appli
                  388 3 US-09-131-247-16
     1233 99.6
19
                                                  Sequence 16, Appl
          99.6
                  389 3 US-09-131-247-14
20
     1233
                                                  Sequence 14, Appl
21
     1233 99.6
                  396 2 US-08-784-512-3
                                                  Sequence 3, Appli
22
     1233 99.6
                 396 3 US-09-176-228-3
                                                  Sequence 3, Appli
23
     1233 99.6 424 4 US-09-333-593A-8
                                                  Sequence 8, Appli
     1233 99.6 424 5 PCT-US95-03866-12
24
                                                  Sequence 12, Appl
                424 5 PCT-US95-03866-14
25
     1233 99.6
                                                  Sequence 14, Appl
     1233 99.6
                437 5 PCT-US96-10043-11
26
                                                  Sequence 11, Appl
27
     1233 99.6 442 5 PCT-US96-10043-9
                                                  Sequence 9, Appli
28
     1233 99.6 446 3 US-08-397-411-7
                                                  Sequence 7, Appli
     1233 99.6 449 1 US-08-458-516-13
29
                                                  Sequence 13, Appl
     1233 99.6 459 1 US-08-157-101A-7
30
                                                  Sequence 7, Appli
     1233 99.6 475 4 US-09-740-002-27
31
                                                  Sequence 27, Appl
                476 2 US-08-378-939-10
     1233 99.6
32
                                                  Sequence 10, Appl
          99.6
                476 3 US-08-487-550-4
33
     1233
                                                  Sequence 4, Appli
34
     1233 99.6 476 3 US-08-487-550-12
                                                  Sequence 12, Appl
35
     1233 99.6 476 4 US-09-526-098-4
                                                  Sequence 4, Appli
36
     1233 99.6 476 4 US-09-526-098-12
                                                  Sequence 12, Appl
     1233 99.6 478 3 US-08-487-550-8
37
                                                  Sequence 8, Appli
     1233 99.6
                478 4 US-09-526-098-8
38
                                                  Sequence 8, Appli
     1233 99.6
                488 3 US-08-776-511-2
39
                                                  Sequence 2, Appli
40
     1233 99.6
                592 4 US-09-313-942-8
                                                  Sequence 8, Appli
41
     1233 99.6 680 3 US-08-227-496C-15
                                                  Sequence 15, Appl
42
     1233 99.6 691 4 US-09-313-942-20
                                                  Sequence 20, Appl
     1233 99.6 694 4 US-09-313-942-22
43
                                                  Sequence 22, Appl
                 859 4 US-09-313-942-7
44
     1233 99.6
                                                  Sequence 7, Appli
                 951 4 US-09-313-942-9
45
     1233 99.6
                                                  Sequence 9, Appli
```

## ALIGNMENTS

```
RESULT 1
US-09-122-144-2
; Sequence 2, Application US/09122144A
; Patent No. 6485726
; GENERAL INFORMATION:
  APPLICANT: Blumberg, Richard S.
; APPLICANT: Simister, Neil E.
  APPLICANT: Lencer, Wayne I.
  TITLE OF INVENTION: RECEPTOR SPECIFIC TRANSPPITHELIAL TRANSPORT OF
THERAPEUTICS
; FILE REFERENCE: S1383/7003
  CURRENT APPLICATION NUMBER: US/09/122,144A
  CURRENT FILING DATE: 1998-07-24
  EARLIER APPLICATION NUMBER: US 09/122,144
  EARLIER FILING DATE: 1998-07-24
  NUMBER OF SEQ ID NOS: 22
; SEQ ID NO 2
   LENGTH: 229
```

```
TYPE: PRT
   ORGANISM: Homo sapiens
US-09-122-144-2
 Query Match
                       99.7%; Score 1234; DB 4; Length 229;
 Best Local Similarity
                      99.6%; Pred. No. 3.5e-117;
 Matches 227; Conservative
                            1; Mismatches
                                            0;
                                               Indels
                                                         0; Gaps
Qу
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
            Db
          2 VDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 61
Qу
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
            Db
         62 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKA 121
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
            Db
        122 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 181
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Qу
            Db
        182 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 229
RESULT 2
US-07-940-861-43
; Sequence 43, Application US/07940861
; Patent No. 5547853
  GENERAL INFORMATION:
    APPLICANT: BIOGEN, INC.
    APPLICANT: WALLNER, Barbara P.
    APPLICANT: MILLER, Glenn T.
    APPLICANT: ROSA, Margaret D.
    TITLE OF INVENTION: CD2-BINDING DOMAIN OF LYMPHOCYTE
    TITLE OF INVENTION: FUNCTION ASSOCIATED ANTIGEN 3
    NUMBER OF SEQUENCES: 43
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Fish & Neave
      STREET: 875 Third Avenue
      CITY: New York
      STATE: New York
      COUNTRY: U.S.A.
      ZIP: 10022-6250
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.25
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/07/940,861
      FILING DATE: 21-OCT-1992
      CLASSIFICATION: 514
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: PCT/US92/02050
      FILING DATE: 12-MAR-1992
    PRIOR APPLICATION DATA:
```

```
FILING DATE: 12-MAR-1991
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US 07/770,967
      FILING DATE: 07-OCT-1991
    ATTORNEY/AGENT INFORMATION:
      NAME: HALEY, James F., Jr.
      REGISTRATION NUMBER: 27,794
      REFERENCE/DOCKET NUMBER: B151CIP2
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (212)715-0600
      TELEFAX: (212)715-0673
      TELEX: 14-8367
  INFORMATION FOR SEQ ID NO: 43:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 347 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-07-940-861-43
                      99.7%; Score 1234; DB 1; Length 347;
 Query Match
 Best Local Similarity
                      99.6%; Pred. No. 6.3e-117;
 Matches 227; Conservative
                            1; Mismatches
                                            0; Indels
                                                         0;
                                                            Gaps
                                                                   0:
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Qу
            120 VDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 179
Db
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
            Db
        180 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 239
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
            240 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 299
Db
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Qу
            Db
        300 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 347
RESULT 3
US-08-459-512-43
; Sequence 43, Application US/08459512
; Patent No. 5728677
  GENERAL INFORMATION:
    APPLICANT: BIOGEN, INC.
    APPLICANT: WALLNER, Barbara P.
    APPLICANT: MILLER, Glenn T.
    APPLICANT: ROSA, Margaret D.
    TITLE OF INVENTION: CD2-BINDING DOMAIN OF LYMPHOCYTE
    TITLE OF INVENTION: FUNCTION ASSOCIATED ANTIGEN 3
    NUMBER OF SEQUENCES: 43
    CORRESPONDENCE ADDRESS:
     ADDRESSEE: Fish & Neave
     STREET: 875 Third Avenue
```

APPLICATION NUMBER: US 07/667,971

```
CITY: New York
      STATE: New York
      COUNTRY: U.S.A.
      ZIP: 10022-6250
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.25
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/459,512
      FILING DATE: 02-JUN-1995
      CLASSIFICATION: 514
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: PCT/US92/02050
      FILING DATE: 12-MAR-1992
      APPLICATION NUMBER: US 07/667,971
      FILING DATE: 12-MAR-1991
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US 07/770,967
      FILING DATE: 07-OCT-1991
    ATTORNEY/AGENT INFORMATION:
      NAME: HALEY, James F., Jr.
      REGISTRATION NUMBER: 27,794
      REFERENCE/DOCKET NUMBER: B151CIP2
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (212)715-0600
      TELEFAX: (212)715-0673
      TELEX: 14-8367
  INFORMATION FOR SEO ID NO: 43:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 347 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-459-512-43
 Query Match
                      99.7%; Score 1234; DB 1; Length 347;
 Best Local Similarity
                      99.6%; Pred. No. 6.3e-117;
 Matches 227; Conservative
                          1; Mismatches
                                            0;
                                               Indels
                                                        0; Gaps
                                                                   0;
Qу
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
            Db
        120 VDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 179
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
            Db
        180 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 239
Qу
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLD 180
            Db
        240 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 299
QУ
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
             300 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 347
Db
```

```
US-08-459-657-43
; Sequence 43, Application US/08459657
; Patent No. 5914111
  GENERAL INFORMATION:
    APPLICANT: BIOGEN, INC.
    APPLICANT: WALLNER, Barbara P.
    APPLICANT: MILLER, Glenn T.
    APPLICANT: ROSA, Margaret D.
    TITLE OF INVENTION: CD2-BINDING DOMAIN OF LYMPHOCYTE
    TITLE OF INVENTION: FUNCTION ASSOCIATED ANTIGEN 3
   NUMBER OF SEQUENCES: 43
    CORRESPONDENCE ADDRESS:
     ADDRESSEE: Fish & Neave
      STREET: 875 Third Avenue
     CITY: New York
     STATE: New York
     COUNTRY: U.S.A.
     ZIP: 10022-6250
   COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.25
   CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/459,657
      FILING DATE: 02-JUN-1995
      CLASSIFICATION: 424
    PRIOR APPLICATION DATA:
    APPLICATION NUMBER: PCT/US92/02050
     FILING DATE: 12-MAR-1992
     APPLICATION NUMBER: US 07/667,971
     FILING DATE: 12-MAR-1991
   PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US 07/770,967
      FILING DATE: 07-OCT-1991
   ATTORNEY/AGENT INFORMATION:
      NAME: HALEY, James F., Jr.
      REGISTRATION NUMBER: 27,794
      REFERENCE/DOCKET NUMBER: B151CIP2
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (212)715-0600
      TELEFAX: (212)715-0673
      TELEX: 14-8367
   INFORMATION FOR SEQ ID NO: 43:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 347 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-459-657-43
 Query Match
                         99.7%; Score 1234; DB 2; Length 347;
 Best Local Similarity 99.6%; Pred. No. 6.3e-117;
 Matches 227; Conservative 1; Mismatches 0; Indels
                                                               0; Gaps
                                                                          0;
```

RESULT 4

```
Qу
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
            Db
        120 VDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 179
         61 DGVEVHNAKTKPREEOYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qy
            180 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 239
Db
Qу
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
            Db
        240 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 299
Qу
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
            Db
        300 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKSLSLSPGK 347
RESULT 5
US-08-460-132-43
; Sequence 43, Application US/08460132
; Patent No. 5928643
  GENERAL INFORMATION:
    APPLICANT: BIOGEN, INC.
    APPLICANT: WALLNER, Barbara P.
    APPLICANT: MILLER, Glenn T.
    APPLICANT: ROSA, Margaret D.
    TITLE OF INVENTION: CD2-BINDING DOMAIN OF LYMPHOCYTE
    TITLE OF INVENTION: FUNCTION ASSOCIATED ANTIGEN 3
    NUMBER OF SEQUENCES: 43
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Fish & Neave
      STREET: 875 Third Avenue
      CITY: New York
      STATE: New York
      COUNTRY: U.S.A.
      ZIP: 10022-6250
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.25
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/460,132
      FILING DATE: 02-JUN-1995
      CLASSIFICATION: 424
    PRIOR APPLICATION DATA:
     APPLICATION NUMBER: US 07/940,861
      FILING DATE: 21-OCT-1992
      APPLICATION NUMBER: PCT/US92/02050
     FILING DATE: 12-MAR-1992
    PRIOR APPLICATION DATA:
     APPLICATION NUMBER: US 07/667,971
      FILING DATE: 12-MAR-1991
    PRIOR APPLICATION DATA:
     APPLICATION NUMBER: US 07/770,967
      FILING DATE: 07-OCT-1991
    ATTORNEY/AGENT INFORMATION:
```

```
NAME: HALEY, James F., Jr.
      REGISTRATION NUMBER: 27,794
      REFERENCE/DOCKET NUMBER: B151CIP2
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (212)715-0600
      TELEFAX: (212)715-0673
      TELEX: 14-8367
  INFORMATION FOR SEQ ID NO: 43:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 347 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-460-132-43
 Query Match
                      99.7%; Score 1234; DB 2; Length 347;
 Best Local Similarity 99.6%; Pred. No. 6.3e-117;
 Matches 227; Conservative 1; Mismatches
                                                Indels
                                            0;
                                                         0; Gaps
                                                                   0;
Qу
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
            120 VDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 179
Db
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
            Db
        180 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 239
Qу
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
            240 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 299
Db
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Qу
            Db
        300 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 347
RESULT 6
US-08-466-465-8
; Sequence 8, Application US/08466465
; Patent No. 6162432
  GENERAL INFORMATION:
    APPLICANT: Wallner, Barbara P.
    APPLICANT: Cooper, Kevin D.
    TITLE OF INVENTION: Method of Prophylaxis or Treatment of Antigen
    TITLE OF INVENTION: Presenting Cell Driven Skin Conditions Using
    TITLE OF INVENTION: Inhibitors of the CD2/LFA-3 Interaction
    NUMBER OF SEQUENCES: 8
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: LAHIVE & COCKFIELD
      STREET: 60 State Street, Suite 510
      CITY: Boston
     STATE: Massachusetts
      COUNTRY: USA
      ZIP: 02109-1875
    COMPUTER READABLE FORM:
     MEDIUM TYPE: Floppy disk
     COMPUTER: IBM PC compatible
```

```
OPERATING SYSTEM: PC-DOS/MS-DOS
;
      SOFTWARE: PatentIn Release #1.0, Version #1.25
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/466,465
      FILING DATE:
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: PCT/US92/08755
      FILING DATE: 06-OCT-1992
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US 07/862,022
      FILING DATE:
                 12-APR-1992
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US 07/770,969
      FILING DATE: 07-OCT-1991
    ATTORNEY/AGENT INFORMATION:
      NAME: Myers, Louis (PLM)
      REGISTRATION NUMBER: 35,965
      REFERENCE/DOCKET NUMBER: BGP-111CP
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (617)227-7400
      TELEFAX: (617)227-5941
  INFORMATION FOR SEQ ID NO:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 347 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-466-465-8
 Query Match
                      99.7%; Score 1234; DB 3; Length 347;
 Best Local Similarity 99.6%; Pred. No. 6.3e-117;
 Matches 227; Conservative 1; Mismatches
                                           0; Indels
                                                        0; Gaps
                                                                   0;
Qу
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
            120 VDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 179
Db
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
            Db
        180 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 239
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
            Db
        240 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 299
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Qу
            Db
        300 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKSLSLSPGK 347
RESULT 7
PCT-US92-02050-43
; Sequence 43, Application PC/TUS9202050
  GENERAL INFORMATION:
    APPLICANT: BIOGEN, INC.
    APPLICANT: WALLNER, Barbara P.
    APPLICANT: MILLER, Glenn T.
```

```
APPLICANT: ROSA, Margaret D.
    TITLE OF INVENTION: CD2-BINDING DOMAIN OF LYMPHOCYTE
    TITLE OF INVENTION: FUNCTION ASSOCIATED ANTIGEN 3
    NUMBER OF SEQUENCES: 43
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Fish & Neave
      STREET: 875 Third Avenue
      CITY: New York
      STATE: New York
      COUNTRY: U.S.A.
      ZIP: 10022-6250
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.25
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: PCT/US92/02050
      FILING DATE: 19920312
      CLASSIFICATION: 435
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US 07/667,971
      FILING DATE: 12-MAR-1991
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US 07/770,967
      FILING DATE: 07-OCT-1991
    ATTORNEY/AGENT INFORMATION:
      NAME: HALEY, James F., Jr.
      REGISTRATION NUMBER: 27,794
      REFERENCE/DOCKET NUMBER: B151CIP2
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (212)715-0600
      TELEFAX: (212)715-0673
      TELEX: 14-8367
  INFORMATION FOR SEO ID NO: 43:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 347 amino acids
      TYPE: AMINO ACID
     TOPOLOGY: linear
    MOLECULE TYPE: protein
PCT-US92-02050-43
 Query Match
                       99.7%; Score 1234; DB 5; Length 347;
 Best Local Similarity 99.6%; Pred. No. 6.3e-117;
 Matches 227; Conservative
                            1; Mismatches
                                            0;
                                                Indels
                                                          0; Gaps
                                                                     0:
Qу
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
            Db
         120 VDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 179
QУ
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
            180 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 239
Db
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
            Db
        240 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 299
```

```
Oy
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
            Db
        300 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 347
RESULT 8
US-09-157-452B-12
; Sequence 12, Application US/09157452B
; Patent No. 6482409
; GENERAL INFORMATION:
  APPLICANT: Lobb, Roy R.
  APPLICANT: Burkly, Linda C.
  TITLE OF INVENTION: TREATMENT FOR INFLAMMATORY BOWEL DISEASE
  FILE REFERENCE: 10274-004003
  CURRENT APPLICATION NUMBER: US/09/157,452B
  CURRENT FILING DATE: 1998-09-21
  PRIOR APPLICATION NUMBER: US 08/950,660
  PRIOR FILING DATE: 1997-10-15
  PRIOR APPLICATION NUMBER: US 08/373,857
  PRIOR FILING DATE: 1995-01-18
  PRIOR APPLICATION NUMBER: US 08/284,603
  PRIOR FILING DATE: 1994-08-11
  PRIOR APPLICATION NUMBER: PCT/US93/00924
  PRIOR FILING DATE: 1993-02-02
  PRIOR APPLICATION NUMBER: US 07/835,139
  PRIOR FILING DATE: 1992-02-12
  NUMBER OF SEQ ID NOS: 16
  SOFTWARE: FastSEQ for Windows Version 3.0
 SEQ ID NO 12
   LENGTH: 446
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-157-452B-12
 Query Match
                      99.7%; Score 1234; DB 4; Length 446;
 Best Local Similarity
                      99.6%;
                             Pred. No. 9.1e-117;
 Matches 227; Conservative
                           1; Mismatches
                                            0;
                                              Indels
                                                        0; Gaps
Qу
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
            Db
        219 VDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 278
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
            279 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 338
Db
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
QУ
            Db
        339 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 398
Qу
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
            Dh
        399 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 446
```

```
US-09-189-129-2
; Sequence 2, Application US/09189129
; Patent No. 6323027
  GENERAL INFORMATION:
    APPLICANT: Burkly, Linda C
    APPLICANT: Benjamin, Christopher D
    APPLICANT: Hession, Catherine A
    APPLICANT: Whitty, Adrian
    TITLE OF INVENTION: COMMON GAMMA CHAIN BLOCKING AGENTS
    NUMBER OF SEQUENCES: 17
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Biogen, Inc.
      STREET: 14 Cambridge Center
      CITY: Cambridge
      STATE: Massachusetts
      COUNTRY: USA
      ZIP: 02142
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.30
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/09/189,129
      FILING DATE:
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: A006 PCT CIP
      FILING DATE: 09-MAY-1997
      APPLICATION NUMBER: 60/017,466
     FILING DATE: 10-MAY-1996
   ATTORNEY/AGENT INFORMATION:
      NAME: Kaplan, Warren A.
      REGISTRATION NUMBER: 34,199
      REFERENCE/DOCKET NUMBER: A006 PCT CIP
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 617 679-2000
      TELEFAX: 617 679-2838
  INFORMATION FOR SEO ID NO: 2:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 482 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
      TOPOLOGY: linear
    MOLECULE TYPE:
    HYPOTHETICAL: YES
    ANTI-SENSE: NO
US-09-189-129-2
                        99.7%; Score 1234; DB 4; Length 482;
 Query Match
 Best Local Similarity 99.6%; Pred. No. 1e-116;
 Matches 227; Conservative 1; Mismatches
                                               0; Indels
                                                             0;
                                                                         0;
Qу
           1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
             Db
         255 VDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 314
Qу
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
```

```
Db
        315 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 374
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
QУ
            Db
        375 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 434
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Qу
            Db
        435 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 482
RESULT 10
US-08-595-043A-50
; Sequence 50, Application US/08595043A
; Patent No. 5935824
  GENERAL INFORMATION:
    APPLICANT: SGARLATO, GREGORY D.
    TITLE OF INVENTION: PROTEIN EXPRESSION SYSTEM
    NUMBER OF SEQUENCES: 90
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: MEDLEN & CARROLL
      STREET: 220 MONTGOMERY STREET, SUITE 2200
      CITY: SAN FRANCISCO
      STATE: CALIFORNIA
      COUNTRY: UNITED STATES OF AMERICA
      ZIP: 94104
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.30
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/595,043A
     FILING DATE: 31-JAN-1996
      CLASSIFICATION: 435
    ATTORNEY/AGENT INFORMATION:
      NAME: CARROLL, PETER G.
      REGISTRATION NUMBER: 32,837
      REFERENCE/DOCKET NUMBER: SGAR-00371
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (415) 705-8410
      TELEFAX: (415) 397-8338
  INFORMATION FOR SEQ ID NO:
    SEQUENCE CHARACTERISTICS:
     LENGTH: 232 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-595-043A-50
 Query Match
                      99.6%; Score 1233; DB 2; Length 232;
 Best Local Similarity
                      100.0%; Pred. No. 4.5e-117;
 Matches 227; Conservative
                            0; Mismatches
                                            0; Indels
                                                        0; Gaps
                                                                   0;
Qу
          2 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 61
```

```
Db
          6 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 65
         62 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 121
Qу
            66 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 125
Db
        122 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 181
Qу
            Db
        126 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLDS 185
Qу
        182 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKSLSLSPGK 228
            Db
        186 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 232
RESULT 11
US-09-131-247-6
; Sequence 6, Application US/09131247
; Patent No. 6294170
; GENERAL INFORMATION:
  APPLICANT: Boone, Thomas C.
  APPLICANT: Hershenson, Susan
  APPLICANT: Bevilacqua, Michael P.
  APPLICANT: Collins, David S.
  TITLE OF INVENTION: COMPOSITION AND METHOD FOR TREATING INFLAMMATORY
  TITLE OF INVENTION: DISEASES
  FILE REFERENCE: A-365F
  CURRENT APPLICATION NUMBER: US/09/131,247
  CURRENT FILING DATE: 1998-08-07
  EARLIER APPLICATION NUMBER: 60/055,185
  EARLIER FILING DATE: 1997-08-08
  EARLIER APPLICATION NUMBER: PCT/US 97/02131
  EARLIER FILING DATE: 1997-02-10
  NUMBER OF SEO ID NOS: 16
  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
   LENGTH: 235
   TYPE: PRT
   ORGANISM: Human
US-09-131-247-6
 Query Match
                      99.6%; Score 1233; DB 3; Length 235;
 Best Local Similarity
                     100.0%; Pred. No. 4.6e-117;
 Matches 227; Conservative 0; Mismatches
                                           0: Indels
                                                       0; Gaps
                                                                 0:
          2 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 61
Qу
            Db
          9 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 68
         62 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKAK 121
Qу
            69 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 128
Db
Qу
        122 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLDS 181
            129 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 188
Db
```

```
Qу
        182 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
            Db
        189 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 235
RESULT 12
US-09-178-869-2
; Sequence 2, Application US/09178869B
; Patent No. 6197294
; GENERAL INFORMATION:
; APPLICANT: Tao, Weng
 APPLICANT: Wong, Shou
  APPLICANT: Hickey, William F
  APPLICANT: Hammang, Joseph P.
  APPLICANT: Baetge, E. Edward
  TITLE OF INVENTION: CELL SURFACE-INDUCED MACROPHAGE ACTIVATION
  FILE REFERENCE: 17810-043
  CURRENT APPLICATION NUMBER: US/09/178,869B
  CURRENT FILING DATE: 1998-10-26
  NUMBER OF SEQ ID NOS: 14
  SOFTWARE: PatentIn Ver. 2.0
; SEO ID NO 2
   LENGTH: 331
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-178-869-2
 Query Match
                      99.6%; Score 1233; DB 3; Length 331;
 Best Local Similarity 100.0%; Pred. No. 7.5e-117;
 Matches 227; Conservative 0; Mismatches
                                         0; Indels
                                                           Gaps
                                                                  0;
Qу
          2 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 61
            Db
        105 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 164
         62 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 121
Qу
            165 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 224
Db
Qу
        122 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 181
            Db
        225 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 284
        182 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Qу
            285 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 331
Dh
RESULT 13
US-09-761-413-2
; Sequence 2, Application US/09761413
; Patent No. 6506891
; GENERAL INFORMATION:
 APPLICANT: Tao, Weng
 APPLICANT: Wong, Shou
APPLICANT: Hickey, William F
```

APPLICANT: Hammang, Joseph P.

```
; APPLICANT: Baetge, E. Edward
  TITLE OF INVENTION: CELL SURFACE-INDUCED MACROPHAGE ACTIVATION
  FILE REFERENCE: 17810-043
  CURRENT APPLICATION NUMBER: US/09/761,413
  CURRENT FILING DATE: 2001-01-16
  PRIOR APPLICATION NUMBER: US/09/178,869
  PRIOR FILING DATE: 1998-10-26
  NUMBER OF SEQ ID NOS: 14
  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
   LENGTH: 331
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-761-413-2
 Query Match
                       99.6%; Score 1233; DB 4; Length 331;
 Best Local Similarity 100.0%; Pred. No. 7.5e-117;
 Matches 227; Conservative 0; Mismatches 0; Indels
                                                         0; Gaps
                                                                    0:
          2 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 61
Qу
            Db
        105 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 164
         62 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 121
Qу
            Db
        165 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 224
        122 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 181
Qу
            Dh
        225 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 284
Qу
        182 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKSLSLSPGK 228
            Db
        285 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 331
RESULT 14
US-09-180-100-11
; Sequence 11, Application US/09180100
; Patent No. 6306395
; GENERAL INFORMATION:
  APPLICANT: NAKAMURA, No. 6306395io
  APPLICANT: NAGATA, Shigekazu
  TITLE OF INVENTION: NOVEL Fas ANTIGEN DERIVATIVE
  FILE REFERENCE: 1110-207P
  CURRENT APPLICATION NUMBER: US/09/180,100
  CURRENT FILING DATE: 1998-11-02
  EARLIER APPLICATION NUMBER: PCT/JP97/01502
  EARLIER FILING DATE: 1997-05-01
  NUMBER OF SEQ ID NOS: 25
  SOFTWARE: PatentIn Ver. 2.0
; SEO ID NO 11
   LENGTH: 360
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-180-100-11
```

```
Query Match
                      99.6%; Score 1233; DB 4; Length 360;
 Best Local Similarity 100.0%; Pred. No. 8.4e-117;
 Matches 227; Conservative 0; Mismatches
                                          0; Indels
                                                        0; Gaps
                                                                   0;
          2 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 61
Qу
            Db
        134 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 193
         62 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 121
Qу
            Db
        194 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 253
Qу
        122 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 181
            Db
        254 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLDS 313
QУ
        182 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKSLSLSPGK 228
            Db
        314 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 360
RESULT 15
US-08-236-311-7
; Sequence 7, Application US/08236311
; Patent No. 5565335
  GENERAL INFORMATION:
    APPLICANT: Capon, Daniel J.
    APPLICANT: Gregory, Timothy J.
    TITLE OF INVENTION: Adheson Variants
    NUMBER OF SEQUENCES: 25
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Genentech, Inc.
      STREET: 460 Point San Bruno Blvd
      CITY: South San Francisco
      STATE: California
      COUNTRY: USA
      ZIP: 94080
    COMPUTER READABLE FORM:
      MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: patin (Genentech)
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/236,311
      FILING DATE: 02-MAY-1994
      CLASSIFICATION: 435
    PRIOR APPLICATION DATA:
     APPLICATION NUMBER: 07/936190
      FILING DATE: 26-AUG-1992
    PRIOR APPLICATION DATA:
     APPLICATION NUMBER: 07/842777
      FILING DATE: 18-FEB-1992
    PRIOR APPLICATION DATA:
     APPLICATION NUMBER: 07/250785
      FILING DATE: 28-SEP-1988
    PRIOR APPLICATION DATA:
     APPLICATION NUMBER: 07/104329
```

```
FILING DATE: 02-OCT-1987
;
    ATTORNEY/AGENT INFORMATION:
     NAME: Hasak, Janet E.
     REGISTRATION NUMBER: 28,616
     REFERENCE/DOCKET NUMBER: 444P1C2
    TELECOMMUNICATION INFORMATION:
     TELEPHONE: 415/225-1896
     TELEFAX: 415/952-9881
     TELEX: 910/371-7168
  INFORMATION FOR SEQ ID NO: 7:
    SEQUENCE CHARACTERISTICS:
     LENGTH: 371 amino acids
     TYPE: amino acid
     TOPOLOGY: linear
US-08-236-311-7
 Query Match
                     99.6%; Score 1233; DB 1; Length 371;
 Best Local Similarity 100.0%; Pred. No. 8.8e-117;
 Matches 227; Conservative 0; Mismatches
                                        0; Indels
                                                     0; Gaps
                                                               0;
         2 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 61
Qу
           Db
        145 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 204
         62 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 121
Qу
           Db
        205 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 264
Qу
        122 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 181
           Db
        265 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 324
Qу
        182 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
           Db
        325 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 371
```

Search completed: January 16, 2004, 09:39:18

Job time : 22 secs

# GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 16, 2004, 09:36:27; Search time 21 Seconds

(without alignments)

1044.117 Million cell updates/sec

Title: US-09-843-221A-2

Perfect score: 1238

Sequence: 1 MDKTHTCPPCPAPELLGGPS.....MHEALHNHYTQKSLSLSPGK 228

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283308 seqs, 96168682 residues

Total number of hits satisfying chosen parameters: 283308

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR\_76:\*
1: pir1:\*
2: pir2:\*
3: pir3:\*

4: pir4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1233	99.6	255	4	S31866	Ig gamma-1 chain C
2	1233	99.6	330	1	GHHU	Ig gamma-1 chain C
3	1227	99.1	374	2	S69339	Ig heavy chain V r
4	1180	95.3	234	2	PT0207	Ig gamma chain C r
5	1146	92.6	377	2	A23511	Ig gamma-3 chain C
6	1144	92.4	377	2	A60764	Ig gamma-3 chain C
7	1142.5	92.3	326	1	G2HU	Ig gamma-2 chain C
8	1135	91.7	327	1	G4HU	Ig gamma-4 chain C
9	1121	90.5	289	1	G3HUWI	Ig gamma-3 heavy c
10	918.5	74.2	323	1	GHRB	Ig gamma chain C r
11	906.5	73.2	328	2	I47160	Ig gamma 2b chain
12	906.5	73.2	328	2	I <b>47</b> 159	Ig gamma 2a chain
13	903.5	73.0	277	2	I47162	Ig gamma 4 chain c

14	889	71.8	329	1	G2GP	Ig gamma-2 chain C
15	885.5	71.5	328	2	I47158	Ig gamma 1 chain c
16	878.5	71.0	328	2	I47161	Ig gamma 3 chain c
17	855.5	69.1	470	2	S22080	Ig heavy chain pre
18	846	68.3	308	2	C30554	Ig heavy chain C r
19	846	68.3	472	2	S31459	Ig gamma-1 chain -
20	845.5	68.3	329	1	G3MSC	Ig gamma-3 chain C
21	838	67.7	333	2	PS0018	Ig gamma-2b chain
22	834.5	67.4	398	1	G3MSM	Ig gamma-3 chain C
23	827.5	66.8	444	2	PC4436	monoclonal antibod
24	818.5	66.1	326	2	PS0017	Ig gamma-1 chain C
25	817.5	66.0	324	1	G1MS	Ig gamma-1 chain C
26	812.5	65.6	393	1	G1MSM	Ig gamma-1 chain C
27	809.5	65.4	329	2	S00847	Ig gamma-2c chain
28	809	65.3	330	1	G2MSA	Ig gamma-2a chain
29	809	65.3	469	2	S37483	Ig gamma-2a chain
30	804	64.9	399	1	G2MSAM	Ig gamma-2a chain
31	802	64.8	335	1	G2MSAB	Ig gamma-2a chain
32	794	64.1	446	2	S40295	Ig gamma-2a chain
33	785.5	63.4	322	2	PS0019	Ig gamma-2a chain
34	779	62.9	474	1	G2MS11	Ig gamma-2b chain
35	774	62.5	405	1	G2MSBM	Ig gamma-2b chain
36	764	61.7	327	2	S06611	Ig gamma-2 chain C
37	757	61.1	475	2	S01321	Ig gamma-2b chain
38	707	57.1	180	2	I46732	Ig gamma heavy cha
39	577.5	46.6	249	2	S69340	Ig heavy chain VHI
40	574.5	46.4	218	2	A36040	Ig heavy chain V-I
41	571	46.1	152	2	S14236	Ig gamma-1 chain C
42	395.5	31.9	572	2	B46529	Ig Y heavy chain (
43	358	28.9	343	2	S25644	Ig mu chain C regi
44	358	28.9	453	2	S37768	Ig mu chain C regi
45	357.5	28.9	549	2	S04845	Ig heavy chain pre

#### ALIGNMENTS

# RESULT 1

Ig gamma-1 chain C region - synthetic

C; Species: synthetic

A;Note: Homo sapiens (man) gene engineered and expressed in Escherichia coli C;Date: 06-Jan-1995 #sequence\_revision 17-Mar-1997 #text\_change 19-May-2000

C;Accession: S31866

R; Filpula, D.

submitted to the EMBL Data Library, February 1993

A; Description: Screeing method for protein-protein interactions of cloned gene products.

A; Reference number: S31866

A; Accession: S31866 A; Molecule type: mRNA A; Residues: 1-255 <FIL>

A; Cross-references: EMBL: X70421; NID: g33068; PIDN: CAA49866.1; PID: g33069

C; Keywords: immunoglobulin

F;1-22/Region: Escherichia coli outer membrane protein A precursor

F;23-255/Region: human Ig gamma-1 chain C region

```
Query Match
                        99.6%; Score 1233; DB 4; Length 255;
  Best Local Similarity 100.0%; Pred. No. 6.8e-89;
 Matches 227; Conservative 0; Mismatches
                                              0; Indels
                                                                       0;
           2 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 61
Qу
             Db
          29 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 88
          62 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 121
Qу
             Db
          89 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKAK 148
Qу
         122 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 181
             Db
         149 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 208
         182 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
QУ
             Db
         209 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 255
RESULT 2
GHHU
Ig gamma-1 chain C region - human
C; Species: Homo sapiens (man)
C;Date: 31-Jan-1981 #sequence revision 18-Aug-1982 #text change 16-Jul-1999
C; Accession: A93433; S36861; S33887; B90563; A90564; B91668; A91723; A02146
R; Ellison, J.W.; Berson, B.J.; Hood, L.E.
Nucleic Acids Res. 10, 4071-4079, 1982
A; Title: The nucleotide sequence of a human immunoglobulin C-gamma1 gene.
A; Reference number: A93433; MUID: 82274238; PMID: 6287432
A; Accession: A93433
A; Molecule type: DNA
A; Residues: 1-330 <ELL>
A; Cross-references: EMBL: Z17370
A; Note: this sequence has the Glm(17) allotypic marker, 97-Lys, and the Glm(1)
markers, 239-Asp and 241-Leu
A; Note: Lys-330 is removed after translation
R; Harris, L.J.
submitted to the EMBL Data Library, October 1992
A; Reference number: S33904
A; Accession: S36861
A; Molecule type: DNA
A; Residues: 2-330 <HAR>
A; Cross-references: EMBL: Z17370
R; Takahashi, N.; Ueda, S.; Obata, M.; Nikaido, T.; Nakai, S.; Honjo, T.
Cell 29, 671-679, 1982
A; Title: Structure of human immunoglobulin gamma genes: implications for
evolution of a gene family.
A; Reference number: S33887; MUID: 83001943; PMID: 6811139
A; Accession: S33887
A; Molecule type: DNA
A; Residues: 88-113; 235-330 < TAK>
A; Cross-references: EMBL: Z17370
R; Cunningham, B.A.; Rutishauser, U.; Gall, W.E.; Gottlieb, P.D.; Waxdal, M.J.;
Edelman, G.M.
Biochemistry 9, 3161-3170, 1970
```

```
A; Title: The covalent structure of a human gammaG-immunoglobulin. VII. Amino
acid sequence of heavy-chain cyanogen bromide fragments H-1-H-4.
A; Reference number: A90563; MUID: 71064024; PMID: 5489771
A; Contents: myeloma protein Eu
A; Accession: B90563
A; Molecule type: protein
A; Residues: 1-96, 'R', 98-135 < CUN>
A; Note: this sequence has the Glm(3) marker, 97-Arg
R; Rutishauser, U.; Cunningham, B.A.; Bennett, C.; Konigsberg, W.H.; Edelman,
G.M.
Biochemistry 9, 3171-3181, 1970
A; Title: The covalent structure of a human gammaG-immunoglobulin. VIII. Amino
acid sequence of heavy-chain cyanogen bromide fragments H-5-H-7.
A; Reference number: A90564; MUID: 71064025; PMID: 5530842
A; Contents: Eu
A; Accession: A90564
A; Molecule type: protein
A; Residues: 136-154, 'Q', 156-165, 'Q', 167-176, 'Q', 178-194, 'N', 196-197, 'D', 199-
238, 'E', 240, 'M', 242-267, 'DGEPE', 273-329 < RUT>
A; Note: this sequence has the Glm(non-1) markers, 239-Glu and 241-Met
R; Ponstingl, H.; Hilschmann, N.
Hoppe-Seyler's Z. Physiol. Chem. 357, 1571-1604, 1976
A; Title: Die Primaerstruktur eines monoklonalen IgG1-Immunglobulins
(Myelomprotein Nie), III. Die chymotryptischen Peptide der H-Kette, Anordnung
der tryptischen Peptide und Diskussion der vollstaendigen Primaerstruktur.
A; Reference number: A91668; MUID: 77070269; PMID: 826475
A; Contents: myeloma protein Nie
A; Accession: B91668
A; Molecule type: protein
A; Residues: 1-34, 'Q', 36-96, 'K', 98-115, 'Q', 117-197, 'D', 199-238, 'D', 240, 'L', 242-
268, 'E', 270-271, 'D', 273-330 < PON>
A; Note: this sequence has the Glm(17) and Glm(1) markers
R; Schmidt, W.E.; Jung, H.D.; Palm, W.; Hilschmann, N.
Hoppe-Seyler's Z. Physiol. Chem. 364, 713-747, 1983
A; Title: Die Primaerstruktur des kristallisierbaren monoklonalen Immunglobulins
IgG1 KOL, I.
A; Reference number: A91723; MUID: 83289131; PMID: 6884994
A; Contents: myeloma protein KOL; disulfide bonds
A; Accession: A91723
A; Molecule type: protein
A; Residues: 1-96, 'R', 98-197, 'D', 199-238, 'E', 240, 'M', 242-266, 'D', 268-271, 'D', 273-
330 <SCH>
A; Note: this sequence has the G1m(3) and G1m(non-1) markers
R; Gall, W.E.; Edelman, G.M.
Biochemistry 9, 3188-3196, 1970
A; Title: The covalent structure of a human gammaG-immunoglobulin. X. Intrachain
disulfide bonds.
A; Reference number: A90565; MUID: 71064027; PMID: 4923144
A; Contents: annotation; disulfide bonds
R; Dreker, L.; Schwarz, J.; Reichel, W.; Hilschmann, N.
Hoppe-Seyler's Z. Physiol. Chem. 357, 1515-1540, 1976
A; Title: Rule of antibody structure. The primary structure of monoclonal IgG1
immunoglobulin (myeloma protein Nie), I: purification and characterization of
the protein, the L- and H-chains the cyanogenbromide cleavage products, and the
disulfide bridges.
A; Reference number: A91667; MUID: 77070267; PMID: 1002129
A; Contents: annotation; disulfide bonds
```

```
A; Gene: GDB: IGHG1
A; Cross-references: GDB:120085; OMIM:147100
A; Map position: 14q32.33-14q32.33
A; Introns: 99/1; 114/1; 224/1
C; Complex: An immunoglobulin heterotetramer subunit consists of two identical
light (kappa or lambda) and two identical heavy (alpha, delta, epsilon, gamma,
or mu) chains usually stabilized by interchain disulfide bonds. In some cases,
such as IgA and IgM, the subunits associate into larger oligomers.
C; Superfamily: immunoglobulin C region; immunoglobulin homology
C; Keywords: duplication; glycoprotein; heterotetramer; immunoglobulin
F;20-85/Domain: immunoglobulin homology <IM1>
F;137-206/Domain: immunoglobulin homology <IM2>
F;243-310/Domain: immunoglobulin homology <IM3>
F;27-83,144-204,250-308/Disulfide bonds: #status experimental
F;103/Disulfide bonds: interchain (to light chain) #status experimental
F;109,112/Disulfide bonds: interchain (to heavy chain) #status experimental
F;180/Binding site: carbohydrate (Asn) (covalent) #status experimental
  Query Match
                        99.6%; Score 1233; DB 1; Length 330;
  Best Local Similarity
                        100.0%; Pred. No. 9.4e-89;
 Matches 227; Conservative 0; Mismatches
                                              0; Indels
                                                            0; Gaps
                                                                       0;
Qу
           2 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 61
             Db
         104 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 163
          62 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKAK 121
QУ
             Db
         164 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 223
         122 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 181
Qу
             Db
         224 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 283
Qу
         182 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
             Db
         284 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 330
RESULT 3
S69339
Ig heavy chain V region precursor - human
C; Species: Homo sapiens (man)
C;Date: 19-Mar-1997 #sequence_revision 19-Mar-1997 #text_change 01-Dec-2000
C; Accession: S69339; S72664
R; Khamlichi, A.A.; Aucouturier, P.; Preud'homme, J.L.; Cogne, M.
Eur. J. Biochem. 229, 54-60, 1995
A; Title: Structure of abnormal heavy chains in human heavy-chain-deposition
disease.
A; Reference number: S69339; MUID: 95262687; PMID: 7744049
A; Accession: S69339
A; Status: preliminary
A; Molecule type: mRNA
A; Residues: 1-374 < KHA>
A; Cross-references: EMBL: X81695
R; Khamlichi, A.A.
```

C; Genetics:

```
submitted to the EMBL Data Library, September 1994
A: Reference number: S72664
A; Accession: S72664
A; Status: preliminary
A; Molecule type: mRNA
A; Residues: 1-140, 'C', 142-374 < KH2>
A; Cross-references: EMBL: X81695
C; Superfamily: immunoglobulin C region; immunoglobulin homology
  Query Match
                      99.1%; Score 1227; DB 2; Length 374;
 Best Local Similarity
                      99.1%; Pred. No. 3.2e-88;
 Matches 225; Conservative
                            2; Mismatches
                                            0; Indels
                                                        0; Gaps
                                                                  0;
Qу
          2 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 61
            Db
        148 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 207
         62 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 121
Qу
            208 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 267
Db
QУ
        122 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 181
            Db
        268 GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 327
Qу
        182 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
            Db
        328 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 374
RESULT 4
PT0207
Ig gamma chain C region - chimpanzee
C; Species: Pan troglodytes (chimpanzee)
C;Date: 23-Nov-1991 #sequence_revision 23-Nov-1991 #text_change 16-Jul-1999
C; Accession: PT0207
R; Ehrlich, P.H.; Moustafa, Z.A.; Oestberg, L.
Mol. Immunol. 28, 319-322, 1991
A; Title: Nucleotide sequence of chimpanzee Fc and hinge regions.
A; Reference number: PT0207; MUID: 91287716; PMID: 2062315
A; Accession: PT0207
A; Molecule type: mRNA
A; Residues: 1-234 < EHR>
C; Superfamily: immunoglobulin C region; immunoglobulin homology
C; Keywords: immunoglobulin
F;48-117/Domain: immunoglobulin homology <IMM>
 Query Match
                      95.3%;
                             Score 1180; DB 2; Length 234;
 Best Local Similarity
                      98.6%; Pred. No. 8.2e-85;
 Matches 217; Conservative
                            1; Mismatches
                                            2: Indels
                                                        0;
                                                           Gaps
                                                                  0;
          2 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 61
Οv
             15 DTTHTCPPCAAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 74
Db
Qу
         62 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 121
```

```
75 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 134
Db
         122 GOPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 181
Qу
            Db
        135 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESSGOPENNYKTTPPVLDS 194
Ov
        182 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS 221
            Db
        195 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKS 234
RESULT 5
A23511
Ig gamma-3 chain C region (allotype G3m(b)) - human
C; Species: Homo sapiens (man)
C;Date: 28-Dec-1987 #sequence_revision 28-Dec-1987 #text change 23-Jul-1999
C; Accession: A23511
R; Huck, S.; Fort, P.; Crawford, D.H.; Lefranc, M.P.; Lefranc, G.
Nucleic Acids Res. 14, 1779-1789, 1986
A; Title: Sequence of a human immunoglobulin gamma 3 heavy chain constant region
gene: comparison with the other human C-gamma genes.
A; Reference number: A23511; MUID: 86148507; PMID: 3081877
A; Accession: A23511
A; Molecule type: DNA
A; Residues: 1-377 < HUC>
A; Cross-references: GB: X03604; GB: M12958; NID: g33070; PIDN: CAA27268.1;
PID: 9577056
C; Genetics:
A; Gene: GDB: IGHG3
A; Cross-references: GDB:119339; OMIM:147120
A; Map position: 14q32.33-14q32.33
A; Introns: 98/3; 115/3; 130/3; 145/3; 160/3; 270/3
C; Superfamily: immunoglobulin C region; immunoglobulin homology
C; Keywords: immunoglobulin
F;20-85/Domain: immunoglobulin homology <IMM>
 Query Match
                       92.6%:
                             Score 1146; DB 2; Length 377;
 Best Local Similarity
                      92.5%;
                             Pred. No. 6.7e-82;
 Matches 210; Conservative
                            8; Mismatches
                                            9; Indels
                                                         0; Gaps
                                                                   0;
          2 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 61
Qу
                 151 DTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVD 210
Db
         62 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 121
Qу
            211 GVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTK 270
Db
Qу
        122 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 181
            271 GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPMLDS 330
Db
QУ
        182 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKSLSLSPGK 228
            Db
        331 DGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTQKSLSLSPGK 377
```

```
RESULT 6
A60764
Ig gamma-3 chain C region, form LAT - human
C; Species: Homo sapiens (man)
C; Date: 14-May-1993 #sequence revision 14-May-1993 #text change 16-Jul-1999
C; Accession: A60764
R; Huck, S.; Lefranc, G.; Lefranc, M.P.
Immunogenetics 30, 250-257, 1989
A; Title: A human immunoglobulin IGHG3 allele (Gmb0, b1, c3, c5, u) with an IGHG4
converted region and three hinge exons.
A; Reference number: A60764; MUID: 90007613; PMID: 2571587
A; Accession: A60764
A; Status: preliminary
A; Molecule type: DNA
A; Residues: 1-377 < HUC>
C; Superfamily: immunoglobulin C region; immunoglobulin homology
C; Keywords: immunoglobulin
F;20-85/Domain: immunoglobulin homology <IMM>
                        92.4%; Score 1144; DB 2; Length 377;
  Query Match
                        92.5%; Pred. No. 9.6e-82;
  Best Local Similarity
 Matches 210; Conservative
                                              9; Indels
                              8; Mismatches
                                                            0; Gaps
                                                                       0;
           2 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 61
Qу
                 Db
         151 DTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVD 210
Qу
          62 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 121
             Db
         211 GVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTK 270
QУ
         122 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLDS 181
             Db
         271 GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPVLDS 330
         182 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Qу
             331 DGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNRFTQKSLSLSPGK 377
Db
RESULT 7
G2HU
Ig gamma-2 chain C region - human
C; Species: Homo sapiens (man)
C;Date: 30-Apr-1981 #sequence_revision 13-Jun-1983 #text_change 21-Jul-2000
C; Accession: A93906; A92809; A90752; A93132; A02148
R; Ellison, J.; Hood, L.
Proc. Natl. Acad. Sci. U.S.A. 79, 1984-1988, 1982
A; Title: Linkage and sequence homology of two human immunoglobulin gamma heavy
chain constant region genes.
A; Reference number: A93906; MUID: 82197621; PMID: 6804948
A; Accession: A93906
A; Molecule type: DNA
A; Residues: 1-326 <ELL>
A; Cross-references: GB: V00554; GB: J00230; NID: g32759; PIDN: CAB58438.1;
PID:g6066056
A; Note: Lys-326 is probably removed posttranslationally
```

```
R; Wang, A.C.; Tung, E.; Fudenberg, H.H.
J. Immunol. 125, 1048-1054, 1980
A; Title: The primary structure of a human IgG2 heavy chain: genetic,
evolutionary, and functional implications.
A; Reference number: A92809; MUID: 81007873; PMID: 6774012
A; Contents: myeloma protein Til
A; Accession: A92809
A; Molecule type: protein
A; Residues: 1-19, 'Q', 21-57, 'Z', 59, 'A', 61-193, 'D', 195-325 < WAN>
A; Note: Trp-156 is at or near the complement-binding site
R; Connell, G.E.; Parr, D.M.; Hofmann, T.
Can. J. Biochem. 57, 758-767, 1979
A; Title: The amino acid sequences of the three heavy chain constant region
domains of a human IgG2 myeloma protein.
A; Reference number: A90752; MUID: 80001357; PMID: 113060
A; Contents: myeloma protein Zie
A; Accession: A90752
A; Molecule type: protein
A; Residues: 1-24, 'E', 26-57, 'EV', 60-85; 132-171, 'ZZZ', 175, 'B', 177-193, 'D', 195-
196, 'Q', 198-234, 'Z', 236-263, 'BGEPZ', 269-325 < CON>
A; Note: this sequence has since been revised
R; Hofmann, T.; Parr, D.M.
Mol. Immunol. 16, 923-925, 1979
A; Title: A note on the amino acid sequence of residues 381-391 of human
immunoglobulin gamma chains.
A; Reference number: A93132; MUID: 80114419; PMID: 118920
A; Contents: Zie
A; Accession: A93132
A; Molecule type: protein
A; Residues: 238-275 < HOF>
R; Hofmann, T.; Parr, D.M.
submitted to the Atlas, March 1980
A; Reference number: A94591
A; Contents: annotation; Zie, revisions to residues 25, 59, 60, and 264-268
A; Note: the revised sequence differs from that shown in having 60-Ala and in the
amidation states of residues 58, 194, and 197; the amidation states of residues
172-174, 176, and 235 were not determined
R; Milstein, C.; Frangione, B.
Biochem. J. 121, 217-225, 1971
A; Title: Disulphide bridges of the heavy chain of human immunoglobulin G2.
A; Reference number: A90253; MUID: 72033500; PMID: 4940472
A; Contents: annotation; myeloma protein Sa, disulfide bonds
R; Frangione, B.; Milstein, C.; Pink, J.R.L.
Nature 221, 145-148, 1969
A; Title: Structural studies of immunoglobulin G.
A; Reference number: A93157; MUID: 69064124; PMID: 5782707
A; Contents: annotation; Sa, disulfide bonds
C; Genetics:
A; Gene: GDB: IGHG2
A; Cross-references: GDB:119338; OMIM:147110
A; Map position: 14q32.33-14q32.33
C; Complex: An immunoglobulin heterotetramer subunit consists of two identical
light (kappa or lambda) and two identical heavy (alpha, delta, epsilon, gamma,
or mu) chains usually stabilized by interchain disulfide bonds. In some cases,
such as IgA and IgM, the subunits associate into larger oligomers.
C; Superfamily: immunoglobulin C region; immunoglobulin homology
C; Keywords: duplication; glycoprotein; heterotetramer; immunoglobulin
```

```
F;20-85/Domain: immunoglobulin homology <IM1>
F;133-202/Domain: immunoglobulin homology <IM2>
F;239-306/Domain: immunoglobulin homology <IM3>
F;14/Disulfide bonds: interchain (to light chain) #status experimental
F;27-83,140-200,246-304/Disulfide bonds: #status experimental
F;102,103,106,109/Disulfide bonds: interchain (to heavy chain) #status
experimental
F;176/Binding site: carbohydrate (Asn) (covalent) #status predicted
  Query Match
                        92.3%; Score 1142.5; DB 1; Length 326;
  Best Local Similarity
                        94.1%; Pred. No. 1e-81;
  Matches 209; Conservative
                              8; Mismatches
                                               4; Indels
                                                            1; Gaps
                                                                       1:
Qу
           7 CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH 66
             Db
         106 CPPCPAPP-VAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVH 164
          67 NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE 126
Qу
             Db
         165 NAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGOPRE 224
         127 PQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF 186
QУ
             Dh
         225 PQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFF 284
Qу
         187 LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
             Db
         285 LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 326
RESULT 8
G4HU
Ig gamma-4 chain C region - human
C; Species: Homo sapiens (man)
C;Date: 02-Apr-1982 #sequence_revision 02-Apr-1982 #text_change 16-Jul-1999
C; Accession: A90933; A90249; A02150
R; Ellison, J.; Buxbaum, J.; Hood, L.
DNA 1, 11-18, 1981
A; Title: Nucleotide sequence of a human immunoglobulin C-gamma4 gene.
A; Reference number: A90933; MUID: 83157104; PMID: 6299662
A; Accession: A90933
A; Molecule type: DNA
A; Residues: 1-327 <ELL>
A; Note: the sequence was determined from the germline gene
R; Pink, J.R.L.; Buttery, S.H.; De Vries, G.M.; Milstein, C.
Biochem. J. 117, 33-47, 1970
A; Title: Human immunoglobulin sublclasses. Partial amino acid sequence of the
constant region of A gamma4 chain.
A; Reference number: A90249; MUID: 70207560; PMID: 4192699
A; Accession: A90249
A; Molecule type: protein
A; Residues: 1-30; 81-326 < PIN>
C; Genetics:
A;Gene: GDB:IGHG4
A; Cross-references: GDB:119340; OMIM:147130
A; Map position: 14q32.33-14q32.33
A; Introns: 99/1; 111/1; 221/1
```

```
C; Complex: An immunoglobulin heterotetramer subunit consists of two identical
light (kappa or lambda) and two identical heavy (alpha, delta, epsilon, gamma,
or mu) chains usually stabilized by interchain disulfide bonds. In some cases,
such as IgA and IgM, the subunits associate into larger oligomers.
C; Superfamily: immunoglobulin C region; immunoglobulin homology
C; Keywords: duplication; glycoprotein; heterotetramer; immunoglobulin
F;20-85/Domain: immunoglobulin homology <IM1>
F;99-110/Region: hinge
F;134-203/Domain: immunoglobulin homology <IM2>
F;240-307/Domain: immunoglobulin homology <IM3>
F;14/Disulfide bonds: interchain (to light chain) #status experimental
F;27-83,141-201,247-305/Disulfide bonds: #status predicted
F;106,109/Disulfide bonds: interchain (to heavy chain) #status experimental
F;177/Binding site: carbohydrate (Asn) (covalent) #status predicted
  Query Match
                        91.7%; Score 1135; DB 1; Length 327;
  Best Local Similarity
                        93.7%; Pred. No. 4e-81;
  Matches 208; Conservative
                              8; Mismatches
                                               6: Indels
                                                            0; Gaps
                                                                        0;
           7 CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH 66
Qу
             Db
         106 CPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVH 165
          67 NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE 126
Qу
             166 NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE 225
Db
         127 PQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF 186
Qу
             Db
         226 PQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF 285
         187 LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Qу
             Db
         286 LYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK 327
RESULT 9
G3HUWI
Ig gamma-3 heavy chain disease proteins - human
C; Species: Homo sapiens (man)
C;Date: 31-Dec-1979 #sequence revision 23-Oct-1981 #text change 16-Jul-1999
C; Accession: A90442; A92219; A90198; A93915; A02149
R; Frangione, B.; Rosenwasser, E.; Prelli, F.; Franklin, E.C.
Biochemistry 19, 4304-4308, 1980
A; Title: Primary structure of human gamma3 immunoglobulin deletion mutant:
gamma3 heavy-chain disease protein Wis.
A; Reference number: A90442; MUID: 81021548; PMID: 6774747
A; Contents: heavy chain disease protein Wis
A; Accession: A90442
A; Molecule type: protein
A; Residues: 1-289 <FRA>
A; Note: the molecule is a dimer linked by 12 disulfide bonds; it has an extra
interchain disulfide bond at position 7 in addition to the 11 normally present
in the hinge region
A; Note: this protein lacks most of the V region and all of the CH1 region.
Residue 12 corresponds to the beginning of the hinge region of normal gamma-3
chains
```

```
A; Note: the sequence of residues 42-76 was taken from the reference that follows
R; Michaelsen, T.E.; Frangione, B.; Franklin, E.C.
J. Biol. Chem. 252, 883-889, 1977
A; Title: Primary structure of the 'hinge' region of human IgG3. Probable
quadruplication of a 15-amino acid residue basic unit.
A; Reference number: A92219; MUID: 77118561; PMID: 402363
A; Contents: normal gamma-3 chains, sequence corresponding to residues 12-97 of
protein Wis
A; Accession: A92219
A; Molecule type: protein
A; Residues: 12-97 <MIC>
A; Note: the hinge region in gamma-3 chains is about four times as long as in
other gamma chains and contains three identical 15-residue segments (29-43, 44-
58, and 59-73) preceded by a similar 17-residue segment (12-28)
A; Note: cysteines at positions 24, 27, 33, 39, 42, 48, 54, 57, 63, 69, and 72
form inter-heavy chain bonds
R; Wolfenstein-Todel, C.; Frangione, B.; Prelli, F.; Franklin, E.C.
Biochem. Biophys. Res. Commun. 71, 907-914, 1976
A; Title: The amino acid sequence of "heavy chain disease" protein ZUC. Structure
of the Fc fragment of immunoglobulin G3.
A; Reference number: A90198; MUID: 77021516; PMID: 823945
A; Contents: heavy chain disease protein Zuc, partial sequence corresponding to
residues 59-289 of protein Wis
A; Accession: A90198
A; Molecule type: protein
A; Residues: 59-125, 'EB', 128-226, 228-289 < WOL>
A; Note: this protein lacks most of the V region, all of the CH1 region, and part
of the hinge compared with normal gamma-3 heavy chains
R; Alexander, A.; Steinmetz, M.; Barritault, D.; Frangione, B.; Franklin, E.C.;
Hood, L.; Buxbaum, J.N.
Proc. Natl. Acad. Sci. U.S.A. 79, 3260-3264, 1982
A; Title: gamma heavy chain disease in man: cDNA sequence supports partial gene
deletion model.
A; Reference number: A93915; MUID: 82247835; PMID: 6808505
A; Contents: heavy chain disease protein Omm
A; Accession: A93915
A; Molecule type: mRNA
A; Residues: 12-70; 72-114; 116-125, 'E', 127-133, 'L', 135-136, 'E', 138, 'Y', 140-
154, 'D', 156-157, 'N', 159-181, 'A', 183-186; 199-226, 'N', 228-278, 'Y', 280-289 <ALE>
A; Note: a carboxyl-terminal Lys is removed posttranslationally
A; Note: this sequence may represent an allelic form or another gamma chain
subclass
C; Comment: The heavy chain disease protein Wis is shown.
C; Genetics:
A; Gene: GDB: IGHG3
A; Cross-references: GDB:119339; OMIM:147120
A; Map position: 14q32.33-14q32.33
C; Superfamily: immunoglobulin C region; immunoglobulin homology
C; Keywords: duplication; glycoprotein; immunoglobulin; pyroglutamic acid
F;203-270/Domain: immunoglobulin homology <IMM>
F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental
F;6,140/Binding site: carbohydrate (Asn) (covalent) #status experimental
  Query Match
                          90.5%; Score 1121; DB 1; Length 289;
  Best Local Similarity 90.3%; Pred. No. 4.2e-80;
  Matches 204; Conservative 13; Mismatches
                                                                 0; Gaps
                                                    9; Indels
```

0;

```
Qу
           2 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 61
                  Db
          64 DTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVOFKWYVD 123
          62 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKAK 121
Qу
             Db
         124 GVQVHNAKTKPREQQFNSTFRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKTK 183
Qу
         122 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 181
             Db
         184 GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPMLDS 243
         182 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 227
Qу
             Db
         244 DGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTQKSLSLSPG 289
RESULT 10
GHRB
Ig gamma chain C region - rabbit
C; Species: Oryctolagus cuniculus (domestic rabbit)
C;Date: 24-Apr-1984 #sequence revision 15-Nov-1984 #text change 16-Jul-1999
C; Accession: A91749; A90290; A93928; A90245; A94416; A02161
R; Bernstein, K.E.; Alexander, C.B.; Mage, R.G.
Immunogenetics 18, 387-397, 1983
A; Title: Nucleotide sequence of a rabbit IgG heavy chain from the recombinant F-
I haplotype.
A; Reference number: A91749; MUID: 84030930; PMID: 6313520
A; Accession: A91749
A; Molecule type: mRNA
A; Residues: 1-323 <BER>
A; Note: this sequence has the d12 allotypic marker, 104-Thr, and the e14 marker,
185-Thr
R; Pratt, D.M.; Mole, L.E.
Biochem. J. 151, 337-349, 1975
A; Title: Sequence studies on the constant region of the Fd sections of rabbit
immunoglobulin G of different allotype.
A; Reference number: A90290; MUID: 76135469; PMID: 1243651
A; Accession: A90290
A; Molecule type: protein
A; Residues: 1-47, 'E', 49-71, 'PV', 72-128 < PRA>
R; Martens, C.L.; Moore, K.W.; Steinmetz, M.; Hood, L.; Knight, K.L.
Proc. Natl. Acad. Sci. U.S.A. 79, 6018-6022, 1982
A; Title: Heavy chain genes of rabbit IgG; isolation of a cDNA encoding gamma
heavy chain and identification of two genomic C-gamma genes.
A; Reference number: A93928; MUID: 83299917; PMID: 6193512
A; Accession: A93928
A; Molecule type: mRNA
A; Residues: 88-103, 'M', 105-143, 'E', 145-184, 'A', 186, 'E', 188-266 < MAR>
A; Cross-references: GB:M16426; NID:g165111; PIDN:AAA31289.1; PID:g165112
A; Note: this sequence has the dll allotypic marker, 104-Met, and the el5
allotypic marker, 185-Ala
R; Fruchter, R.G.; Jackson, S.A.; Mole, L.E.; Porter, R.R.
Biochem. J. 116, 249-259, 1970
A; Title: Sequence studies of the Fd section of the heavy chain of rabbit
immunoglobulin G.
```

A; Reference number: A90245; MUID: 70110015; PMID: 5461106

```
A; Molecule type: protein
A; Residues: 132-143, 'E', 145-161 < FRU>
R; Hill, R.L.; Lebovitz, H.E.; Fellows Jr., R.E.; Delaney, R.
in Gamma Globulins, Nobel Symp. 3, Killander, J., ed., pp.109-127, Almqvist and
Wiksell, Stockholm, 1967
A; Reference number: A94416
A; Accession: A94416
A; Molecule type: protein
A; Residues: 129-131; 155-172, 'D', 174-184, 'A', 186, 'E', 188-200, 'D', 202-217, 'E', 219-
232, 'Q', 234-245, 'D', 247-255, 'G', 257-259, 'D', 261-265, 'D', 267-279, 'W', 281-
283, 'S', 285-322 <HIL>
A; Note: this has the el5 allotypic marker, 185-Ala
C; Complex: An immunoglobulin heterotetramer subunit consists of two identical
light (kappa or lambda) and two identical heavy (alpha, delta, epsilon, gamma,
or mu) chains usually stabilized by interchain disulfide bonds. In some cases,
such as IgA and IgM, the subunits associate into larger oligomers.
C; Superfamily: immunoglobulin C region; immunoglobulin homology
C; Keywords: duplication; glycoprotein; heterotetramer; immunoglobulin
F;20-82/Domain: immunoglobulin homology <IM1>
F;130-199/Domain: immunoglobulin homology <IM2>
F;236-303/Domain: immunoglobulin homology <IM3>
F;173/Binding site: carbohydrate (Asn) (covalent) #status predicted
 Query Match
                        74.2%; Score 918.5; DB 1; Length 323;
 Best Local Similarity
                        71.7%; Pred. No. 2.9e-64;
 Matches 167; Conservative 29; Mismatches
                                              32; Indels
           1 MDKT---HTC--PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK 55
Qу
                   Db
          91 VDKTVAPSTCSKPTCPPPELLGGPSVFIFPPKPKDTLMISRTPEVTCVVVDVSQDDPEVQ 150
QУ
          56 FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK 115
             Db
         151 FTWYINNEQVRTARPPLREQQFNSTIRVVSTLPITHQDWLRGKEFKCKVHNKALPAPIEK 210
         116 TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT 175
QУ
             211 TISKARGOPLEPKVYTMGPPREELSSRSVSLTCMINGFYPSDISVEWEKNGKAEDNYKTT 270
Db
Qу
         176 PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKSLSLSPGK 228
             271 PAVLDSDGSYFLYNKLSVPTSEWQRGDVFTCSVMHEALHNHYTQKSISRSPGK 323
Db
RESULT 11
I47160
Ig gamma 2b chain constant region - pig (fragment)
C; Species: Sus scrofa domestica (domestic pig)
C;Date: 21-Feb-1997 #sequence_revision 21-Feb-1997 #text change 21-Jan-2000
C; Accession: I47160
R; Kacskovics, I.; Sun, J.; Butler, J.E.
J. Immunol. 153, 3565-3573, 1994
A; Title: Five putative subclasses of swine IgG identified from the cDNA
sequences of a single animal.
A; Reference number: I47158; MUID: 95015845; PMID: 7930579
A; Accession: I47160
```

A; Accession: A90245

```
A; Molecule type: mRNA
A; Residues: 1-328 < KAC>
A; Cross-references: EMBL: U03780; NID: g433125; PIDN: AAA52218.1; PID: q433126
C; Genetics:
A;Gene: IgG2b
C; Superfamily: immunoglobulin C region; immunoglobulin homology
F;133-202/Domain: immunoglobulin homology <IMM>
 Query Match
                       73.2%; Score 906.5; DB 2; Length 328;
 Best Local Similarity
                       73.2%; Pred. No. 2.6e-63;
 Matches 164; Conservative 29; Mismatches
                                             28; Indels
                                                          3; Gaps
                                                                     2;
Qу
          7 CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH 66
             Db
         106 CPICPACE-SPGPSVFIFPPKPKDTLMISRTPQVTCVVVDVSQENPEVQFSWYVDGVEVH 164
          67 NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGOPRE 126
QУ
             165 TAQTRPKEEQFNSTYRVVSVLPIQHQDWLNGKEFKCKVNNKDLPAPITRIISKAKGQTRE 224
Db
         127 PQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ--PENNYKTTPPVLDSDGS 184
Qу
            Db
         225 PQVYTLPPHAEELSRSKVSITCLVIGFYPPDIDVEWQRNGQPEPEGNYRTTPPQODVDGT 284
Qу
         185 FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
            :[]]] :[]]: [] :[] :[]]]
         285 YFLYSKFSVDKASWQGGGIFQCAVMHEALHNHYTQKSISKTPGK 328
Db
RESULT 12
I47159
Ig gamma 2a chain constant region - pig (fragment)
C; Species: Sus scrofa domestica (domestic pig)
C;Date: 21-Feb-1997 #sequence revision 21-Feb-1997 #text change 21-Jan-2000
C; Accession: I47159
R; Kacskovics, I.; Sun, J.; Butler, J.E.
J. Immunol. 153, 3565-3573, 1994
A; Title: Five putative subclasses of swine IgG identified from the cDNA
sequences of a single animal.
A; Reference number: I47158; MUID: 95015845; PMID: 7930579
A; Accession: I47159
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-328 < KAC>
A; Cross-references: EMBL: U03779; NID: q433123; PIDN: AAA52217.1; PID: q433124
C; Genetics:
A;Gene: IqG2a
C; Superfamily: immunoglobulin C region; immunoglobulin homology
F;133-202/Domain: immunoglobulin homology <IMM>
 Query Match
                       73.2%; Score 906.5; DB 2;
                                                 Length 328;
 Best Local Similarity
                       73.2%; Pred. No. 2.6e-63;
 Matches 164; Conservative 29; Mismatches
                                             28;
                                                 Indels
                                                          3; Gaps
                                                                     2;
Qу
          7 CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH 66
```

A; Status: preliminary; translated from GB/EMBL/DDBJ

```
106 CPICPACE-SPGPSVFIFPPKPKDTLMISRTPQVTCVVVDVSQENPEVQFSWYVDGVEVH 164
Db
Qу
         67 NAKTKPREEQYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKAKGOPRE 126
             165 TAQTRPKEEQFNSTYRVVSVLPIQHQDWLNGKEFKCKVNNKDLPAPITRIISKAKGQTRE 224
Db
        127 PQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ--PENNYKTTPPVLDSDGS 184
Qу
            Db
        225 PQVYTLPPHAEELSRSKVSITCLVIGFYPPDIDVEWQRNGQPEPEGNYRTTPPQQDVDGT 284
Qу
        185 FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
            Db
        285 YFLYSKFSVDKASWQGGGIFQCAVMHEALHNHYTOKSISKTPGK 328
RESULT 13
I47162
Ig gamma 4 chain constant region - pig (fragment)
C; Species: Sus scrofa domestica (domestic pig)
C;Date: 21-Feb-1997 #sequence revision 21-Feb-1997 #text change 21-Jan-2000
C; Accession: I47162
R; Kacskovics, I.; Sun, J.; Butler, J.E.
J. Immunol. 153, 3565-3573, 1994
A; Title: Five putative subclasses of swine IqG identified from the cDNA
sequences of a single animal.
A; Reference number: I47158; MUID: 95015845; PMID: 7930579
A; Accession: I47162
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-277 < KAC>
A; Cross-references: EMBL: U03782; NID: g433129; PIDN: AAA52220.1; PID: g433130
C; Genetics:
A; Gene: IqG4
C; Superfamily: immunoglobulin C region; immunoglobulin homology
F;82-151/Domain: immunoglobulin homology <IMM>
 Query Match
                      73.0%; Score 903.5; DB 2; Length 277;
 Best Local Similarity
                      71.1%; Pred. No. 3.6e-63;
 Matches 167; Conservative 30; Mismatches
                                          31: Indels
                                                       7; Gaps
                                                                 4;
          1 MDK---THTCPPCP-APELLG-GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK 55
Qу
                43 VDKRVGTKTKPPCPICPACEGPGPSAFIFPPKPKDTLMISRTPKVTCVVVDVSOENPEVO 102
Db
Qу
         56 FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK 115
            103 FSWYVDGVEVHTAQTRPKEEQFNSTYRVVSVLPIQHQDWLNGKEFKCKVNNKDLPAPITR 162
Db
Qу
        116 TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ--PENNYK 173
             Db
        163 IISKAKGQTREPQVYTLPPPTEELSRSKVTLTCLVTGFYPPDIDVEWQRNGQPEPEGNYR 222
        174 TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
QУ
            Db
        223 TTPPQQDVDGTYFLYSKLAVDKASWQRGDTFQCAVMHEALHNHYTOKSIFKTPGK 277
```

```
RESULT 14
G2GP
Ig gamma-2 chain C region - quinea pig
C; Species: Cavia porcellus (quinea pig)
C;Date: 07-May-1981 #sequence_revision 07-May-1981 #text change 16-Jul-1999
C; Accession: A94553; A90352; A90359; A90384; A90385; A02151
R; Trischmann, T.M.
submitted to the Atlas, April 1975
A; Reference number: A94553
A; Accession: A94553
A; Molecule type: protein
A; Residues: 1-3 <TRI>
R; Birshtein, B.K.; Hussain, Q.Z.; Cebra, J.J.
Biochemistry 10, 18-25, 1971
A; Title: Structure of heavy chain from strain 13 guinea pig immunoglobulin-G(2).
III. Amino acid sequence of the region around the half-cystine joining heavy and
light chains.
A; Reference number: A90352; MUID: 71058471; PMID: 5538606
A; Accession: A90352
A; Molecule type: protein
A; Residues: 4-68 <BIR>
R; Turner, K.J.; Cebra, J.J.
Biochemistry 10, 9-17, 1971
A; Title: Structure of heavy chain from strain 13 guinea pig immunoglobulin-G(2).
II. Amino acid sequence of the carboxyl-terminal and hinge region cyanogen
bromide fragments.
A; Reference number: A90359; MUID: 71058486; PMID: 5538616
A; Accession: A90359
A; Molecule type: protein
A; Residues: 69-133;312-329 < TUR>
R; Tracey, D.E.; Cebra, J.J.
Biochemistry 13, 4796-4803, 1974
A; Title: Primary structure of the C-H2 homology region from guinea pig IgG2
antibodies.
A; Reference number: A90384; MUID: 75036072; PMID: 4429665
A; Accession: A90384
A; Molecule type: protein
A; Residues: 134-226 < TRA>
R; Trischmann, T.M.; Cebra, J.J.
Biochemistry 13, 4804-4811, 1974
A; Title: Primary structure of the C-H3 homology region from guinea pig IgG2
antibodies.
A; Reference number: A90385; MUID: 75036073; PMID: 4609467
A; Accession: A90385
A; Molecule type: protein
A; Residues: 227-311 <TR2>
R;Oliveira, B.; Lamm, M.E.
Biochemistry 10, 26-31, 1971
A; Title: Interchain disulfide bridges of guinea pig gamma-2- immunoglobulin.
A; Reference number: A90354; MUID: 71058474; PMID: 4922544
A; Contents: annotation; disulfide bonds
A; Note: Cys-16 is involved in a heavy-light chain bond
A; Note: Cys-105, Cys-107, and Cys-110 form inter-heavy chain bonds
C; Comment: This chain was isolated from pooled serum of strain 13 inbred guinea
C; Complex: An immunoglobulin heterotetramer subunit consists of two identical
light (kappa or lambda) and two identical heavy (alpha, delta, epsilon, gamma,
```

```
or mu) chains usually stabilized by interchain disulfide bonds. In some cases,
such as IqA and IqM, the subunits associate into larger oligomers.
C; Superfamily: immunoglobulin C region; immunoglobulin homology
C; Keywords: duplication; glycoprotein; heterotetramer; immunoglobulin
F;21-81/Domain: immunoglobulin homology <IM1>
F;135-204/Domain: immunoglobulin homology <IM2>
F;241-310/Domain: immunoglobulin homology <IM3>
F;28-79/Disulfide bonds: #status experimental
F;142-202/Disulfide bonds: #status experimental
F;178/Binding site: carbohydrate (Asn) (covalent) #status experimental
F;248-308/Disulfide bonds: #status experimental
                        71.8%; Score 889; DB 1; Length 329;
  Query Match
 Best Local Similarity
                        72.3%; Pred. No. 6e-62;
 Matches 162; Conservative 24; Mismatches
                                             36; Indels
                                                            2; Gaps
                                                                       1;
Qу
           6 TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV 65
             106 TCPKCPPPENLGGPSVFIFPPKPKDTLMISLTPRVTCVVVDVSQDEPEVQFTWFVDNKPV 165
Db
          66 HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR 125
Qу
              Db
         166 GNAETKPRVEQYNTTFRVESVLPIQHQDWLRGKEFKCKVYNKALPAPIEKTISKTKGAPR 225
Qу
         126 EPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP--ENNYKTTPPVLDSDG 183
              Db
         226 MPDVYTLPPSRDELSKSKVSVTCLIINFFPADIHVEWASNRVPVSEKEYKNTPPIEDADG 285
         184 SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 227
Qу
             Db
         286 SYFLYSKLTVDKSAWDQGTVYTCSVMHEALHNHVTQKAISRSPG 329
RESULT 15
I47158
Ig gamma 1 chain constant region - pig (fragment)
C; Species: Sus scrofa domestica (domestic pig)
C;Date: 21-Feb-1997 #sequence revision 21-Feb-1997 #text change 21-Jan-2000
C; Accession: I47158
R; Kacskovics, I.; Sun, J.; Butler, J.E.
J. Immunol. 153, 3565-3573, 1994
A; Title: Five putative subclasses of swine IgG identified from the cDNA
sequences of a single animal.
A; Reference number: I47158; MUID: 95015845; PMID: 7930579
A; Accession: I47158
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-328 < KAC>
A; Cross-references: EMBL: U03778; NID: g433121; PIDN: AAA52216.1; PID: g433122
C:Genetics:
A;Gene: IgG1
C; Superfamily: immunoglobulin C region; immunoglobulin homology
F;133-202/Domain: immunoglobulin homology <IMM>
 Query Match
                        71.5%; Score 885.5; DB 2; Length 328;
 Best Local Similarity
                      72.4%; Pred. No. 1.1e-61;
 Matches 163; Conservative 27; Mismatches
                                             32; Indels
                                                                       2;
```

Qу		TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV 65
Db	105	TCPICPGCE-VAGPSVFIFPPKPKDTLMISQTPEVTCVVVDVSKEHAEVQFSWYVDGVEV 163
Qy	66	HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR 125
Db	164	HTAETRPKEEQFNSTYRVVSVLPIQHQDWLKGKEFKCKVNNVDLPAPITRTISKAIGQSR 223
Qу	126	EPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG 183
Db	224	EPQVYTLPPPAEELSRSKVTLTCLVIGFYPPDIHVEWKSNGQPEPENTYRTTPPQQDVDG 283
Qy	184	SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228 :         :    :   :           : :
Db	284	TFFLYSKLAVDKARWDHGDKFECAVMHEALHNHYTQKSISKTQGK 328

Search completed: January 16, 2004, 09:39:52 Job time: 22 secs

# GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

January 16, 2004, 09:38:52; Search time 34 Seconds Run on:

(without alignments)

1371.227 Million cell updates/sec

Title: US-09-843-221A-2

Perfect score: 1238

Sequence: 1 MDKTHTCPPCPAPELLGGPS.....MHEALHNHYTQKSLSLSPGK 228

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 762491 segs, 204481190 residues

Total number of hits satisfying chosen parameters: 762491

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:\*

1: /cgn2 6/ptodata/1/pubpaa/US07 PUBCOMB.pep:\*

2: /cgn2 6/ptodata/1/pubpaa/PCT NEW PUB.pep:\*

3: /cgn2\_6/ptodata/1/pubpaa/US06\_NEW\_PUB.pep:\*

/cgn2 6/ptodata/1/pubpaa/US06 PUBCOMB.pep:\* 4:

/cgn2\_6/ptodata/1/pubpaa/US07\_NEW\_PUB.pep:\*

/cgn2 6/ptodata/1/pubpaa/PCTUS PUBCOMB.pep:\* 6:

7: /cgn2 6/ptodata/1/pubpaa/US08 NEW PUB.pep:\*

8: /cgn2 6/ptodata/1/pubpaa/US08 PUBCOMB.pep:\*

9: /cgn2\_6/ptodata/1/pubpaa/US09A PUBCOMB.pep:\*

10: /cgn2\_6/ptodata/1/pubpaa/US09B PUBCOMB.pep:\*

11: /cgn2 6/ptodata/1/pubpaa/US09C PUBCOMB.pep:\*

12: /cgn2\_6/ptodata/1/pubpaa/US09\_NEW\_PUB.pep:\*

13: /cgn2\_6/ptodata/1/pubpaa/US10A PUBCOMB.pep:\*

14: /cqn2 6/ptodata/1/pubpaa/US10B PUBCOMB.pep:\*

15: /cgn2 6/ptodata/1/pubpaa/US10C PUBCOMB.pep:\*

16: /cgn2\_6/ptodata/1/pubpaa/US10\_NEW\_PUB.pep:\*

17: /cgn2\_6/ptodata/1/pubpaa/US60 NEW PUB.pep:\*

/cgn2\_6/ptodata/1/pubpaa/US60 PUBCOMB.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

응

Result Query

> No. Score Match Length DB ID

Description

	- <b>-</b>			- <b>-</b> -		
1	1238	100.0	228	9	US-09-847-712-2	Sequence 2, Appli
2	1238	100.0	228	10	US-09-840-277-2	Sequence 2, Appli
3	1238	100.0	228	11	US-09-847-249A-2	Sequence 2, Appli
4	1238	100.0	228	11	US-09-843-221A-2	Sequence 2, Appli
5	1238	100.0	228	11	US-09-840-669B-2	Sequence 2, Appli
6	1238	100.0	228	12	US-10-269-806-32	Sequence 32, Appl
7	1238	100.0	228	12	US-10-145-206-2	Sequence 2, Appli
8	1238	100.0	243	12	US-10-269-806-152	Sequence 152, App
9	1238	100.0	250	12	US-10-269-695-243	Sequence 243, App
10	1238	100.0	250	12	US-10-410-998-243	Sequence 243, App
11	1238	100.0	282	10	US-09-840-277-109	Sequence 109, App
12	1238	100.0	401	12	US-09-389-782-8	Sequence 8, Appli
13	1234	99.7	229	14	US-10-215-297-2	Sequence 2, Appli
14	1234	99.7	229	15	US-10-215-298-2	Sequence 2, Appli
15	1234	99.7	248	12	US-10-145-206-111	Sequence 111, App
16	1234	99.7	248	12	US-10-145-206-112	Sequence 112, App
17	1234	99.7	248	12	US-10-145-206-113	Sequence 113, App
18	1234	99.7	252	12	US-10-145-206-114	Sequence 114, App
19	1234	99.7	252	12	US-10-145-206-115	Sequence 115, App
20	1234	99.7	252	12	US-10-145-206-116	Sequence 116, App
21	1234	99.7	252	12	US-10-145-206-117	Sequence 117, App
22	1234	99.7	252	12	US-10-145-206-118	Sequence 118, App
23	1234	99.7	252	12	US-10-145-206-119	Sequence 119, App
24	1234	99.7	252	12	US-10-145-206-120	Sequence 120, App
25	1234	99.7	252	12	US-10-145-206-121	Sequence 121, App
26	1234	99.7	252	12	US-10-145-206-122	Sequence 122, App
27	1234	99.7	261	12	US-10-435-608-6	Sequence 6, Appli
28	1234	99.7	266	12	US-10-390-566-8	Sequence 8, Appli
29	1234	99.7	266	12	US-10-390-566-15	Sequence 15, Appl
30	1234	99.7	266	12	US-10-390-566-21	Sequence 21, Appl
31	1234	99.7	266	12	US-10-390-566-28	Sequence 28, Appl
32	1234	99.7	293	12	US-10-145-206-123	Sequence 123, App
33	1234	99.7	293	12	US-10-145-206-124	Sequence 124, App
34	1234	99.7	302	15	US-10-115 <b>-</b> 192-12	Sequence 12, Appl
35	1234	99.7	347	9	US-09-796-033-8	Sequence 8, Appli
36	1234	99.7	347	9	US-09-730-465-8	Sequence 8, Appli
37	1234	99.7	347	12	US-10-329-599-8	Sequence 8, Appli
38	1234	99.7	347	14	US-10-091-236-17	Sequence 17, Appl
39	1234	99.7				Sequence 7, Appli
40	1234	99.7	347	15	US-10-091-268-7	Sequence 7, Appli
41	1234	99.7	360	12	US-10-390-566-7	Sequence 7, Appli
42	1234	99.7	360	12	US-10-390-566-14	Sequence 14, Appl
43	1234	99.7	360	12	US-10-390-566-20	Sequence 20, Appl
44	1234	99.7	360	12	US-10-390-566-27	Sequence 27, Appl
45	1234	99.7	367	12	US-10-390-566-6	Sequence 6, Appli

# ALIGNMENTS

#### RESULT 1

US-09-847-712-2

<sup>;</sup> Sequence 2, Application US/09847712 ; Patent No. US20020090646A1

<sup>;</sup> GENERAL INFORMATION:

<sup>;</sup> APPLICANT: LIU, CHUAN-FA

```
APPLICANT: MARSHALL, WILLIAM S.
  APPLICANT: REYNOLDS, ANGELA
  TITLE OF INVENTION: CALCITONIN-RELATED MOLECULES
  FILE REFERENCE: A-684
  CURRENT APPLICATION NUMBER: US/09/847,712
  CURRENT FILING DATE: 2001-05-02
  PRIOR APPLICATION NUMBER: 60/201,511
  PRIOR FILING DATE: 2000-05-03
  NUMBER OF SEQ ID NOS: 26
  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
   LENGTH: 228
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-847-712-2
 Query Match
                      100.0%; Score 1238; DB 9; Length 228;
 Best Local Similarity
                      100.0%; Pred. No. 1.9e-99;
 Matches 228; Conservative 0; Mismatches
                                            0; Indels
                                                         0; Gaps
                                                                    0;
Qу
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
            1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Db
         61 DGVEVHNAKTKPREEOYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
            Db
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
            Db
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
            Db
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKSLSLSPGK 228
RESULT 2
US-09-840-277-2
; Sequence 2, Application US/09840277
; Patent No. US20020168363A1
; GENERAL INFORMATION:
  APPLICANT: FEIGE, ULRICH
  APPLICANT: KOHNO, TADAHIKO
  APPLICANT: LACEY, DAVID LEE
  APPLICANT: BOONE, THOMAS CHARLES
  TITLE OF INVENTION: INTEGRIN/ADHESION ANTAGONISTS
  FILE REFERENCE: A-688A
  CURRENT APPLICATION NUMBER: US/09/840,277
  CURRENT FILING DATE: 2001-08-14
  PRIOR APPLICATION NUMBER: 60/198,919
  PRIOR FILING DATE: 2000-04-21
  PRIOR APPLICATION NUMBER: 60/201,394
  PRIOR FILING DATE: 2000-05-03
  NUMBER OF SEQ ID NOS: 135
 SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
```

```
LENGTH: 228
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-840-277-2
 Query Match
                     100.0%; Score 1238; DB 10; Length 228;
 Best Local Similarity
                     100.0%; Pred. No. 1.9e-99;
 Matches 228; Conservative
                           0; Mismatches
                                          0;
                                             Indels
                                                      0; Gaps
                                                                0;
Qу
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
            Db
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
QУ
            Db
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
            Db
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
            Db
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
RESULT 3
US-09-847-249A-2
; Sequence 2, Application US/09847249A
; Publication No. US20030032588A1
; GENERAL INFORMATION:
  APPLICANT: MARSHALL, WILLIAM S.
  APPLICANT: STARK, KEVIN LEE
  TITLE OF INVENTION: GLUCAGON ANTAGONIST
  FILE REFERENCE: A-693
  CURRENT APPLICATION NUMBER: US/09/847,249A
  CURRENT FILING DATE: 2001-05-02
  PRIOR APPLICATION NUMBER: 60/201,436
  PRIOR FILING DATE: 2000-05-03
  NUMBER OF SEQ ID NOS: 80
  SOFTWARE: PatentIn version 3.1
 SEQ ID NO 2
   LENGTH: 228
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-847-249A-2
 Query Match
                     100.0%; Score 1238; DB 11;
                                             Length 228;
 Best Local Similarity
                     100.0%; Pred. No. 1.9e-99;
 Matches 228; Conservative
                         0; Mismatches
                                          0:
                                             Indels
                                                      0; Gaps
                                                                0;
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Qу
           Db
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Qу
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
```

```
Db
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
            121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Db
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Qу
            Db
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
RESULT 4
US-09-843-221A-2
; Sequence 2, Application US/09843221A
; Publication No. US20030039654A1
; GENERAL INFORMATION:
  APPLICANT: KOSTENUIK, PAUL
  APPLICANT: LIU, CHUAN-FA
  APPLICANT: LACEY, DAVID LEE
  TITLE OF INVENTION: MODULATORS OF RECEPTORS FOR PARATHYROID HORMONE AND
PARATHYROID HORMONE-
  TITLE OF INVENTION: RELATED PROTEIN
  FILE REFERENCE: A-665B
  CURRENT APPLICATION NUMBER: US/09/843,221A
  CURRENT FILING DATE: 2001-04-26
  PRIOR APPLICATION NUMBER: 60/266,673
  PRIOR FILING DATE: 2001-02-06
  PRIOR APPLICATION NUMBER: 60/214,860
  PRIOR FILING DATE: 2000-06-28
  PRIOR APPLICATION NUMBER: 60/200,053
  PRIOR FILING DATE: 2000-04-27
  NUMBER OF SEQ ID NOS: 170
  SOFTWARE: PatentIn version 3.1
 SEO ID NO 2
   LENGTH: 228
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-843-221A-2
 Query Match
                      100.0%; Score 1238; DB 11;
                                              Length 228;
 Best Local Similarity
                      100.0%; Pred. No. 1.9e-99;
 Matches 228; Conservative
                          0; Mismatches
                                              Indels
                                           0;
                                                       0;
                                                          Gaps
                                                                 0;
Qу
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
            Db
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Qу
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKA 120
            Db
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
            Db
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Qу
```

```
RESULT 5
US-09-840-669B-2
; Sequence 2, Application US/09840669B
; Publication No. US20030040470A1
; GENERAL INFORMATION:
  APPLICANT: KOHNO, TADAHIKO
  TITLE OF INVENTION: APO-AI/AII PEPTIDE DERIVATIVES
  FILE REFERENCE: A-690
  CURRENT APPLICATION NUMBER: US/09/840,669B
  CURRENT FILING DATE: 2002-06-07
  PRIOR APPLICATION NUMBER: 60/198,920
  PRIOR FILING DATE: 2000-04-21
  NUMBER OF SEQ ID NOS: 11
  SOFTWARE: PatentIn version 3.1
; SEO ID NO 2
   LENGTH: 228
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-840-669B-2
 Query Match
                       100.0%; Score 1238; DB 11; Length 228;
 Best Local Similarity 100.0%; Pred. No. 1.9e-99;
 Matches 228; Conservative 0; Mismatches
                                            0; Indels
                                                         0; Gaps
                                                                   0;
Qу
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
            Db
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Qу
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKA 120
            Db
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKA 120
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Оy
            Db
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLD 180
Qу
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
            Db
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
RESULT 6
US-10-269-806-32
; Sequence 32, Application US/10269806
; Publication No. US20030176352A1
; GENERAL INFORMATION:
; APPLICANT: Min, Hosung
; APPLICANT: Sitney, Karen
  APPLICANT: Hartley, Cynthia
  TITLE OF INVENTION: Peptides and Related Compounds Having Thrombopoietic
Activity
; FILE REFERENCE: A-750
  CURRENT APPLICATION NUMBER: US/10/269,806
```

; CURRENT FILING DATE: 2002-10-10

```
; NUMBER OF SEQ ID NOS: 199
  SOFTWARE: PatentIn version 3.1
; SEO ID NO 32
   LENGTH: 228
   TYPE: PRT
   ORGANISM: Artificial Sequence
   FEATURE:
   OTHER INFORMATION: Synthesized Peptide Sequence
US-10-269-806-32
 Query Match
                       100.0%; Score 1238; DB 12; Length 228;
 Best Local Similarity 100.0%; Pred. No. 1.9e-99;
 Matches 228; Conservative
                          0; Mismatches
                                            0; Indels
                                                         0; Gaps
                                                                    0;
Qу
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
            Db
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
0v
            Db
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
            Db
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
            Db
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
RESULT 7
US-10-145-206-2
; Sequence 2, Application US/10145206
; Publication No. US20030195156A1
; GENERAL INFORMATION:
; APPLICANT: MIN, HOSUNG
  APPLICANT: HSU, HAILING
  APPLICANT: ZIONG, FEI
  TITLE OF INVENTION: PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1
  FILE REFERENCE: A-743
  CURRENT APPLICATION NUMBER: US/10/145,206
  CURRENT FILING DATE: 2002-05-13
  PRIOR APPLICATION NUMBER: US 60/290,196
  PRIOR FILING DATE: 2001-05-11
  NUMBER OF SEO ID NOS: 197
  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
   LENGTH: 228
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-145-206-2
 Query Match 100.0%; Score 1238; DB 12; Length 228; Best Local Similarity 100.0%; Pred. No. 1.9e-99;
 Matches 228; Conservative 0; Mismatches 0; Indels
                                                         0; Gaps
                                                                    0;
```

```
Qу
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
            Db
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
           61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Dh
Qу
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
            Db
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
            Db
        181 SDGSFFLYSKLTVDKSRWOOGNVFSCSVMHEALHNHYTOKSLSLSPGK 228
RESULT 8
US-10-269-806-152
; Sequence 152, Application US/10269806
; Publication No. US20030176352A1
; GENERAL INFORMATION:
  APPLICANT: Min, Hosung
  APPLICANT: Sitney, Karen
  APPLICANT: Hartley, Cynthia
  TITLE OF INVENTION: Peptides and Related Compounds Having Thrombopoietic
Activity
  FILE REFERENCE: A-750
  CURRENT APPLICATION NUMBER: US/10/269,806
  CURRENT FILING DATE: 2002-10-10
  NUMBER OF SEQ ID NOS: 199
  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 152
   LENGTH: 243
   TYPE: PRT
   ORGANISM: Artificial Sequence
   FEATURE:
   OTHER INFORMATION: Synthesized Peptide Sequence
US-10-269-806-152
 Query Match
                     100.0%; Score 1238; DB 12; Length 243;
 Best Local Similarity
                     100.0%; Pred. No. 2e-99;
 Matches 228; Conservative
                           0; Mismatches
                                         0;
                                             Indels
                                                        Gaps
                                                               0;
Qу
         1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
           Db
         1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Qу
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
           61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Dh
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Οv
           121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Db
Qу
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
```

Db

```
RESULT 9
US-10-269-695-243
; Sequence 243, Application US/10269695
; Publication No. US20030229023A1
; GENERAL INFORMATION:
  APPLICANT: OLINER, JONATHAN DANIEL
  APPLICANT: MIN, HOSUNG
  TITLE OF INVENTION: SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2
; FILE REFERENCE: A-801A
  CURRENT APPLICATION NUMBER: US/10/269,695
; CURRENT FILING DATE: 2002-10-10
  PRIOR APPLICATION NUMBER: US 60/414,155
  PRIOR FILING DATE: 2002-09-27
  PRIOR APPLICATION NUMBER: US 60/328,624
  PRIOR FILING DATE: 2001-10-11
  NUMBER OF SEQ ID NOS: 359
  SOFTWARE: PatentIn version 3.1
; SEO ID NO 243
   LENGTH: 250
   TYPE: PRT
   ORGANISM: Artificial Sequence
   OTHER INFORMATION: DNA encoding peptide capable of binding to Ang-2
US-10-269-695-243
 Query Match
                      100.0%; Score 1238; DB 12; Length 250;
 Best Local Similarity 100.0%; Pred. No. 2.1e-99;
 Matches 228; Conservative 0; Mismatches
                                          0;
                                               Indels
                                                        0; Gaps 0;
Qу
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
            Db
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
            61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Db
Qу
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
            Db
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
            Db
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKSLSLSPGK 228
```

#### RESULT 10

US-10-410-998-243

- ; Sequence 243, Application US/10410998
- ; Publication No. US20030236193A1
- ; GENERAL INFORMATION:
- ; APPLICANT: OLINER, JONATHAN DANIEL
- ; APPLICANT: MIN, HOSUNG

```
TITLE OF INVENTION: SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2
  FILE REFERENCE: A-801A
  CURRENT APPLICATION NUMBER: US/10/410,998
  CURRENT FILING DATE: 2003-04-09
  PRIOR APPLICATION NUMBER: US/10/269,695
  PRIOR FILING DATE: 2002-10-10
  PRIOR APPLICATION NUMBER: US 60/414,155
  PRIOR FILING DATE: 2002-09-27
  PRIOR APPLICATION NUMBER: US 60/328,624
  PRIOR FILING DATE: 2001-10-11
  NUMBER OF SEQ ID NOS: 359
  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 243
   LENGTH: 250
   TYPE: PRT
   ORGANISM: Artificial Sequence
   FEATURE:
   OTHER INFORMATION: DNA encoding peptide capable of binding to Ang-2
US-10-410-998-243
                       100.0%; Score 1238; DB 12; Length 250; 100.0%; Pred. No. 2.1e-99;
 Query Match
 Best Local Similarity
 Matches 228; Conservative 0; Mismatches
                                             0;
                                                 Indels
                                                          0; Gaps
                                                                     0:
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Qу
            Db
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
QУ
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
            Dh
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLD 180
            Db
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLD 180
Qу
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
            Db
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
RESULT 11
US-09-840-277-109
; Sequence 109, Application US/09840277
; Patent No. US20020168363A1
; GENERAL INFORMATION:
; APPLICANT: FEIGE, ULRICH
  APPLICANT: KOHNO, TADAHIKO
  APPLICANT: LACEY, DAVID LEE
  APPLICANT: BOONE, THOMAS CHARLES
  TITLE OF INVENTION: INTEGRIN/ADHESION ANTAGONISTS
  FILE REFERENCE: A-688A
  CURRENT APPLICATION NUMBER: US/09/840,277
  CURRENT FILING DATE: 2001-08-14
  PRIOR APPLICATION NUMBER: 60/198,919
  PRIOR FILING DATE: 2000-04-21
  PRIOR APPLICATION NUMBER: 60/201,394
```

```
PRIOR FILING DATE: 2000-05-03
  NUMBER OF SEQ ID NOS: 135
  SOFTWARE: PatentIn version 3.1
; SEO ID NO 109
   LENGTH: 282
   TYPE: PRT
   ORGANISM: Artificial Sequence
   FEATURE:
   OTHER INFORMATION: Echistatin Fc-peptide
   NAME/KEY: misc_feature
   LOCATION: (1)..(1)
   OTHER INFORMATION: NdeI site
   NAME/KEY: misc_feature
   LOCATION: (854)..(854)
   OTHER INFORMATION: BamHI site
US-09-840-277-109
  Query Match
                       100.0%; Score 1238; DB 10; Length 282;
 Best Local Similarity
                       100.0%; Pred. No. 2.5e-99;
 Matches 228; Conservative 0; Mismatches
                                            0; Indels
                                                         0; Gaps
                                                                    0;
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Qу
            Db
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Qу
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
            Db
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
            Db
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
QУ
            Db
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
RESULT 12
US-09-389-782-8
; Sequence 8, Application US/09389782
; Publication No. US20030144187A1
; GENERAL INFORMATION:
; APPLICANT: Wooden, Scott K.
  APPLICANT: Mann, Michael B.
  APPLICANT: Dunstan, Colin R.
  TITLE OF INVENTION: OPG Fusion Protein Compositions and Methods
  FILE REFERENCE: A-604
  CURRENT APPLICATION NUMBER: US/09/389,782
  CURRENT FILING DATE: 1999-09-03
  NUMBER OF SEQ ID NOS: 50
  SOFTWARE: PatentIn Ver. 2.1
; SEO ID NO 8
   LENGTH: 401
   TYPE: PRT
   ORGANISM: Human
US-09-389-782-8
```

```
Query Match
                      100.0%; Score 1238; DB 12; Length 401;
 Best Local Similarity 100.0%; Pred. No. 3.8e-99;
 Matches 228; Conservative 0; Mismatches 0; Indels
                                                       0; Gaps
                                                                 0;
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Qу
            Db
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
QУ
            Db
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLD 180
QУ
            Db
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
QУ
            Db
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
RESULT 13
US-10-215-297-2
; Sequence 2, Application US/10215297
; Publication No. US20020192222A1
; GENERAL INFORMATION:
  APPLICANT: Blumberg, Richard S.
  APPLICANT: Simister, Neil E.
  APPLICANT: Lencer, Wayne I.
  TITLE OF INVENTION: RECEPTOR SPECIFIC TRANSEPITHELIAL TRANSPORT OF
  TITLE OF INVENTION: THERAPEUTICS
  FILE REFERENCE: S1383/7003
  CURRENT APPLICATION NUMBER: US/10/215,297
  CURRENT FILING DATE: 2002-08-08
  PRIOR APPLICATION NUMBER: US 08/578,171
  PRIOR FILING DATE: 1995-12-29
  PRIOR APPLICATION NUMBER: US 08/374,159
  PRIOR FILING DATE: 1995-01-17
  PRIOR APPLICATION NUMBER: US 09/122,144
  PRIOR FILING DATE: 1998-07-24
 NUMBER OF SEQ ID NOS: 22
; SEQ ID NO 2
   LENGTH: 229
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-215-297-2
 Query Match
                      99.7%; Score 1234; DB 14; Length 229;
 Best Local Similarity 99.6%; Pred. No. 4.2e-99;
 Matches 227; Conservative 1; Mismatches
                                          0; Indels
                                                       0; Gaps
Qу
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
            Db
          2 VDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 61
Qу
        61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
```

```
Db
        62 DGVEVHNAKTKPREEOYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKA 121
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
           122 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 181
Db
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Qу
           Db
        182 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 229
RESULT 14
US-10-215-298-2
; Sequence 2, Application US/10215298
; Publication No. US20030012789A1
; GENERAL INFORMATION:
  APPLICANT: Blumberg, Richard S.
  APPLICANT: Simister, Neil E.
  APPLICANT: Lencer, Wayne I.
  TITLE OF INVENTION: RECEPTOR SPECIFIC TRANSEPITHELIAL TRANSPORT OF
THERAPEUTICS
  FILE REFERENCE: S1383/7003
  CURRENT APPLICATION NUMBER: US/10/215,298
  CURRENT FILING DATE: 2002-08-08
  PRIOR APPLICATION NUMBER: US 09/122,144
  PRIOR FILING DATE: 1998-07-24
  NUMBER OF SEQ ID NOS: 22
 SEQ ID NO 2
   LENGTH: 229
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-215-298-2
 Query Match
                     99.7%; Score 1234; DB 15; Length 229;
 Best Local Similarity
                    99.6%; Pred. No. 4.2e-99;
 Matches 227; Conservative
                          1; Mismatches
                                        0; Indels
                                                    0;
                                                       Gaps
                                                              0;
Qу
         1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
           Dh
         2 VDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 61
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
           Db
         62 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 121
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
           122 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLD 181
Db
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Qу
           182 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 229
Db
```

RESULT 15 US-10-145-206-111

```
; Sequence 111, Application US/10145206
; Publication No. US20030195156A1
; GENERAL INFORMATION:
  APPLICANT: MIN, HOSUNG
  APPLICANT: HSU, HAILING
  APPLICANT: ZIONG, FEI
  TITLE OF INVENTION: PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1
  FILE REFERENCE: A-743
  CURRENT APPLICATION NUMBER: US/10/145,206
  CURRENT FILING DATE: 2002-05-13
  PRIOR APPLICATION NUMBER: US 60/290,196
  PRIOR FILING DATE: 2001-05-11
  NUMBER OF SEQ ID NOS: 197
  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 111
   LENGTH: 248
   TYPE: PRT
   ORGANISM: Artificial Sequence
   OTHER INFORMATION: TALL-1 inhibitory peptibodies
US-10-145-206-111
 Query Match
                      99.7%; Score 1234; DB 12; Length 248;
 Best Local Similarity
                      99.6%;
                             Pred. No. 4.6e-99;
 Matches 227; Conservative
                            1; Mismatches
                                          0; Indels
                                                       0; Gaps
                                                                  0;
Qу
          1 MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
            Db
         21 VDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 80
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
            81 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 140
Db
Qу
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
            141 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 200
Db
QУ
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
            Db
        201 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 248
```

Search completed: January 16, 2004, 09:46:30 Job time: 34 secs

# GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 16, 2004, 09:36:27; Search time 36 Seconds

(without alignments)

1634.333 Million cell updates/sec

Title: US-09-843-221A-2

Perfect score: 1238

Sequence: 1 MDKTHTCPPCPAPELLGGPS......MHEALHNHYTQKSLSLSPGK 228

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 830525 seqs, 258052604 residues

Total number of hits satisfying chosen parameters: 830525

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SPTREMBL 23:\*

1: sp\_archea:\*
2: sp bacteria:\*

3: sp\_fungi:\*

4: sp\_human:\*

5: sp\_invertebrate:\*

6: sp\_mammal:\*

7: sp mhc:\*

8: sp organelle:\*

9: sp\_phage:\*

10: sp\_plant:\*

11: sp rodent:\*

12: sp\_virus:\*

13: sp\_vertebrate:\*

14: sp\_unclassified:\*

15: sp\_rvirus:\*

16: sp\_bacteriap:\*

17: sp\_archeap:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

### SUMMARIES

Result Query

No. Score Match Length DB ID Description

1	1233	99.6	471	4	Q8TC77	Q8tc77 homo sapien
2	1233	99.6	701	4	Q96PQ8	Q96pq8 homo sapien
3	1142	92.2	521	4	Q8N4Y9	Q8n4y9 homo sapien
4	1135	91.7	473	4	Q8TC63	Q8tc63 homo sapien
5	1131	91.4	509	4	Q8NF17	Q8nf17 homo sapien
6	909	73.4	337	6	Q95M34	Q95m34 equus cabal
7	831.5	67.2	469	11	Q8R3V9	Q8r3v9 mus musculu
8	828.5	66.9	463	11	Q99LC4	Q991c4 mus musculu
9	824.5	66.6	437	11	Q9R1A4	Q9rla4 mus musculu
10	811	65.5	473	11	Q9D8L4	Q9d8l4 mus musculu
11	805	65.0	468	11	Q99L31	Q99131 mus musculu
12	805	65.0	473	11	Q99L25	Q99125 mus musculu
13	780	63.0	473	11	Q91Z05	Q91z05 mus musculu
14	780	63.0	474	11	Q8R3H6	Q8r3h6 mus musculu
15	358	28.9	375	4	Q9BSZ1	Q9bsz1 homo sapien
16	358	28.9	597	4	Q9BU10	Q9bu10 homo sapien
17	358	28.9	597	4	Q9BQB8	Q9bqb8 homo sapien
18	358	28.9	597	4	Q96BB9	Q96bb9 homo sapien
19	348	28.1	588	4	Q8WUX4	Q8wux4 homo sapien
20	348	28.1	613	4	Q96EY0	Q96ey0 homo sapien
21	348	28.1	613	4	Q8WUK1	Q8wuk1 homo sapien
22	348	28.1	614	4	Q96GA6	Q96ga6 homo sapien
23	348	28.1	618	4	Q96AA6	Q96aa6 homo sapien
24	347	28.0	613	11	Q8VCX7	Q8vcx7 mus musculu
25	272.5	22.0	684	13	Q90544	Q90544 ginglymosto
26	272	22.0	384	4	Q9UP60	Q9up60 homo sapien
27	272	22.0	493	4	Q8NCL6	Q8ncl6 homo sapien
28	272	22.0	494	4	Q96K68	Q96k68 homo sapien
29	272	22.0	496	4	Q96KX8	Q96kx8 homo sapien
30	269	21.7	496	4	Q96DK0	Q96dk0 homo sapien
31	269	21.7	499	4	Q8N5K4	Q8n5k4 homo sapien
32	267	21.6	416	4	Q9NPP6	Q9npp6 homo sapien
33	267	21.6	497	4	Q8WY24	Q8wy24 homo sapien
34	267	21.6	500	4	Q9BRV0	Q9brv0 homo sapien
35	261	21.1	486	11	Q91Z07	Q91z07 mus musculu
36	261	21.1	487	11	Q99KA4	Q99ka4 mus musculu
37	260	21.0	426	11	Q9DCD9	Q9dcd9 mus musculu
38	253.5	20.5	481	11	Q91WT3	Q91wt3 mus musculu
39	253.5	20.5	481	11	Q91WT1	Q91wt1 mus musculu
40	253.5	20.5	482	11	Q91X92	Q91x92 mus musculu
41	253.5	20.5	482	11	Q8K172	Q8k172 mus musculu
42	253.5	20.5	484	11	Q8VEA0	Q8vea0 mus musculu
43	253.5	20.5	488	11	Q91WR1	Q91wr1 mus musculu
44	253.5	20.5	488	11	Q8K0F2	Q8k0f2 mus musculu
45	253.5	20.5	489	11	Q8VCX4	Q8vcx4 mus musculu
						~

# ALIGNMENTS

# RESULT 1 Q8TC77 ID Q8TC77 PRELIMINARY; PRT; 471 AA. AC Q8TC77; DT 01-JUN-2002 (TrEMBLrel. 21, Created) DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update) DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)

```
Hypothetical protein.
OS
    Homo sapiens (Human).
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
    NCBI TaxID=9606;
RN
     [1]
RP
    SEQUENCE FROM N.A.
RC
    TISSUE=Spleen;
RA
    Strausberg R.;
RL
    Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
DR
    EMBL; BC024289; AAH24289.1; -.
DR
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003006; Ig MHC.
DR
    InterPro; IPR003596; Ig v.
DR
    Pfam; PF00047; ig; 4.
DR
    SMART; SM00406; IGv; 1.
DR
    PROSITE; PS50835; IG LIKE; 4.
DR
    PROSITE; PS00290; IG MHC; 2.
KW
    Hypothetical protein.
              471 AA; 51791 MW; 388F7F4CF588660E CRC64;
SQ
    SEQUENCE
                       99.6%; Score 1233; DB 4; Length 471;
  Query Match
  Best Local Similarity
                       100.0%; Pred. No. 3.9e-108;
 Matches 227; Conservative 0; Mismatches
                                              0; Indels
                                                           0;
                                                              Gaps
                                                                      0;
Qу
           2 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 61
             Db
         245 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 304
Qу
          62 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 121
             Db
         305 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 364
Qу
         122 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 181
             Db
         365 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLDS 424
Qу
         182 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
             Db
         425 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 471
RESULT 2
Q96P08
ΙD
    Q96PQ8
               PRELIMINARY;
                               PRT;
                                      701 AA.
AC
DΨ
    01-DEC-2001 (TrEMBLrel. 19, Created)
    01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT
    01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DT
DE
    Factor VII active site mutant immunoconjugate.
OS
    Homo sapiens (Human).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
OX
    NCBI TaxID=9606;
RN
    [1]
ŘР
    SEQUENCE FROM N.A.
RX
    MEDLINE=21477448; PubMed=11593034;
```

DE

```
RA
     Hu Z., Garen A.;
RT
     "Targeting tissue factor on tumor vascular endothelial cells and tumor
RT
     cells for immunotherapy in mouse models of prostatic cancer.";
RL
     Proc. Natl. Acad. Sci. U.S.A. 98:12180-12185(2001).
CC
     -!- SIMILARITY: BELONGS TO PEPTIDASE FAMILY S1.
DR
     EMBL; AF272774; AAK58686.1; -.
DR
    HSSP; P00761; 1AN1.
DR
     InterPro; IPR000152; Asx hydroxyl.
DR
     InterPro; IPR001314; Chymotrypsin.
DR
     InterPro; IPR000742; EGF 2.
DR
     InterPro; IPR001881; EGF Ca.
DR
     InterPro; IPR001438; EGF II.
     InterPro; IPR006209; EGF like.
DR
     InterPro; IPR002383; GLA blood.
DR
     InterPro; IPR007110; Ig-like.
DR
DR
     InterPro; IPR003597; Ig c1.
DR
     InterPro; IPR003006; Ig MHC.
DR
     InterPro; IPR001254; Ser protease Try.
DR
     InterPro; IPR000294; VitK dep GLA.
DR
     Pfam; PF00008; EGF; 2.
DR
    Pfam; PF00594; gla; 1.
DR
    Pfam; PF00047; ig; 2.
DR
    Pfam; PF00089; trypsin; 1.
DR
    PRINTS; PR00722; CHYMOTRYPSIN.
    PRINTS; PR00010; EGFBLOOD.
DR
DR
    PRINTS; PR00001; GLABLOOD.
    SMART; SM00179; EGF_CA; 1.
DR
    SMART; SM00069; GLA; 1.
DR
DR
    SMART; SM00407; IGc1; 1.
DR
    SMART; SM00020; Tryp SPc; 1.
DR
    PROSITE; PS00010; ASX HYDROXYL: 1.
DR
    PROSITE; PS00022; EGF 1; 1.
DR
    PROSITE; PS01186; EGF 2; 1.
    PROSITE; PS01187; EGF_CA; 1.
DR
DR
    PROSITE; PS00011; GLU_CARBOXYLATION; 1.
DR
    PROSITE; PS50835; IG LIKE; 2.
DR
    PROSITE; PS00290; IG MHC; 1.
    PROSITE; PS50240; TRYPSIN_DOM; 1.
DR
DR
    PROSITE; PS00134; TRYPSIN HIS; 1.
DR
    PROSITE; PS00135; TRYPSIN SER; 1.
KW
    EGF-like domain; Hydrolase; Protease; Serine protease.
SO
              701 AA; 77826 MW; 94AC6CEB42CC992F CRC64;
    SEQUENCE
 Query Match
                        99.6%; Score 1233; DB 4; Length 701;
 Best Local Similarity
                        100.0%; Pred. No. 6.4e-108;
 Matches 227; Conservative 0; Mismatches
                                              0;
                                                  Indels
                                                             0; Gaps
                                                                        0:
           2 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 61
Ov
             Db
         475 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 534
          62 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 121
Ov
             535 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 594
Db
         122 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 181
Qу
```

```
Db
        595 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 654
OУ
        182 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKSLSLSPGK 228
            Db
         655 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 701
RESULT 3
Q8N4Y9
ID
    Q8N4Y9
              PRELIMINARY;
                              PRT;
                                     521 AA.
AC
    Q8N4Y9;
DT
    01-OCT-2002 (TrEMBLrel. 22, Created)
    01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT
    01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DT
    Hypothetical protein.
DE
OS
    Homo sapiens (Human).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
    NCBI TaxID=9606:
RN
    [1]
RΡ
    SEQUENCE FROM N.A.
RC
    TISSUE=Primary B-Cells from Tonsils;
RA
    Strausberg R.;
RL
    Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases.
DR
    EMBL; BC033178; AAH33178.1; -.
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003597; Ig cl.
    InterPro; IPR003006; Ig MHC.
DR
DR
    InterPro; IPR003596; Ig v.
DR
    Pfam; PF00047; ig; 4.
DR
    SMART; SM00407; IGc1; 3.
DR
    SMART; SM00406; IGv; 1.
DR
    PROSITE; PS50835; IG LIKE; 4.
DR
    PROSITE; PS00290; IG MHC; 2.
KW
    Hypothetical protein.
SO
    SEOUENCE
             521 AA; 57156 MW; 2AC7D22E72D6CAA2 CRC64;
 Query Match
                      92.2%; Score 1142; DB 4; Length 521;
 Best Local Similarity
                      92.1%; Pred. No. 1.8e-99;
 Matches 209; Conservative 9; Mismatches
                                           9; Indels
                                                         0; Gaps
                                                                    0;
Qу
          2 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 61
                Db
        295 DTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVD 354
Qу
         62 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 121
            Db
        355 GVEVHNAKTKPREEOFNSTFRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKTK 414
        122 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 181
Qу
            Db
        415 GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPMLDS 474
Qу
        182 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
            Db
        475 DGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTQKSLSLSPGK 521
```

```
RESULT 4
08TC63
ID
               PRELIMINARY;
                               PRT;
    08TC63
                                     473 AA.
AC
    O8TC63;
DT
    01-JUN-2002 (TrEMBLrel. 21, Created)
    01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT
    01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DT
DE
    Hypothetical protein.
OS
    Homo sapiens (Human).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
    NCBI TaxID=9606;
RN
    [1]
RP
    SEQUENCE FROM N.A.
    TISSUE=Kidney;
RC
RA
    Strausberg R.;
    Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RL
DR
    EMBL; BC025985; AAH25985.1; -.
DR
    InterPro; IPR000923; BlueCu 1.
    InterPro; IPR007110; Ig-like.
DR
DR
    InterPro; IPR003006; Ig MHC.
DR
    InterPro; IPR003596; Ig v.
DR
    Pfam; PF00047; ig; 4.
DR
    SMART; SM00406; IGv; 1.
    PROSITE; PS00196; COPPER BLUE; 1.
DR
    PROSITE; PS50835; IG LIKE; 4.
DR
DR
    PROSITE; PS00290; IG MHC; 3.
KW
    Hypothetical protein.
SO
    SEQUENCE
            473 AA; 51986 MW; E29920B09BA369F5 CRC64;
  Query Match
                       91.7%; Score 1135; DB 4; Length 473;
 Best Local Similarity
                       93.7%; Pred. No. 7.1e-99;
 Matches 208; Conservative
                             8; Mismatches
                                            6;
                                                Indels
                                                          0;
                                                              Gaps
                                                                     0;
Qу
           7 CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH 66
            Db
         252 CPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVH 311
Qу
          67 NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE 126
            Db
         312 NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE 371
         127 PQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF 186
Qу
            Db
         372 PQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF 431
Qу
         187 LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
            Db
         432 LYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK 473
RESULT 5
Q8NF17
TD
    O8NF17
               PRELIMINARY;
                               PRT:
                                     509 AA.
AC
    O8NF17;
    01-OCT-2002 (TrEMBLrel. 22, Created)
DT
```

```
DT
    01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT
     01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE
    FLJ00385 protein (Fragment).
    FLJ00385.
GN
OS
    Homo sapiens (Human).
OC.
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
OX
    NCBI TaxID=9606;
RN
     [1]
RP
    SEQUENCE FROM N.A.
RC
    TISSUE=Spleen;
    Jikuya H., Takano J., Kikuno R., Nagase T., Ohara O.;
RA
RT
     "The nucleotide sequence of a long cDNA clone isolated from human
RT
RL
    Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
DR
    EMBL; AK090464; BAC03445.1; -.
DR
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003597; Iq cl.
DR
    InterPro; IPR003006; Ig MHC.
    Pfam; PF00047; ig; 3.
DR
    SMART; SM00407; IGc1; 3.
DR
    PROSITE; PS50835; IG_LIKE; 3.
DR
DR
    PROSITE; PS00290; IG MHC; 2.
FT
    NON TER
                 1
SO
    SEQUENCE
              509 AA;
                      56111 MW; 089498D8076E863C CRC64;
 Query Match
                       91.4%; Score 1131; DB 4; Length 509;
 Best Local Similarity
                       92.0%; Pred. No. 1.9e-98;
 Matches 207; Conservative 9; Mismatches
                                             9; Indels
                                                         0; Gaps
                                                                      0:
Qу
           2 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 61
                 214 DTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVD 273
Db
          62 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 121
QУ
             Db
         274 GVEVHNAKTKPREEQFNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTK 333
QУ
         122 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 181
             Db
         334 GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPMLDS 393
         182 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP 226
Qу
             Db
         394 DGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTQKSLSLSP 438
RESULT 6
Q95M34
ID
    Q95M34
               PRELIMINARY;
                                PRT:
                                      337 AA.
AC
DT
    01-DEC-2001 (TrEMBLrel. 19, Created)
DT
    01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
    01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DT
DE
    Immunogobulin gamma 1 heavy chain constant region (Fragment).
GN
    IGHC1.
    Equus caballus (Horse).
OS
```

```
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Perissodactyla; Equidae; Equus.
OX
    NCBI TaxID=9796;
RN
     [1]
RP
    SEQUENCE FROM N.A.
RA
     Wagner B.;
     Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
RL
RN
    SEQUENCE FROM N.A.
RΡ
RX
    MEDLINE=98383416; PubMed=9717671;
RA
    Wagner B., Overesch G., Sheoran A., Holmes M., Richards C.,
RA
    Leibold W., Radbruch A.;
RT
     "Organization of the equine immunoglobulin heavy chain constant region
RT
    genes. III. Alignment of c-mu, c-gamma, c-epsilon and c-alpha genes.";
RL
     Immunobiology 199:105-119(1998).
     EMBL; AJ300675; CAC44624.1; -.
DR
DR
     InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003597; Ig c1.
DR
    InterPro; IPR003006; Iq MHC.
    Pfam; PF00047; ig; 2.
DR
DR
    SMART; SM00407; IGc1; 2.
    PROSITE; PS50835; IG_LIKE; 3.
DR
    PROSITE; PS00290; IG MHC; 2.
DR
FT
    NON TER
                 1
    SEQUENCE
SO
              337 AA; 37438 MW; A60BF2B01DEFD1F6 CRC64;
 Query Match
                        73.4%; Score 909; DB 6; Length 337;
 Best Local Similarity
                       71.9%; Pred. No. 1.1e-77;
 Matches 161; Conservative 32; Mismatches
                                             29; Indels
                                                           2; Gaps
Qу
           7 CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH 66
             114 CPKCPAPELLGGPSVFIFPPNPKDTLMITRTPEVTCVVVDVSQENPDVKFNWYMDGVEVR 173
Db
          67 NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE 126
QУ
              Db
         174 TATTRPKEEQFNSTYRVVSVLRIQHQDWLSGKEFKCKVNNQALPOPIERTITKTKGRSOE 233
         127 PQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP--ENNYKTTPPVLDSDGS 184
QУ
             234 PQVYVLAPHPDELSKSKVSVTCLVKDFYPPEINIEWQSNGQPELETKYSTTQAQQDSDGS 293
Db
Qу
         185 FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
             Db
         294 YFLYSKLSVDRNRWQQGTTFTCGVMHEALHNHYTOKNVSKNPGK 337
RESULT 7
Q8R3V9
ID
    Q8R3V9
               PRELIMINARY;
                                PRT:
                                      469 AA.
AC
    Q8R3V9;
DT
    01-JUN-2002 (TrEMBLrel. 21, Created)
DT
    01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT
    01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE
    Hypothetical 52.0 kDa protein.
OS
    Mus musculus (Mouse).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

```
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
    NCBI TaxID=10090;
OX
RN
    [1]
RP
    SEQUENCE FROM N.A.
RA
    Strausberg R.;
RL
    Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
    EMBL; BC024405; AAH24405.1; -.
DR
DR
    InterPro; IPR007110; Ig-like.
    InterPro; IPR003006; Iq MHC.
DR
DR
    InterPro; IPR003596; Ig_v.
DR
    Pfam; PF00047; ig; 4.
DR
    SMART; SM00406; IGv; 1.
DR
    PROSITE; PS50835; IG LIKE; 4.
DR
    PROSITE; PS00290; IG MHC; 1.
KW
    Hypothetical protein.
SO
    SEQUENCE
             469 AA; 51976 MW; 534793F155D05457 CRC64;
 Query Match
                       67.2%; Score 831.5; DB 11; Length 469;
 Best Local Similarity 63.8%; Pred. No. 3.5e-70;
 Matches 143; Conservative 41; Mismatches 35; Indels
                                                           5; Gaps
                                                                      2;
           7 CPP--CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE 64
Qу
                         | | | ||:
Db
         249 CKPCICTVPEV---SSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVOFSWFVDDVE 305
          65 VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGOP 124
Qу
             306 VHTAQTKPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRP 365
Db
         125 REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS 184
Qy
             Db
         366 KAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGS 425
Qу
         185 FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
             Db
         426 YFVYSKLNVOKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK 469
RESULT 8
Q99LC4
ID
    Q99LC4
               PRELIMINARY;
                               PRT;
                                      463 AA.
AC
    Q99LC4;
DT
    01-JUN-2001 (TrEMBLrel. 17, Created)
DT
    01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT
    01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE
    Similar to RIKEN cDNA 1810060009 gene.
GN
    IGH-4.
OS
    Mus musculus (Mouse).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciuroqnathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
    [1]
RP
    SEQUENCE FROM N.A.
RA
    Strausberg R.;
RL
    Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases.
DR
    EMBL; BC003435; AAH03435.1; -.
DR
    HSSP; P01842; 7FAB.
```

OC

```
DR
    MGD; MGI:96446; Igh-4.
DR
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003006; Iq MHC.
    InterPro; IPR003596; Iq v.
DR
    Pfam; PF00047; iq; 4.
DR
    SMART; SM00406; IGv; 1.
DR
DR
    PROSITE; PS50835; IG LIKE; 4.
DR
    PROSITE; PS00290; IG MHC; 1.
              463 AA; 51007 MW; EAA674C6BBC30783 CRC64;
SO
    SEOUENCE
 Query Match
                        66.9%; Score 828.5; DB 11; Length 463;
 Best Local Similarity 63.4%; Pred. No. 6.6e-70;
 Matches 142; Conservative 42; Mismatches 35; Indels
                                                           5; Gaps
                                                                      2;
           7 CPP--CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE 64
Qу
                | ||:
                          243 CKPCICTVPEV---SSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVE 299
Db
          65 VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP 124
Qу
             Db
         300 VHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRP 359
         125 REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS 184
Qу
             360 KAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGS 419
Db
Qу
         185 FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
             Db
         420 YFIYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK 463
RESULT 9
Q9R1A4
ID
    O9R1A4
               PRELIMINARY;
                                PRT:
                                      437 AA.
AC
    O9R1A4;
    01-MAY-2000 (TrEMBLrel. 13, Created)
DT
DT
    01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT
    01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE
    Gammal heavy chain of Mab7 (Fragment).
GN
    IGH-4.
OS
    Mus musculus (Mouse).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
    [1]
RP
    SEQUENCE FROM N.A.
    Wilde K.G., Yu X., Ekramoddoullah A.K.M., Misra S.;
RA
    "Cloning of cDNAs encoding for anti-white pine blister rust monoclonal
RT
RT
    antibody (Mab 7, its light and heavy chains) and construction of a
RT
    single chain antibody (scFV).";
RL
    Submitted (MAY-1999) to the EMBL/GenBank/DDBJ databases.
DR
    EMBL; AF152372; AAD40243.1; -.
DR
    HSSP; P01842; 7FAB.
DR
    MGD; MGI:96446; Igh-4.
DR
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003006; Ig MHC.
DR
    InterPro; IPR003596; Ig v.
```

```
DR
     Pfam; PF00047; ig; 4.
DR
     SMART; SM00406; IGv; 1.
DR
     PROSITE; PS50835; IG LIKE; 4.
DR
     PROSITE; PS00290; IG MHC; 1.
FT
     NON TER
FT
     NON TER
                437
                       437
SO
     SEOUENCE
               437 AA; 48142 MW; 5C3A7BB3EE7D697C CRC64;
                         66.6%; Score 824.5; DB 11; Length 437;
  Query Match
  Best Local Similarity
                         62.9%; Pred. No. 1.5e-69;
  Matches 141; Conservative 43; Mismatches
                                                35; Indels
                                                              5; Gaps
                                                                          2;
Qу
           7 CPP--CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE 64
              | | | ||:
                           Db
         217 CKPCICTVPEV---SSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVOFSWFVDDVE 273
Qу
          65 VHNAKTKPREEQYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKAKGOP 124
             Db
         274 VHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRP 333
Qу
         125 REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLDSDGS 184
             : ||||||:|| :::: |::||||||:: |:| || |||: |||| ||| ||| ||| |||
Db
         334 KAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGS 393
         185 FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Qу
             Db
         394 YFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKNLSHSPGK 437
RESULT 10
Q9D8L4
ID
    Q9D8L4
                PRELIMINARY;
                                 PRT;
                                        473 AA.
AC
    Q9D8L4;
DT
     01-JUN-2001 (TrEMBLrel. 17, Created)
DT
     01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT
     01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE
     1810060009Rik protein.
GN
     IGH-1 OR 1810060009RIK.
OS
    Mus musculus (Mouse).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI_TaxID=10090;
RN
     [1]
RP
    SEQUENCE FROM N.A.
RC
    STRAIN=C57BL/6J; TISSUE=Pancreas;
RX
    MEDLINE=21085660; PubMed=11217851;
RA
    Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA
    Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA
    Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
RA
    Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
RA
    Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
    Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
RA
    Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,
RA
    Schriml L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,
RA
RA
    Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
RA
    Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RΑ
    Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
```

```
RA
    Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
RA
    Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA
    Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
    Suzuki H., Toyo-oka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
RA
RA
    Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohtsuki S.,
    Hayashizaki Y.;
RA
RT
    "Functional annotation of a full-length mouse cDNA collection.":
RL
    Nature 409:685-690(2001).
DR
    EMBL; AK007918; BAB25349.1; -.
DR
    HSSP; P01842; 7FAB.
DR
    MGD; MGI:96443; Igh-1.
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003006; Ig MHC.
DR
DR
    InterPro; IPR003596; Ig v.
DR
    Pfam; PF00047; ig; 4.
DR
    SMART; SM00406; IGv; 1.
DR
    PROSITE; PS50835; IG LIKE; 4.
DR
    PROSITE; PS00290; IG MHC; 1.
              473 AA; 51699 MW; 9DED57A514475FBB CRC64;
SO
    SEQUENCE
 Query Match
                        65.5%; Score 811; DB 11; Length 473;
 Best Local Similarity
                        64.0%; Pred. No. 3.1e-68;
 Matches 142; Conservative 38; Mismatches
                                             42; Indels
                                                            0; Gaps
                                                                       0;
Qу
           7 CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH 66
             Db
         252 CPPCAAPDLLGGPSVFIFPPKIKDVLMISLSPMVTCVVVDVSEDDPDVQISWFVNNVEVH 311
Qу
          67 NAKTKPREEOYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKAKGOPRE 126
                   Db
         312 TAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNRALPSPIEKTISKPRGPVRA 371
         127 PQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLDSDGSFF 186
Qу
             Db
         372 PQVYVLPPPAEEMTKKEFSLTCMITGFLPAEIAVDWTSNGRTEONYKNTATVLDSDGSYF 431
Qу
         187 LYSKLTVDKSRWOOGNVFSCSVMHEALHNHYTOKSLSLSPGK 228
             Db
         432 MYSKLRVQKSTWERGSLFACSVVHEGLHNHLTTKTISRSLGK 473
RESULT 11
Q99L31 -
ID
    Q99L31
               PRELIMINARY;
                                PRT;
                                      468 AA.
AC
    099L31;
DT
    01-JUN-2001 (TrEMBLrel. 17, Created)
DT
    01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT
    01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE
    Similar to RIKEN cDNA 1810060009 gene.
OS
    Mus musculus (Mouse).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
    SEQUENCE FROM N.A.
RΡ
RA
    Strausberg R.;
```

Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,

RA

```
Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases.
RL
    EMBL; BC003878; AAH03878.1; -.
DR
ĎR
    HSSP; P01842; 7FAB.
DR
    InterPro; IPR007110; Iq-like.
DR
    InterPro; IPR003006; Ig MHC.
    InterPro; IPR003596; Ig v.
DR
    Pfam; PF00047; ig; 3.
DR
DR
    SMART; SM00406; IGv; 1.
DR
    PROSITE; PS50835; IG LIKE; 4.
DR
    PROSITE; PS00290; IG MHC; 1.
SO
    SEQUENCE 468 AA; 51661 MW; 96352328B3332ADB CRC64;
 Query Match
                       65.0%; Score 805; DB 11; Length 468;
 Best Local Similarity 65.2%; Pred. No. 1.1e-67;
 Matches 146; Conservative 30; Mismatches 46; Indels
                                                           2; Gaps
                                                                      1;
           7 CPP--CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE 64
QУ
                Db
         245 CPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPMVTCVVVDVSEDDPDVOISWFVNNVE 304
QУ
          65 VHNAKTKPREEOYNSTYRVVSVLTVLHODWLNGKEYKCKVSNKALPAPIEKTISKAKGOP 124
                    Db
         305 VLTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKALPAPIERTISKPKGSV 364
         125 REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS 184
Oy
             Db
         365 RAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGS 424
Qу
         185 FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
             Db
         425 YFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK 468
RESULT 12
Q99L25
ID
    099L25
               PRELIMINARY;
                               PRT;
                                      473 AA.
AC
    Q99L25;
DT
    01-JUN-2001 (TrEMBLrel. 17, Created)
DT
    01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT
    01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DΕ
    Similar to RIKEN cDNA 1810060009 gene.
OS
    Mus musculus (Mouse).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
    [1]
    SEQUENCE FROM N.A.
RΡ
RA
    Strausberg R.;
RL
    Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases.
DR
    EMBL; BC003888; AAH03888.1; -.
DR
    HSSP; P01842; 7FAB.
DR
    InterPro; IPR007110; Iq-like.
DR
    InterPro; IPR003006; Ig MHC.
    InterPro; IPR003596; Ig v.
DR
DR
    Pfam; PF00047; ig; 3.
DR
    SMART; SM00406; IGv; 1.
DR
    PROSITE; PS50835; IG LIKE; 4.
```

```
DR
    PROSITE; PS00290; IG MHC; 1.
    SEQUENCE 473 AA; 52449 MW; BE9889B7986DA155 CRC64;
SO
                       65.0%; Score 805; DB 11; Length 473;
  Query Match
  Best Local Similarity 65.2%; Pred. No. 1.1e-67;
 Matches 146; Conservative 30; Mismatches 46; Indels
                                                          2; Gaps
                                                                     1;
           7 CPP--CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE 64
Qу
             Db
         250 CPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPMVTCVVVDVSEDDPDVQISWFVNNVE 309
          65 VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP 124
QУ
                    310 VLTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKALPAPIERTISKPKGSV 369
Db
         125 REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS 184
Qу
            Db
         370 RAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGS 429
Qу
         185 FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
            430 YFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK 473
Db
RESULT 13
Q91Z05
ID
    Q91Z05
               PRELIMINARY;
                               PRT;
                                     473 AA.
AC
    Q91Z05;
DT
    01-DEC-2001 (TrEMBLrel. 19, Created)
DT
    01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT
    01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DΕ
    Hypothetical 51.9 kDa protein.
GN
    AU044919.
OS
    Mus musculus (Mouse).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
    [1]
RP
    SEQUENCE FROM N.A.
RA
    Strausberg R.;
RL
    Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
DR
    EMBL; BC010327; AAH10327.1; -.
DR
    MGD; MGI:2144967; AU044919.
DR
    InterPro; IPR000345; CytC heme bind.
DR
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003006; Ig MHC.
    InterPro; IPR003596; Ig v.
DR
DR
    Pfam; PF00047; ig; 3.
    SMART; SM00406; IGv; 1.
DR
DR
    PROSITE; PS00190; CYTOCHROME_C; 1.
DR
    PROSITE; PS50835; IG LIKE; 4.
DR
    PROSITE; PS00290; IG MHC; 1.
    Hypothetical protein.
KW
SQ
    SEQUENCE 473 AA; 51946 MW; CF625F008932AF12 CRC64;
 Query Match
                       63.0%; Score 780; DB 11; Length 473;
 Best Local Similarity 61.8%; Pred. No. 2.6e-65;
```

```
Matches 141; Conservative 34; Mismatches
                                          47; Indels
                                                                    1;
                                                         6; Gaps
           7 CPP-----CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Qу
            Db
         246 CPPCKECHKCPAPNLEGGPSVFIFPPNIKDVLMISLTPKVTCVVVDVSEDDPDVOISWFV 305
          61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
Qу
            Db
         306 NNVEVHTAQTQTHREDYNSTIRVVSALPIQHQDWMSGKEFKCKVNNKDLPSPIERTISKI 365
         121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
Qу
            Dh
         366 KGLVRAPQVYILPPPAEQLSRKDVSLTCLVVGFNPGDISVEWTSNGHTEENYKDTAPVLD 425
         181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
Qу
             Db
         426 SDGSYFIYSKLDIKTSKWEKTDSFSCNVRHEGLKNYYLKKTISRSPGK 473
RESULT 14
08R3H6
               PRELIMINARY;
ID
    Q8R3H6
                               PRT;
                                     474 AA.
AC
    Q8R3H6;
DТ
    01-JUN-2002 (TrEMBLrel. 21, Created)
    01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT
DT
    01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE
    Hypothetical 51.7 kDa protein.
OS
    Mus musculus (Mouse).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi:
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
    NCBI TaxID=10090;
RN
    [1]
RP
    SEQUENCE FROM N.A.
RA
    Strausberg R.;
RL
    Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
DR
    EMBL; BC025447; AAH25447.1; -.
    InterPro; IPR000345; CytC heme bind.
DR
DR
    InterPro; IPR007110; Iq-like.
DR
    InterPro; IPR003006; Ig MHC.
DR
    InterPro; IPR003596; Ig v.
DR
    Pfam; PF00047; ig; 3.
DR
    SMART; SM00406; IGv; 1.
DR
    PROSITE; PS00190; CYTOCHROME_C; 1.
DR
    PROSITE; PS50835; IG_LIKE; 4.
DR
    PROSITE; PS00290; IG MHC; 1.
KW
    Hypothetical protein.
SQ
    SEQUENCE 474 AA; 51748 MW; 8608B57C6CD2874A CRC64;
 Query Match
                      63.0%; Score 780; DB 11; Length 474;
 Best Local Similarity
                      61.8%; Pred. No. 2.6e-65;
 Matches 141; Conservative 34; Mismatches
                                           47; Indels
                                                       6; Gaps
          7 CPP-----CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV 60
Qу
                    247 CPPCKECHKCPAPNLEGGPSVFIFPPNIKDVLMISLTPKVTCVVVDVSEDDPDVQISWFV 306
Db
Qу
         61 DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA 120
```

```
307 NNVEVHTAQTQTHREDYNSTIRVVSALPIQHQDWMSGKEFKCKVNNKDLPSPIERTISKI 366
Db
        121 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD 180
QУ
            Db
        367 KGLVRAPQVYILPPPAEQLSRKDVSLTCLVVGFNPGDISVEWTSNGHTEENYKDTAPVLD 426
        181 SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
QУ
            Db
        427 SDGSYFIYSKLDIKTSKWEKTDSFSCNVRHEGLKNYYLKKTISRSPGK 474
RESULT 15
Q9BSZ1
    Q9BSZ1
              PRELIMINARY;
ID
                              PRT;
                                    375 AA.
AC
    Q9BSZ1;
DT
    01-JUN-2001 (TrEMBLrel. 17, Created)
DT
    01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT
    01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE
    Hypothetical protein.
    Homo sapiens (Human).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
    NCBI TaxID=9606;
RN
    [1]
RΡ
    SEQUENCE FROM N.A.
RC
    TISSUE=Lymph;
RA
    Strausberg R.;
    Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
RL
    EMBL; BC004476; AAH04476.1; -.
DR
DR
    HSSP; P01857; 1FC1.
DR
    InterPro; IPR007110; Iq-like.
    InterPro; IPR003597; Ig_c1.
DR
    InterPro; IPR003006; Ig MHC.
DR
DR
    Pfam; PF00047; iq; 3.
DR
    SMART; SM00407; IGc1; 2.
DR
    PROSITE; PS50835; IG LIKE; 3.
DR
    PROSITE; PS00290; IG MHC; 3.
KW
    Hypothetical protein.
SO
    SEQUENCE
             375 AA; 41314 MW; B1A0A0998F473619 CRC64;
 Query Match
                      28.9%; Score 358; DB 4; Length 375;
 Best Local Similarity 34.1%; Pred. No. 1.5e-25;
 Matches
         73; Conservative 48; Mismatches 85; Indels
                                                        8; Gaps
                                                                  6:
Qу
         21 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEOYNST 80
            Db
        146 VFAIPPS-FASIFLTKSTKLTCLVTDLTTYD-SVTISWTRQNGEAVKTHTNISESHPNAT 203
         81 YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP-REPQVYTLPPSRDEL 139
QУ
                      204 FSAVGEASICEDDWNSGERFTCTVTHTDLPSPLKQTISRPKGVALHRPDVYLLPPAREQL 263
Db
        140 T-KNQVSLTCLVKGFYPSDIAVEWESNGOP--ENNYKTTPPVLD--SDGSFFLYSKLTVD 194
Qу
                 264 NLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVS 323
Db
```

QУ	195	KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 2						
		:     ::						
Db	324	EEEWNTGETYTCVVAHEALPNRVTERTVDKSTGK 35	57					

Search completed: January 16, 2004, 09:38:45 Job time : 38 secs

# GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 16, 2004, 09:36:26; Search time 17 Seconds

(without alignments)

630.711 Million cell updates/sec

Title: US-09-843-221A-2

Perfect score: 1238

Sequence: 1 MDKTHTCPPCPAPELLGGPS.....MHEALHNHYTQKSLSLSPGK 228

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 127863 seqs, 47026705 residues

Total number of hits satisfying chosen parameters: 127863

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt 41:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

		٥			Boining	
Result		% Query				
No.	Score	Match	Length	DB	ID	Description
1	1233	99.6	330	1	GC1 HUMAN	P01857 homo sapien
2	1142.5	92.3	326	1	GC2 HUMAN	P01859 homo sapien
3	1135	91.7	327	1	GC4 HUMAN	P01861 homo sapien
4	1126	91.0	290	1	GC3 HUMAN	P01860 homo sapien
5	918.5	74.2	323	1	GC_RABIT	P01870 oryctolagus
6	889	71.8	329	1	GC2_CAVPO	P01862 cavia porce
7	845.5	68.3	329	1	GC3_MOUSE	P22436 mus musculu
8	838	67.7	333	1	GCB_RAT	P20761 rattus norv
9	834.5	67.4	398	1	GC3M_MOUSE	P03987 mus musculu
10	818.5	66.1	326	1	GC1_RAT	P20759 rattus norv
11	817.5	66.0	324	1	GC1_MOUSE	P01868 mus musculu
12	812.5	65.6	393	1	GC1M_MOUSE	P01869 mus musculu
13	809.5	65.4	329	1	GCC_RAT	P20762 rattus norv
14	809	65.3	330	1	GCAA MOUSE	P01863 mus musculu
15	804	64.9	399	1	GCAM_MOUSE	P01865 mus musculu
16	802	64.8	335	1	GCAB_MOUSE	P01864 mus musculu
17	785.5	63.4	322	1	GCA_RAT	P20760 rattus norv

10	770	60.0	226	-	aan waxan	20000	-
18	779	62.9	336	1	GCB_MOUSE		mus musculu
19	774	62.5	405	1	GCBM_MOUSE		mus musculu
20	358	28.9	454	1	MUC_HUMAN		homo sapien
21	357	28.8	455	1	MUC_MOUSE	P01872 i	mus musculu
22	356	28.8	391	1	MUCB_HUMAN	P04220 1	homo sapien
23	354	28.6	421	1	EPC_MOUSE	P06336 t	mus musculu
24	353	28.5	429	1	EPC_RAT	P01855 :	rattus norv
25	352	28.4	428	1	EPC_HUMAN	P01854 1	homo sapien
26	347	28.0	476	1	MUCM MOUSE		mus musculu
27	342	27.6	458	1	MUC_RABIT	P03988 (	oryctolagus
28	332	26.8	450	1	MUC CANFA	P01874	canis famil
29	332	26.8	454	1	MUC MESAU	P06337 i	mesocricetu
30	332	26.8	479	1	MUCM_RABIT	P04221 (	oryctolagus
31	329	26.6	457	1	MUC_SUNMU	P20768 :	suncus muri
32	297	24.0	438	1	HVC2_HETFR	P23085 ]	heterodontu
33	295.5	23.9	299	1	ALC_RABIT	P01879 (	oryctolagus
34	287.5	23.2	438	1	HVCS_HETFR	P23087 1	heterodontu
35	287.5	23.2	446	1	MUC_CHICK	P01875	gallus gall
36	278.5	22.5	461	1	HVCM_HETFR	P23088	heterodontu
37	276.5	22.3	393	1	HVC3_HETFR	P23086 1	heterodontu
38	272	22.0	353	1	ALC1 HUMAN	P01876 1	homo sapien
39	272	22.0	370	1	HVC1 HETFR		heterodontu
40	267.5	21.6	353	1	ALC1 GORGO	P20758 9	gorilla gor
41	267	21.6	340	1	ALC2 HUMAN		homo sapien
42	248.5	20.1	481	1	MUCM ICTPU		ictalurus p
43	245	19.8	344	1	ALC MOUSE		mus musculu
44	179	14.5	513	1	SHS1_MOUSE	P97797 1	m protein-t
45	177.5	14.3	105	1	LAC1_MOUSE		mus musculu

## ALIGNMENTS

```
RESULT 1
GC1 HUMAN
     GC1 HUMAN
ID
                    STANDARD;
                                    PRT:
                                           330 AA.
AC
     P01857;
DT
     21-JUL-1986 (Rel. 01, Created)
     21-JUL-1986 (Rel. 01, Last sequence update)
DT
DT
     15-SEP-2003 (Rel. 42, Last annotation update)
     Ig gamma-1 chain C region.
DE
GN
     IGHG1.
     Homo sapiens (Human).
OS
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
     NCBI_TaxID=9606;
RN
     [1]
RP
     SEQUENCE FROM N.A.
RX
     MEDLINE=82274238; PubMed=6287432;
     Ellison J.W., Berson B.J., Hood L.E.;
RΑ
     "The nucleotide sequence of a human immunoglobulin C gamma1 gene.";
RT
RL
     Nucleic Acids Res. 10:4071-4079(1982).
RN
RΡ
     SEQUENCE OF 1-135 (MYELOMA PROTEIN EU).
     MEDLINE=71064024; PubMed=5489771;
RX
RA
     Cunningham B.A., Rutishauser U., Gall W.E., Gottlieb P.D.,
RA
     Waxdal M.J., Edelman G.M.;
```

```
RT
     "The covalent structure of a human gamma G-immunoglobulin. VII. Amino
RT
     acid sequence of heavy-chain cyanogen bromide fragments H1-H4.";
RL
     Biochemistry 9:3161-3170(1970).
RN
     [3]
     SEOUENCE OF 136-329 (EU).
RP
RX
     MEDLINE=71064025; PubMed=5530842;
     Rutishauser U., Cunningham B.A., Bennett C., Konigsberg W.H.,
RA
RA
     Edelman G.M.;
RT
     "The covalent structure of a human gamma G-immunoglobulin. 8. Amino
RT
     acid sequence of heavy-chain cyanogen bromide fragments H5-H7.";
RL
     Biochemistry 9:3171-3181(1970).
RN
RP
     SEQUENCE (MYELOMA PROTEIN NIE).
RX
     MEDLINE=77070269; PubMed=826475;
     Ponstingl H., Hilschmann N.;
RA
RT
     "The rule of antibody structure. The primary structure of a
RT
     monoclonal IgG1 immunoglobulin (myeloma protein Nie). III. The
RT
     chymotryptic peptides of the H-chain, alignment of the tryptic
RT
     peptides and discussion of the complete structure.";
RL
     Hoppe-Seyler's Z. Physiol. Chem. 357:1571-1604(1976).
RN
RP
     SEQUENCE (MYELOMA PROTEIN KOL), AND DISULFIDE BONDS.
RX
     MEDLINE=83289131; PubMed=6884994;
RA
     Schmidt W.E., Jung H.-D., Palm W., Hilschmann N.;
RT
     "Three-dimensional structure determination of antibodies. Primary
RT
     structure of crystallized monoclonal immunoglobulin IgG1 KOL, I.";
RL
     Hoppe-Seyler's Z. Physiol. Chem. 364:713-747(1983).
RN
     [6]
RΡ
     DISULFIDE BONDS.
RX
     MEDLINE=71064027; PubMed=4923144;
RA
     Gall W.E., Edelman G.M.;
     "The covalent structure of a human gamma G-immunoglobulin. X.
RT
RT
     Intrachain disulfide bonds.";
RL
     Biochemistry 9:3188-3196(1970).
RN
     [7]
RP
     DISULFIDE BONDS.
RX
     MEDLINE=77070267; PubMed=1002129;
RA
     Dreker L., Schwarz J., Reichel W., Hilschmann N.;
RT
     "Rule of antibody structure. The primary structure of a monoclonal
RT
     IgG1 immunoglobulin (myeloma protein Nie), I: Purification and
RT
     characterization of the protein, the L- and H-chains, the
RT
     cyanogen bromide cleavage products, and the disulfide bridges.";
RL
     Hoppe-Seyler's Z. Physiol. Chem. 357:1515-1540(1976).
RN
     X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS).
RΡ
     MEDLINE=81208100; PubMed=7236608;
RX
RA
     Deisenhofer J.;
RT
     "Crystallographic refinement and atomic models of a human Fc fragment
RT
     and its complex with fragment B of protein A from Staphylococcus
RT
     aureus at 2.9- and 2.8-A resolution.";
RL
     Biochemistry 20:2361-2370(1981).
     -!- MISCELLANEOUS: NIE HAS THE G1M(17) ALLOTYPIC MARKER, 97-K, & THE
CC
CC
         G1M(1) MARKERS, 239-D & 241-L. KOL & EU SEQUENCES HAVE THE G1M(3)
CC
         MARKER & THE G1M (NON-1) MARKERS.
CC
     -!- MISCELLANEOUS: NIE ALSO DIFFERS IN THE AMIDATION STATES OF
CC
         35,116,198,269 & 272.
CC
     -!- MISCELLANEOUS: EU ALSO DIFFERS IN THE AMIDATION STATES OF RESIDUES
```

```
CC
        155, 166, 177, 195, 198, 269, AND 272 AND IN THE ORDER OF RESIDUES
CC
        268-272.
CC
     -!- MISCELLANEOUS: KOL ALSO DIFFERS IN THE AMIDATION STATES OF
CC
        RESIDUES 198,267&272.
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
CC
     modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
     DR
     EMBL; J00228; AAC82527.1; ALT_INIT.
DR
     PIR; A93433; GHHU.
     PDB; 1FC1; 15-JUL-92.
DR
DR
     PDB; 1FC2; 15-JUL-92.
DR
     PDB; 1AJ7; 12-NOV-97.
DR
    PDB; 1D5B; 09-FEB-00.
DR
     PDB; 1D5I; 09-FEB-00.
DR
    PDB; 1D6V; 04-OCT-00.
     PDB; 1DN2; 17-MAY-00.
DR
    PDB; 1E4K; 06-JUN-01.
DR
    PDB; 1FCC; 20-JUL-95.
DR
DR
    PDB; 1HZH; 12-JUN-02.
DR
    PDB; 117Z; 08-AUG-01.
    PDB; 1IIS; 16-MAY-01.
DR
    PDB; 1IIX; 16-MAY-01.
DR
    PDB; 1L6X; 10-APR-02.
DR
DR
    PDB; 2RCS; 12-NOV-97.
DR
    Genew; HGNC:5525; IGHG1.
DR
    MIM; 147100; -.
    GO; GO:0005624; C:membrane fraction; NAS.
DR
DR
    GO; GO:0003823; F:antigen binding activity; TAS.
DR
    GO; GO:0006955; P:immune response; NAS.
DR
    InterPro; IPR007110; Ig-like.
    InterPro; IPR003597; Ig_c1.
DR
DR
    InterPro; IPR003006; Iq MHC.
DR
    Pfam; PF00047; ig; 3.
    SMART; SM00407; IGc1; 2.
DR
DR
    PROSITE; PS50835; IG LIKE; 3.
    PROSITE; PS00290; IG MHC; 2.
DR
    Immunoglobulin domain; Immunoglobulin C region; Glycoprotein;
KW
KW
    3D-structure.
FT
    NON TER
                1
                       1
FT
    DOMAIN
                1
                       98
                               CH1.
FT
    DOMAIN
                99
                      110
                               HINGE.
FT
    DOMAIN
               111
                      223
                               CH2.
FT
    DOMAIN
               224
                     330
                               CH3.
FT
    DISULFID
                27
                       83
FT
    DISULFID
               103
                    103
                               INTERCHAIN (WITH LIGHT CHAIN).
FT
    DISULFID
               109
                    109
                               INTERCHAIN (WITH HEAVY CHAIN).
FΤ
    DISULFID
               112
                     112
                               INTERCHAIN (WITH HEAVY CHAIN).
FT
    DISULFID
               144
                     204
FT
    DISULFID
               250
                      308
FT
    CARBOHYD
               180
                      180
                               N-LINKED (GLCNAC. . .).
FT
    MOD RES
               330
                      330
                               REMOVED POST-TRANSLATIONALLY.
```

```
FT
    VARIANT
                97
                       97
                                K \rightarrow R (IN G1M(3) MARKER).
FT
                                /FTId=VAR 003886.
FT
    VARIANT
                239
                      239
                                D -> E (IN G1M(NON-1) MARKER).
FT
                                /FTId=VAR 003887.
    VARIANT
FT
                241
                      241
                               L \rightarrow M (IN G1M(NON-1) MARKER).
FT
                                /FTId=VAR 003888.
FT
    STRAND
                122
                      126
FT
    HELIX
                130
                      134
FT
    TURN
                136
                      137
FT
    STRAND
                141
                      147
FT
    STRAND
                157
                      162
FT
    TURN
                163
                      164
FT
    STRAND
               165
                      166
FT
    TURN
                168
                      171
FT
    STRAND
                176
                      179
FT
    TURN
               180
                      181
FT
    STRAND
               182
                      190
FT
    HELIX
               193
                      197
FT
    TURN
               198
                      199
FT
    STRAND
               202
                      207
FT
    TURN
                209
                      210
    STRAND
FT
                215
                      219
FТ
    STRAND
               227
                      227
FT
    STRAND
               230
                      234
FT
    HELIX
               238
                      242
FT
    STRAND
               245
                      256
FT
    STRAND
               260
                      265
FT
    STRAND
               270
                      270
FT
    STRAND
               274
                      276
FT
    STRAND
               280
                      281
FT
    TURN
               283
                      284
ĖΤ
    STRAND
               287
                      296
FT
    HELIX
               297
                      301
FT
    TURN
               302
                      303
FT
    STRAND
                305
                      312
FT
    TURN
               313
                      314
FT
    TURN
               316
                      317
FT
    STRAND
               320
                      325
SO
    SEQUENCE
              330 AA; 36106 MW; 3770EE106C2FA33D CRC64;
 Query Match
                        99.6%; Score 1233; DB 1; Length 330;
 Best Local Similarity
                        100.0%; Pred. No. 2.2e-93;
 Matches 227; Conservative 0; Mismatches
                                             0; Indels
                                                            0; Gaps
                                                                        0;
Qу
           2 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 61
             Db
         104 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 163
          62 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 121
Qу
             164 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 223
Db
         122 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 181
Qу
             Db
         224 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 283
Qу
         182 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
```

```
284 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 330
```

```
RESULT 2
GC2 HUMAN
     GC2 HUMAN
ID
                    STANDARD;
                                    PRT;
                                           326 AA.
AC
     P01859;
DT
     21-JUL-1986 (Rel. 01, Created)
DT
     21-JUL-1986 (Rel. 01, Last sequence update)
DT
     16-OCT-2001 (Rel. 40, Last annotation update)
     Ig gamma-2 chain C region.
GN
     IGHG2.
OS
     Homo sapiens (Human).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
     NCBI TaxID=9606;
RN
RΡ
     SEQUENCE OF 2-326 FROM N.A.
RX
     MEDLINE=82197621; PubMed=6804948;
RA
     Ellison J.W., Hood L.E.;
RT
     "Linkage and sequence homology of two human immunoglobulin gamma
RT
     heavy chain constant region genes.";
RL
     Proc. Natl. Acad. Sci. U.S.A. 79:1984-1988(1982).
RN
RΡ
     SEQUENCE OF 88-115 FROM N.A.
RC
     TISSUE=Fetal liver;
RX
     MEDLINE=83001943; PubMed=6811139;
     Takahashi N., Ueda S., Obata M., Nikaido T., Nakai S., Honjo T.;
RA
RT
     "Structure of human immunoglobulin gamma genes: implications for
RT
     evolution of a gene family.";
RL
     Cell 29:671-679(1982).
RN
     [3]
RΡ
     SEQUENCE OF 99-177 AND 310-326 FROM N.A.
RC
     TISSUE=Fetal liver:
RX
     MEDLINE=84235992; PubMed=6329676;
RA
     Krawinkel U., Rabbitts T.H.;
     "Comparison of the hinge-coding segments in human immunoglobulin gamma
RT
RT
     heavy chain genes and the linkage of the gamma 2 and gamma 4 subclass
RT
     genes.";
RL
     EMBO J. 1:403-407(1982).
RN
RP
     SEQUENCE OF 1-325 (MYELOMA PROTEIN TIL).
RX
     MEDLINE=81007873; PubMed=6774012;
RA
     Wang A.-C., Tung E., Fudenberg H.H.;
RT
     "The primary structure of a human IgG2 heavy chain: genetic,
RT
     evolutionary, and functional implications.";
RL
     J. Immunol. 125:1048-1054(1980).
RN
RP
     SEQUENCE OF 1-85 AND 132-325 (MYELOMA PROTEIN ZIE).
RX
     MEDLINE=80001357; PubMed=113060;
RA
     Connell G.E., Parr D.M., Hofmann T.;
     "The amino acid sequences of the three heavy chain constant region
RT
RT
     domains of a human IgG2 myeloma protein.";
RL
     Can. J. Biochem. 57:758-767(1979).
RN
     [6]
RP
     SEQUENCE OF 238-275 (ZIE).
```

```
RX
     MEDLINE=80114419; PubMed=118920;
RA
     Hofmann T., Parr D.M.;
RT
     "A note of the amino acid sequence of residues 381-391 of human
RT
     immunoglobulins gamma chains.";
RL
     Mol. Immunol. 16:923-925(1979).
RN
     [7]
     REVISIONS TO 25; 59; 60 AND 264-268 (ZIE).
RP
RA
     Hofmann T., Parr D.M.;
RL
     Submitted (MAR-1980) to the PIR data bank.
RN
RP
     SEQUENCE OF 1-121 (DOT).
RX
     MEDLINE=95255298; PubMed=7737190;
RA
     Stoppini M., Bellotti V., Negri A., Merlini G., Garver F., Ferri G.;
RT
     "Characterization of the two unique human anti-flavin monoclonal
RT
     immunoglobulins.";
RL
     Eur. J. Biochem. 228:886-893(1995).
RN
     [9]
RP
     DISULFIDE BONDS.
RX
    MEDLINE=72033500; PubMed=4940472;
RA
    Milstein C., Frangione B.;
RT
     "Disulphide bridges of the heavy chain of human immunoglobulin G2.";
RL
    Biochem. J. 121:217-225(1971).
RN
     [10]
RΡ
    DISULFIDE BONDS.
RX
    MEDLINE=69064124; PubMed=5782707;
RA
    Frangione B., Milstein C., Pink J.R.L.;
RT
     "Structural studies of immunoglobulin G.";
RL
    Nature 221:145-148(1969).
CC
     -----
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
     the European Bioinformatics Institute. There are no restrictions on its
CC
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
     CC
DR
    EMBL; J00230; AAB59393.1; -.
DR
    PIR; A93906; G2HU.
DR
    HSSP; P01857; 1FC1.
DR
    Genew; HGNC:5526; IGHG2.
DR
    MIM; 147110; -.
DR
    GO; GO:0005624; C:membrane fraction; NAS.
DR
    GO; GO:0003823; F:antigen binding activity; TAS.
DR
    GO; GO:0006955; P:immune response; NAS.
DR
    InterPro; IPR007110; Ig-like.
    InterPro; IPR003597; Iq cl.
DR
    InterPro; IPR003006; Ig_MHC.
DR
    Pfam; PF00047; ig; 3.
DR
DR
    SMART; SM00407; IGc1; 2.
DR
    PROSITE; PS50835; IG LIKE; 3.
DR
    PROSITE; PS00290; IG MHC; 2.
KW
    Immunoglobulin domain; Immunoglobulin C region.
FT
    NON TER
                 1
                       1
FT
    DOMAIN
                 1
                       98
                                CH1.
FT
    DOMAIN
                99
                      110
                                HINGE.
FT
    DOMAIN
               111
                      219
                                CH2.
```

```
FT
    DOMAIN
               220
                      326
                               CH3.
FT
    DISULFID
                      14
                14
                               INTERCHAIN (WITH A LIGHT CHAIN).
FT
    DISULFID
                27
                      83
FT
    DISULFID
               102
                      102
                               INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
               103
                      103
                               INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
               106
                      106
                               INTERCHAIN (WITH A HEAVY CHAIN).
                               INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
               109
                      109
FT
    DISULFID
               140
                      200
FT
    DISULFID
               246
                      304
FT
    SITE
               156
                      156
                               AT OR NEAR THE COMPLEMENT-BINDING SITE.
FT
    MOD RES
               326
                      326
                               REMOVED POST-TRANSLATIONALLY (PROBABLE).
FT
    VARIANT
                60
                      60
                               S -> A (IN MYELOMA PROTEINS TIL & ZIE).
FT
                               /FTId=VAR 003889.
FT
    CONFLICT
              109
                      109
                               C \rightarrow S (IN REF. 3).
SO
    SEQUENCE
              326 AA; 35884 MW; 8310878C6878CF9C CRC64;
  Query Match
                       92.3%; Score 1142.5; DB 1; Length 326;
  Best Local Similarity 94.1%; Pred. No. 5e-86;
  Matches 209; Conservative 8; Mismatches
                                              4; Indels
                                                           1;
                                                               Gaps
                                                                      1;
Qу
           7 CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH 66
             Db
         106 CPPCPAPP-VAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVOFNWYVDGVEVH 164
Qу
          67 NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGOPRE 126
             Db
         165 NAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGOPRE 224
         127 PQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF 186
QУ
             Db
         225 PQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFF 284
Qу
         187 LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKSLSLSPGK 228
             Db
         285 LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 326
RESULT 3
GC4 HUMAN
ΙD
    GC4 HUMAN
                  STANDARD;
                                PRT;
                                      327 AA.
AC
    P01861;
DT
    21-JUL-1986 (Rel. 01, Created)
DT
    21-JUL-1986 (Rel. 01, Last sequence update)
DT
    15-SEP-2003 (Rel. 42, Last annotation update)
DE
    Ig gamma-4 chain C region.
GN
    IGHG4.
OS
    Homo sapiens (Human).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
    NCBI TaxID=9606;
RN
    [1]
RP
    SEOUENCE FROM N.A.
RX
    MEDLINE=83157104; PubMed=6299662;
RA
    Ellison J.W., Buxbaum J.N., Hood L.E.;
    "Nucleotide sequence of a human immunoglobulin C gamma 4 gene.";
RT
RL
    DNA 1:11-18(1981).
RN
    [2]
```

```
SEQUENCE OF 1-30 AND 81-326.
RX
    MEDLINE=70207560; PubMed=4192699;
    Pink J.R.L., Buttery S.H., de Vries G.M., Milstein C.;
RA
RT
    "Human immunoglobulin subclasses. Partial amino acid sequence of the
RT
    constant region of a gamma 4 chain.";
RL
    Biochem. J. 117:33-47(1970).
    ------
CC
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
    EMBL; K01316; AAB59394.1; ALT INIT.
DR
DR
    PIR; A90933; G4HU.
DR
    PDB; 1ADQ; 16-SEP-98.
DR
    Genew; HGNC:5528; IGHG4.
DR
    MIM; 147130; -.
DR
    GO; GO:0005624; C:membrane fraction; NAS.
DR
    GO; GO:0003823; F:antigen binding activity; TAS.
    GO; GO:0006955; P:immune response; NAS.
DR
DR
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003597; Ig c1.
DR
    InterPro; IPR003006; Ig MHC.
    Pfam; PF00047; ig; 3.
DR
    SMART; SM00407; IGc1; 2.
DR
DR
    PROSITE; PS50835; IG_LIKE; 3.
DR
    PROSITE; PS00290; IG_MHC; 2.
KW
    Immunoglobulin domain; Immunoglobulin C region; 3D-structure.
FT
    NON TER
               1
                      1
FT
    DOMAIN
                      98
               1
                              CH1.
FT
    DOMAIN
               99
                     110
                              HINGE.
FT
    DOMAIN
               111
                    220
                              CH2.
                   327
FT
    DOMAIN
              221
                              CH3.
FT
    DISULFID
               14
                     14
                              INTERCHAIN (WITH A LIGHT CHAIN).
FT
    DISULFID
              27
                     83
FT
    DISULFID
            106
                   106
                             INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
              109
                   109
                              INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
              141
                     201
FT
    DISULFID
              247
                     305
SO
    SEQUENCE
              327 AA; 35940 MW; 3EDBD811EF208E7A CRC64;
 Query Match
                       91.7%; Score 1135; DB 1; Length 327;
 Best Local Similarity 93.7%; Pred. No. 2.1e-85;
 Matches 208; Conservative 8; Mismatches 6; Indels
                                                                    0:
          7 CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH 66
Qу
            Db
        106 CPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVH 165
         67 NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE 126
QУ
            166 NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE 225
Db
Qу
        127 PQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF 186
```

RP

```
Db
          226 PQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF 285
          187 LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKSLSLSPGK 228
Qу
              Db
          286 LYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK 327
RESULT 4
GC3 HUMAN
ID
     GC3 HUMAN
                   STANDARD;
                                  PRT;
                                         290 AA.
AC
     P01860;
DT
     21-JUL-1986 (Rel. 01, Created)
DT
     21-JUL-1986 (Rel. 01, Last sequence update)
DT
     28-FEB-2003 (Rel. 41, Last annotation update)
DE
     Ig gamma-3 chain C region (Heavy chain disease protein) (HDC).
GN
     IGHG3.
OS
     Homo sapiens (Human).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
     NCBI TaxID=9606;
OX
RN
RP
     SEQUENCE (DISEASE PROTEIN WIS).
RX
     MEDLINE=81021548; PubMed=6774747;
RA
     Frangione B., Rosenwasser E., Prelli F., Franklin E.C.;
     "Primary structure of human gamma 3 immunoglobulin deletion mutant:
RT
RT
     gamma 3 heavy-chain disease protein Wis.";
RL
     Biochemistry 19:4304-4308(1980).
RN
RP
     REVISIONS TO 12-97 (PROTEIN WIS).
     MEDLINE=77118561; PubMed=402363;
RX
RA
     Michaelsen T.E., Frangione B., Franklin E.C.;
     "Primary structure of the 'hinge' region of human IgG3. Probable
RT
     quadruplication of a 15-amino acid residue basic unit.";
RT
RL
     J. Biol. Chem. 252:883-889(1977).
RN
     [3]
     REVISIONS TO 59-289 (PROTEIN WIS/DISEASE PROTEIN ZUC).
RP
RX
     MEDLINE=77021516; PubMed=823945;
     Wolfenstein-Todel C., Frangione B., Prelli F., Franklin E.C.;
RA
RТ
     "The amino acid sequence of 'heavy chain disease' protein ZUC.
     Structure of the Fc fragment of immunoglobulin G3.";
RT
RL
     Biochem. Biophys. Res. Commun. 71:907-914(1976).
RN
     [4]
RP
     SEQUENCE FROM N.A. (DISEASE PROTEIN OMM).
RX
    MEDLINE=82247835; PubMed=6808505;
RA
    Alexander A., Steinmetz M., Barritault D., Frangione B.,
RA
     Franklin E.C., Hood L., Buxbaum J.N.;
RT
     "Gamma Heavy chain disease in man: cDNA sequence supports partial
     gene deletion model.";
RT
RL
     Proc. Natl. Acad. Sci. U.S.A. 79:3260-3264(1982).
CC
     -!- SUBUNIT: DIMER LINKED BY 12 DISULFIDE BONDS; IT HAS AN EXTRA
CC
        INTERCHAIN DISULFIDE BOND AT POSITION 7 IN ADDITION TO THE 11
CC
        NORMALLY PRESENT IN THE HINGE REGION.
CC
     -!- MISCELLANEOUS: THE HEAVY CHAIN DISEASE PROTEIN WIS IS SHOWN.
CC
     -!- MISCELLANEOUS: THE SEQUENCE OF RESIDUES 42-76 WAS TAKEN FROM THE
CC
        REF.2.
     -!- MISCELLANEOUS: DISEASE PROTEIN WIS IS LACKING MOST OF THE V REGION
CC
```

```
CC
        AND ALL OF THE CH1 REGION.
CC
    -!- MISCELLANEOUS: DISEASE PROTEIN ZUC LACK MOST OF THE V REGION. ALL
CC
        OF THE CH1 REGION, AND PART OF THE HINGE COMPARED WITH NORMAL
CC
        GAMMA-3 HEAVY CHAINS.
CC
    -!- MISCELLANEOUS: DISEASE PROTEIN OMM MAY REPRESENT AN ALLELIC FORM
CC
        OR ANOTHER GAMMA CHAIN SUBCLASS.
CC
    -!- MISCELLANEOUS: THE HINGE REGION IN GAMMA-3 CHAINS IS ABOUT FOUR
CC
        TIMES AS LONG AS IN OTHER GAMMA CHAINS AND CONTAINS THREE
CC
        IDENTICAL 15-RESIDUE SEGMENTS PRECEDED BY A SIMILAR 17-RESIDUE
        SEGMENT (12-28).
CC
CC
    CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
    use by non-profit institutions as long as its content is in no way
CC
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
    or send an email to license@isb-sib.ch).
CC
    ______
CC
    EMBL; J00231; AAA52805.1; ALT SEQ.
DR
DR
    HSSP; P01857; 1FC1.
DR
    Genew; HGNC:5527; IGHG3.
    MIM; 147120; -.
DR
DR
    GO; GO:0005624; C:membrane fraction; NAS.
    GO; GO:0003823; F:antigen binding activity; TAS.
    GO; GO:0006955; P:immune response; NAS.
DR
    InterPro; IPR007110; Ig-like.
    InterPro; IPR003597; Ig cl.
DR
    InterPro; IPR003006; Ig_MHC.
DR
    Pfam; PF00047; ig; 2.
DR
DR
    SMART; SM00407; IGc1; 1.
DR
    PROSITE; PS50835; IG LIKE; 2.
DR
    PROSITE; PS00290; IG MHC; 1.
KW
    Immunoglobulin domain; Immunoglobulin C region; Glycoprotein; Repeat;
KW
    Pyrrolidone carboxylic acid.
FT
    DOMAIN
               12
                     73
                               HINGE.
FT
    DOMAIN
               74
                      183
                               CH2.
FT
                    289
    DOMAIN
              184
                               CH3.
FT
    REPEAT
               29
                      43
FT
    REPEAT
               44
                      58
FT
                      73
    REPEAT
                59
FT
                      1
    MOD RES
                1
                               PYRROLIDONE CARBOXYLIC ACID.
FT
    CARBOHYD
                      6
                               N-LINKED (GLCNAC. . .).
                6
FT
                7
                      7
    DISULFID
                               INTERCHAIN (WITH HEAVY CHAIN DIMER).
    DISULFID
                24
                      24
                               INTERCHAIN (WITH HEAVY CHAIN DIMER).
FT
                27
    DISULFID
                      27
                               INTERCHAIN (WITH HEAVY CHAIN DIMER).
                               INTERCHAIN (WITH HEAVY CHAIN DIMER).
FT
    DISULFID
                33
                      33
                     39
                               INTERCHAIN (WITH HEAVY CHAIN DIMER).
FT
    DISULFID
                39
FT
    DISULFID
                42 42
                               INTERCHAIN (WITH HEAVY CHAIN DIMER).
FT
    DISULFID
                48 48
                               INTERCHAIN (WITH HEAVY CHAIN DIMER).
FT
    DISULFID
                54
                     54
                               INTERCHAIN (WITH HEAVY CHAIN DIMER).
FT
    DISULFID
               57
                     57
                               INTERCHAIN (WITH HEAVY CHAIN DIMER).
FT
                              INTERCHAIN (WITH HEAVY CHAIN DIMER).
    DISULFID
               63
                   63
               69 69
72 72
140 140
FT
    DISULFID
                              INTERCHAIN (WITH HEAVY CHAIN DIMER).
FT
    DISULFID
                              INTERCHAIN (WITH HEAVY CHAIN DIMER).
    CARBOHYD
FT
                              N-LINKED (GLCNAC. . .).
```

REMOVED POST-TRANSLATIONALLY.

FT

MOD RES

290 290

```
FT
    VARIANT
                126
                      127
                               OV -> EB (IN ZUC).
FT
                                /FTId=VAR 003890.
FT
    VARIANT
                134
                      134
                               P \rightarrow L (IN OMM).
FT
                               /FTId=VAR 003891.
FT
    VARIANT
                139
                      139
                               F \rightarrow Y (IN OMM).
FT
                               /FTId=VAR 003892.
FT
    VARIANT
                182
                      182
                               T \rightarrow A (IN OMM).
FT
                               /FTId=VAR 003893.
FT
    VARIANT
                227
                      227
                               S \rightarrow N (IN OMM).
FT
                               /FTId=VAR 003894.
FT
    VARIANT
                227
                      227
                               MISSING (IN ZUC).
FT
                               /FTId=VAR 003895.
FT
    VARIANT
               279
                      279
                               F \rightarrow Y (IN OMM).
FT
                               /FTId=VAR 003896.
SO
    SEQUENCE
               290 AA; 32331 MW; E69CBC95705B2F46 CRC64;
 Query Match
                        91.0%; Score 1126; DB 1; Length 290;
 Best Local Similarity
                        90.3%; Pred. No. 9.6e-85;
 Matches 205; Conservative 13; Mismatches
                                              9; Indels
                                                            0; Gaps
                                                                       0;
           2 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 61
Qу
                  Db
          64 DTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVOFKWYVD 123
          62 GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 121
QУ
             Db
         124 GVQVHNAKTKPREQQFNSTFRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKTK 183
Qу
         122 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS 181
             Db
         184 GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPMLDS 243
Qу
         182 DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
             Db
         244 DGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTOKSLSLSPGK 290
RESULT 5
GC RABIT
ID
    GC RABIT
                  STANDARD;
                                PRT;
                                       323 AA.
AC
    P01870;
DT
    21-JUL-1986 (Rel. 01, Created)
DT
    21-JUL-1986 (Rel. 01, Last sequence update)
DT
    15-SEP-2003 (Rel. 42, Last annotation update)
DE
    Ig gamma chain C region.
OS
    Oryctolagus cuniculus (Rabbit).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
OC
OX
    NCBI TaxID=9986;
RN
    [1]
RP
    SEQUENCE FROM N.A.
RX
    MEDLINE=84030930; PubMed=6313520;
RA
    Bernstein K.E., Alexander C.B., Mage R.G.;
RT
    "Nucleotide sequence of a rabbit IgG heavy chain from the recombinant
RT
    F-I haplotype.";
RL
    Immunogenetics 18:387-397(1983).
RN
    [2]
```

```
RP
     SEQUENCE OF 1-128.
RX
    MEDLINE=76135469; PubMed=1243651;
RA
     Pratt D.M., Mole L.E.;
     "Sequence studies on the constant region of the Fd sections of rabbit
RT
     immunoglobulin G of different allotype.";
RT
RL
     Biochem. J. 151:337-349(1975).
RN
RP
     SEQUENCE OF 88-266 FROM N.A.
RX
    MEDLINE=83299917; PubMed=6193512;
    Martens C.L., Moore K.W., Steinmetz M., Hood L., Knight K.L.;
RA
RT
     "Heavy chain genes of rabbit IgG: isolation of a cDNA encoding gamma
    heavy chain and identification of two genomic C gamma genes.";
RT
RL
     Proc. Natl. Acad. Sci. U.S.A. 79:6018-6022(1982).
RN
RP
     SEQUENCE OF 132-161.
RX
    MEDLINE=70110015; PubMed=5461106;
RA
     Fruchter R.G., Jackson S.A., Mole L.E., Porter R.R.;
RT
     "Sequence studies of the Fd section of the heavy chain of rabbit
RT
     immunoglobulin G.";
     Biochem. J. 116:249-259(1970).
RL
RN
RP
     SEQUENCE OF 129-131 AND 155-322.
RA
    Hill R.L., Lebovitz H.E., Fellows R.E. Jr., Delaney R.;
RL
     (In) Killander J. (eds.);
RL
    Gamma globulins, Nobel symp. 3, pp.109-127, Almqvist and Wiksell,
     Stockholm (1967).
RL
CC
     -!- MISCELLANEOUS: REF.1 SEQUENCE HAS THE D12 ALLOTYPIC MARKER,
CC
        104-THR, AND THE E14 MARKER, 185-THR. REF.3 HAS THE D11 AND E15
CC
        MARKERS AND REF.5 THE E15 MARKER.
CC
     -!- SIMILARITY: Contains 3 immunoglobulin-like domains.
CC
     -----
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
DR
    EMBL; M16426; AAA31289.1; -.
DR
     PIR; A91749; GHRB.
DR
    HSSP; P01857; 1FC1.
DR
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003597; Ig cl.
     InterPro; IPR003006; Ig MHC.
DR
DR
    Pfam; PF00047; ig; 2.
    SMART; SM00407; IGc1; 2.
DR
DR
    PROSITE; PS50835; IG LIKE; 3.
DR
    PROSITE; PS00290; IG MHC; 1.
KW
    Immunoglobulin domain; Immunoglobulin C region; Repeat.
FT
    NON TER
                 1
                        1
FT
    DOMAIN
                        96
                 6
                                 IG-LIKE 1.
FT
    DOMAIN
                114
                     213
                                IG-LIKE 2.
FT
    DOMAIN
                222
                      318
                                IG-LIKE 3.
FT
    VARIANT
                104
                     104
                               T -> M (IN D11 MARKER).
               185
FT
    VARIANT
                    185
                               T -> A (IN E15 MARKER).
FT
    CONFLICT
               48
                      48
                               N -> E (IN REF. 2).
```

```
71
                                  V \rightarrow VPV (IN REF. 2).
FT
     CONFLICT
                 144
                        144
                                  Q -> E (IN REF. 3 AND 4).
FT
     CONFLICT
                 173
                        173
                                  N \rightarrow D (IN REF. 5).
FT
                 187
     CONFLICT
                        187
                                  Q \rightarrow E (IN REF. 3 AND 5).
FT
     CONFLICT
                 201
                        201
                                  N \rightarrow D (IN REF. 5).
     CONFLICT
FT
                 218
                        218
                                  Q \rightarrow E (IN REF. 5).
FT
     CONFLICT
                 233
                        233
                                  E \rightarrow Q (IN REF. 5).
                                  N \rightarrow D (IN REF. 5).
FT
     CONFLICT
                 246
                        246
                                  E \rightarrow G (IN REF. 5).
FT
     CONFLICT
                 256
                        256
FT
     CONFLICT
                 260
                        260
                                  N \rightarrow D (IN REF. 5).
FT
     CONFLICT
                 266
                        266
                                  N \rightarrow D (IN REF. 5).
FT
     CONFLICT
                 280
                        280
                                  Y \rightarrow W (IN REF. 5).
FT
     CONFLICT
                284
                        284
                                  N \rightarrow S (IN REF. 5).
SO
     SEQUENCE
                323 AA; 35404 MW; 69E8AA118D579A8B CRC64;
  Query Match
                          74.2%; Score 918.5; DB 1; Length 323;
  Best Local Similarity
                        71.7%; Pred. No. 8.9e-68;
  Matches 167; Conservative 29; Mismatches
                                                 32; Indels
                                                                5; Gaps
                                                                             2;
            1 MDKT---HTC--PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK 55
Qу
                     Db
           91 VDKTVAPSTCSKPTCPPPELLGGPSVFIFPPKPKDTLMISRTPEVTCVVVDVSODDPEVO 150
           56 FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK 115
Qу
              | ||:: :| |:
                              151 FTWYINNEQVRTARPPLREQQFNSTIRVVSTLPITHQDWLRGKEFKCKVHNKALPAPIEK 210
Db
          116 TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTT 175
Qу
              Db
          211 TISKARGQPLEPKVYTMGPPREELSSRSVSLTCMINGFYPSDISVEWEKNGKAEDNYKTT 270
Qу
          176 PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKSLSLSPGK 228
              Db
          271 PAVLDSDGSYFLYNKLSVPTSEWQRGDVFTCSVMHEALHNHYTOKSISRSPGK 323
RESULT 6
GC2 CAVPO
ID
     GC2 CAVPO
                    STANDARD:
                                   PRT:
                                         329 AA.
AC
     P01862;
DT
     21-JUL-1986 (Rel. 01, Created)
     21-JUL-1986 (Rel. 01, Last sequence update)
15-JUL-1999 (Rel. 38, Last annotation update)
DT
DT
DE
     Ig gamma-2 chain C region.
OS
     Cavia porcellus (Guinea pig).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
     Mammalia; Eutheria; Rodentia; Hystricognathi; Caviidae; Cavia.
OC
OX
     NCBI TaxID=10141;
RN
     [1]
RP
     SEQUENCE OF 1-3.
RA
     Trischmann T.M.;
RL
     Submitted (APR-1975) to the PIR data bank.
RN
RP
     SEQUENCE OF 4-68.
RX
     MEDLINE=71058471; PubMed=5538606;
     Birshtein B.K., Hussain Q.Z., Cebra J.J.;
RA
RT
     "Structure of heavy chain from strain 13 quinea pig
```

FT

CONFLICT

71

```
RT
     immunoglobulin-G(2). 3. Amino acid sequence of the region around the
RT
     half-cystine joining heavy and light chains.";
RL
     Biochemistry 10:18-25(1971).
RN
     [3]
RP
     SEQUENCE OF 69-133 AND 312-329.
     MEDLINE=71058486; PubMed=5538616;
     Turner K.J., Cebra J.J.;
RΑ
RT
     "Structure of heavy chain from strain 13 guinea pig
RT
     immunoglobulin-G(2). II. Amino acid sequence of the carboxyl-terminal
RT
     and hinge region cyanogen bromide fragments.";
RL
     Biochemistry 10:9-17(1971).
RN
RP
     SEQUENCE OF 134-226.
RX
     MEDLINE=75036072; PubMed=4429665;
RA
     Tracey D.E., Cebra J.J.;
RT
     "Primary structure of the CH2 homology region from quinea pig IqG2
RT
     antibodies.";
RL
     Biochemistry 13:4796-4803(1974).
RN
RP
     SEQUENCE OF 227-311.
RX
     MEDLINE=75036073; PubMed=4609467;
RA
     Trischmann T.M., Cebra J.J.;
RT
     "Primary structure of the CH3 homology region from quinea pig IqG2
RT
     antibodies.";
RL
     Biochemistry 13:4804-4811(1974).
RN
     [6]
RP
     DISULFIDE BONDS.
     MEDLINE=71058474; PubMed=4922544;
RX
RA
     Oliveira B., Lamm M.E.;
     "Interchain disulfide bridges of guinea pig gamma-2-immunoglobulin.";
RT
RL
     Biochemistry 10:26-31(1971).
CC
     -!- MISCELLANEOUS: THIS CHAIN WAS ISOLATED FROM POOLED SERUM OF STRAIN
CC
         13 INBRED GUINEA PIGS.
DR
     PIR; A94553; G2GP.
DR
    HSSP; P01842; 7FAB.
DR
     InterPro; IPR007110; Ig-like.
DR
     InterPro; IPR003597; Ig c1.
DR
     InterPro; IPR003006; Iq MHC.
DR
     Pfam; PF00047; iq; 2.
DR
     SMART; SM00407; IGc1; 2.
DR
     PROSITE; PS50835; IG_LIKE; 3.
DR
     PROSITE; PS00290; IG MHC; 1.
KW
     Immunoglobulin domain; Immunoglobulin C region; Glycoprotein.
FT
    NON TER
                   1
                          1
FT
    DISULFID
                                  INTERCHAIN (WITH A LIGHT CHAIN).
                  16
                         16
FT
    DISULFID
                  28
                         79
FT
    DISULFID
                105
                        105
                                  INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
                107
                        107
                                  INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
                110
                        110
                                  INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
                142
                        202
FT
    CARBOHYD
                178
                        178
                                  N-LINKED (GLCNAC. . .).
FT
    DISULFID
                248
                        308
    SEQUENCE 329 AA; 36074 MW; 5D231B7164D1FBA9 CRC64;
SO
 Query Match
                          71.8%; Score 889; DB 1; Length 329;
 Best Local Similarity
                         72.3%; Pred. No. 2.3e-65;
 Matches 162; Conservative 24; Mismatches
                                                 36; Indels
                                                                 2; Gaps
                                                                              1;
```

```
Оy
          6 TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV 65
            Db
         106 TCPKCPPPENLGGPSVFIFPPKPKDTLMISLTPRVTCVVVDVSODEPEVOFTWFVDNKPV 165
         66 HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR 125
Qу
             Db
         166 GNAETKPRVEQYNTTFRVESVLPIQHQDWLRGKEFKCKVYNKALPAPIEKTISKTKGAPR 225
Qу
         126 EPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP--ENNYKTTPPVLDSDG 183
             226 MPDVYTLPPSRDELSKSKVSVTCLIINFFPADIHVEWASNRVPVSEKEYKNTPPIEDADG 285
Db
         184 SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 227
Qу
            Db
         286 SYFLYSKLTVDKSAWDQGTVYTCSVMHEALHNHVTQKAISRSPG 329
RESULT 7
GC3 MOUSE
    GC3 MOUSE
                STANDARD;
                            PRT; 329 AA.
AC
    P22436;
DT
    01-AUG-1991 (Rel. 19, Created)
DT
    01-AUG-1991 (Rel. 19, Last sequence update)
    16-OCT-2001 (Rel. 40, Last annotation update)
DT
DE
    Ig gamma-3 chain C region, secreted form.
OS
    Mus musculus (Mouse).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
    [1]
RP
    SEQUENCE FROM N.A.
    MEDLINE=85027161; PubMed=6092053;
RX
RA
    Wels J.A., Word C.J., Rimm D., Der-Balan G.P., Martinez H.M.,
RA
    Tucker P.W., Blattner F.R.;
    "Structural analysis of the murine IgG3 constant region gene.";
RT
    EMBO J. 3:2041-2046(1984).
RL
CC
    CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
    use by non-profit institutions as long as its content is in no way
CC
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
    ------
DR
    EMBL; J00451; -; NOT ANNOTATED CDS.
DR
    PIR; B02156; G3MSC.
DR
    HSSP; P01857; 1FC1.
DR
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003597; Ig_c1.
DR
    InterPro; IPR003006; Iq MHC.
    Pfam; PF00047; ig; 3.
DR
DR
    SMART; SM00407; IGc1; 2.
    PROSITE; PS50835; IG LIKE; 3.
DR
DR
    PROSITE; PS00290; IG MHC; 1.
KW
    Immunoglobulin domain; Immunoglobulin C region; Glycoprotein;
```

```
Transmembrane; Alternative splicing.
FT
    NON TER
               1
                       1
FT
    DOMAIN
                      97
                1
                               CH1.
FT
    DOMAIN
                98
                     113
                              HINGE.
    DOMAIN
                      223
                               CH2.
FT ·
               114
FT
    DOMAIN
               224
                     327
                               CH3.
SO
    SEQUENCE
              329 AA; 36228 MW; F45827174182BAD6 CRC64;
 Query Match
                       68.3%; Score 845.5; DB 1; Length 329;
 Best Local Similarity
                       67.0%; Pred. No. 8.1e-62;
 Matches 150; Conservative 34; Mismatches
                                            37; Indels
                                                           3; Gaps
                                                                      1:
Qу
           8 PP---CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE 64
                    Db
         106 PPGSSCPPGNILGGPSVFIFPPKPKDALMISLTPKVTCVVVDVSEDDPDVHVSWFVDNKE 165
          65 VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGOP 124
Qу
            Db
         166 VHTAWTQPREAQYNSTFRVVSALPIQHQDWMRGKEFKCKVNNKALPAPIERTISKPKGRA 225
         125 REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS 184
QУ
             Db
         226 QTPQVYTIPPPREQMSKKKVSLTCLVTNFFSEAISVEWERNGELEQDYKNTPPILDSDGT 285
         185 FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
QУ
            Dh
         286 YFLYSKLTVDTDSWLQGEIFTCSVVHEALHNHHTQKNLSRSPGK 329
RESULT 8
GCB RAT
ID
    GCB RAT
                  STANDARD;
                               PRT;
                                      333 AA.
AC
    P20761;
DT
    01-FEB-1991 (Rel. 17, Created)
    01-FEB-1991 (Rel. 17, Last sequence update)
DT
DT
    15-SEP-2003 (Rel. 42, Last annotation update)
DE
    Ig gamma-2B chain C region.
OS
    Rattus norvegicus (Rat).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC.
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX
    NCBI TaxID=10116;
RN
RP
    SEQUENCE FROM N.A.
RX
    MEDLINE=89232738; PubMed=3149946;
RA
    Brueggemann M.;
RT
    "Evolution of the rat immunoglobulin gamma heavy-chain gene family.";
RL
    Gene 74:473-482(1988).
CC
    -!- SIMILARITY: Contains 3 immunoglobulin-like domains.
DR
    PIR; PS0018; PS0018.
DR
    HSSP; P01842; 7FAB.
DR
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003597; Iq c1.
DR
    InterPro; IPR003006; Ig MHC.
DR
    Pfam; PF00047; ig; 3.
    SMART; SM00407; IGc1; 2.
DR
DR
    PROSITE; PS50835; IG_LIKE; 3.
DR
    PROSITE; PS00290; IG MHC; 1.
```

KW

```
KW
     Immunoglobulin domain; Immunoglobulin C region; Repeat.
FT
    NON TER
                 1
                        1
FT
     DOMAIN
                 6
                       96
                               IG-LIKE 1.
FT
    DOMAIN
                      223
               124
                               IG-LIKE 2.
FT
    DOMAIN
               232
                      328
                               IG-LIKE 3.
FT
    DISULFID
                15
                       15
                               INTERCHAIN (WITH A LIGHT CHAIN).
FΤ
    DISULFID
                27
                       80
FT
    DISULFID
               106
                      106
                               INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
               109
                      109
                               INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
               112
                      112
                               INTERCHAIN (WITH A HEAVY CHAIN).
FΤ
    DISULFID
               115
                      115
                               INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
               147
                      207
FT
    DISULFID
               253
                      311
SO
    SEQUENCE
              333 AA; 36497 MW; 55F8B64D48D460A6 CRC64;
  Query Match
                        67.7%; Score 838; DB 1; Length 333;
  Best Local Similarity
                        66.4%; Pred. No. 3.3e-61;
  Matches 148; Conservative 33; Mismatches 42; Indels
                                                                       0:
Qу
           6 TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV 65
             Db
         111 TCHKCPVPELLGGPSVFIFPPKPKDILLISONAKVTCVVVDVSEEEPDVOFSWFVNNVEV 170
Qу
          66 HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR 125
             171 HTAQTQPREEQYNSTFRVVSALPIQHQDWMSGKEFKCKVNNKALPSPIEKTISKPKGLVR 230
Db
         126 EPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLDSDGSF 185
Qу
             231 KPQVYVMGPPTEQLTEQTVSLTCLTSGFLPNDIGVEWTSNGHIEKNYKNTEPVMDSDGSF 290
Db
         186 FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKSLSLSPGK 228
Qу
             1:|||| |::|||
                            291 FMYSKLNVERSRWDSRAPFVCSVVHEGLHNHHVEKSISRPPGK 333
Db
RESULT 9
GC3M MOUSE
    GC3M MOUSE
ID
                  STANDARD;
                                PRT:
                                       398 AA.
AC
    P03987:
DT
    23-OCT-1986 (Rel. 02, Created)
    01-AUG-1991 (Rel. 19, Last sequence update)
DT
    15-JUL-1999 (Rel. 38, Last annotation update)
DT
DE
    Ig gamma-3 chain C region, membrane-bound form.
OS
    Mus musculus (Mouse).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae: Mus.
OX
    NCBI TaxID=10090;
RN
    [1]
RΡ
    SEQUENCE FROM N.A.
RX
    MEDLINE=85027161; PubMed=6092053;
RA
    Wels J.A., Word C.J., Rimm D., Der-Balan G.P., Martinez H.M.,
RA
    Tucker P.W., Blattner F.R.;
    "Structural analysis of the murine IgG3 constant region gene.";
RT
RL
    EMBO J. 3:2041-2046(1984).
RN
    [2]
RP
    SEQUENCE OF 328-398 FROM N.A.
```

```
RX
    MEDLINE=84041483; PubMed=6314258;
RA
    Komaromy M., Clayton L., Rogers J., Robertson S., Kettman J.,
RA
    Wall R.;
RT
    "The structure of the mouse immunoglobulin in gamma 3 membrane gene
RT
    segment.":
    Nucleic Acids Res. 11:6775-6785(1983).
RL
CC
    ______
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
CC
    the European Bioinformatics Institute. There are no restrictions on its
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
    EMBL; J00451; AAB59655.1; -.
DR
DR
    EMBL; V01526; CAA24767.1; ALT SEQ.
DR
    PIR; A02156; G3MSM.
DR
    HSSP: P01857: 1FC1.
DR
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003597; Ig cl.
DR
    InterPro; IPR003006; Ig MHC.
DR
    Pfam; PF00047; ig; 3.
DR
    SMART; SM00407; IGc1; 2.
    PROSITE; PS50835; IG LIKE; 3.
DR
DR
    PROSITE; PS00290; IG MHC; 1.
KW
    Immunoglobulin domain; Immunoglobulin C region; Glycoprotein;
KW
    Transmembrane; Alternative splicing.
FT
    NON TER
               1
                      1
FT
    DOMA I N
                1
                      97
                              CH1.
FT
    DOMAIN
               98
                     113
                             HINGE.
FT
    DOMAIN
              114 223
                             CH2.
FT
               224 327
    DOMAIN
                              CH3.
            346 362
363 398
333 333
342 342
FT
    TRANSMEM
                             POTENTIAL.
FT
    DOMAIN
                              CYTOPLASMIC (POTENTIAL).
FT
    CONFLICT
                             E \rightarrow G (IN REF. 2).
FT
    CONFLICT
                             E \rightarrow Q (IN REF. 2).
FT
    CONFLICT
              388
                    388
                             P \rightarrow F (IN REF. 2).
SO
    SEQUENCE 398 AA; 43929 MW; CF7F264B50A41B95 CRC64;
 Query Match 67.4%; Score 834.5; DB 1; Length 398; Best Local Similarity 66.7%; Pred. No. 8e-61;
 Matches 148; Conservative 34; Mismatches 37; Indels
                                                          3; Gaps
                                                                     1;
          8 PP---CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE 64
Qу
                Db
         106 PPGSSCPPGNILGGPSVFIFPPKPKDALMISLTPKVTCVVVDVSEDDPDVHVSWFVDNKE 165
         65 VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP 124
Qу
            Db
         166 VHTAWTQPREAQYNSTFRVVSALPIQHQDWMRGKEFKCKVNNKALPAPIERTISKPKGRA 225
         125 REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS 184
Qу
            Db
        226 QTPQVYTIPPPREQMSKKKVSLTCLVTNFFSEAISVEWERNGELEQDYKNTPPILDSDGT 285
Qу
        185 FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP 226
```

```
RESULT 10
GC1 RAT
ID
     GC1 RAT
                   STANDARD;
                                  PRT;
                                        326 AA.
AC
     P20759;
DΤ
     01-FEB-1991 (Rel. 17, Created)
DT
     01-FEB-1991 (Rel. 17, Last sequence update)
DT
     15-JUL-1999 (Rel. 38, Last annotation update)
     Ig gamma-1 chain C region.
DE
OS
     Rattus norvegicus (Rat).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX
     NCBI TaxID=10116;
RN
     [1]
RP
     SEQUENCE FROM N.A.
RX
    MEDLINE=89232738; PubMed=3149946;
RA
    Brueggemann M.;
RT
     "Evolution of the rat immunoglobulin gamma heavy-chain gene family.";
RL
     Gene 74:473-482(1988).
DR
     PIR; PS0017; PS0017.
DR
    HSSP; P01842; 7FAB.
DR
     InterPro; IPR007110; Iq-like.
     InterPro; IPR003597; Ig cl.
DR
     InterPro; IPR003006; Ig MHC.
DR
     Pfam; PF00047; ig; 3.
     SMART; SM00407; IGc1; 2.
DR
DR
     PROSITE; PS50835; IG LIKE; 3.
DR
     PROSITE; PS00290; IG MHC; 1.
     Immunoglobulin domain; Immunoglobulin C region; Glycoprotein.
KW
FΤ
    NON TER
                  1
                         1
FT
    DOMAIN
                  1
                        97
                                 CH1.
FT
    DOMAIN
                 98
                       112
                                 HINGE.
FT
    DOMAIN
                113
                       219
                                 CH2.
FT
    DOMAIN
                220
                       326
                                 CH3.
FT
    DISULFID
                 27
                        82
FT
    DISULFID
                102
                       102
                                 INTERCHAIN (WITH A HEAVY CHAIN).
FΤ
    DISULFID
                106
                       106
                                 INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
                109
                       109
                                 INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
                111
                       111
                                 INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
                140
                       200
FT
    DISULFID
                246
                       304
FT
    CARBOHYD
                176
                       176
                                N-LINKED (GLCNAC. . .) (POTENTIAL).
SO
    SEQUENCE
               326 AA; 35946 MW; 013BAB45EF49B9DA CRC64;
  Query Match
                         66.1%; Score 818.5; DB 1; Length 326;
 Best Local Similarity
                         63.1%; Pred. No. 1.3e-59;
 Matches 142; Conservative 41; Mismatches
                                                35; Indels
                                                               7;
                                                                  Gaps
                                                                          2;
           7 CPPCPAPELLGG---PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV 63
Qу
                    :
                             Db
         106 CKPC----ICTGSEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISQDDPEVHFSWFVDDV 161
          64 EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ 123
Qу
```

```
Db
          162 EVHTAQTRPPEEQFNSTFRSVSELPILHQDWLNGRTFRCKVTSAAFPSPIEKTISKPEGR 221
Qу
          124 PREPOVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLDSDG 183
               Db
          222 TQVPHVYTMSPTKEEMTQNEVSITCMVKGFYPPDIYVEWOMNGOPOENYKNTPPTMDTDG 281
Qу
          184 SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
              Db
          282 SYFLYSKLNVKKEKWOOGNTFTCSVLHEGLHNHHTEKSLSHSPGK 326
RESULT 11
GC1 MOUSE
     GC1 MOUSE
ID
                   STANDARD;
                                  PRT;
                                        324 AA.
AC
     P01868;
DT
     21-JUL-1986 (Rel. 01, Created)
DT
     21-JUL-1986 (Rel. 01, Last sequence update)
DT
     15-SEP-2003 (Rel. 42, Last annotation update)
DΕ
     Ig gamma-1 chain C region secreted form.
OS
     Mus musculus (Mouse).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
     Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
     NCBI TaxID=10090;
RN
     [1]
RP
     SEQUENCE FROM N.A.
RX
    MEDLINE=80045036; PubMed=115593;
     Honjo T., Obata M., Yamawaki-Kataoka Y., Kataoka T., Kawakami T.,
RA
RA
     Takahashi N., Mano Y.;
RT
     "Cloning and complete nucleotide sequence of mouse immunoglobulin
RT
     gamma 1 chain gene.";
RL
    Cell 18:559-568(1979).
RN
    [2]
     SEQUENCE OF 76-324 FROM N.A. (MYELOMA PROTEIN MOPC 31C).
RP
RX
    MEDLINE=80202559; PubMed=6769752;
RA
    Obata M., Yamawaki-Kataoka Y., Takahashi N., Kataoka T., Shimizu A.,
RA
     Mano Y., Seidman J.G., Peterlin B.M., Leder P., Honjo T.;
RT
     "Immunoglobulin gamma 1 heavy chain gene: structural gene sequences
RT
    cloned in a bacterial plasmid.";
RL
    Gene 9:87-97(1980).
RN
    SEQUENCE OF 70-322 FROM N.A. (MYELOMA PROTEIN MOPC 21).
RP
RX
    MEDLINE=80012837; PubMed=113776;
    Rogers J., Clarke P., Salser W.;
RA
RT
     "Sequence analysis of cloned cDNA encoding part of an immunoglobulin
RT
    heavy chain.";
RL
    Nucleic Acids Res. 6:3305-3321(1979).
RN
RP
    SEQUENCE (MYELOMA PROTEIN MOPC 21).
    MEDLINE=78242288; PubMed=98524;
RX
    Adetugbo K.;
RA
RT
    "Evolution of immunoglobulin subclasses. Primary structure of a
RT
    murine myeloma gammal chain.";
RL
    J. Biol. Chem. 253:6068-6075(1978).
RN
    [5]
RP
    DISULFIDE BONDS (MOPC 21).
RX
    MEDLINE=73008889; PubMed=5073237;
    Svasti J., Milstein C.;
RA
```

```
RT
     "The disulphide bridges of a mouse immunoglobulin G1 protein.";
RL
     Biochem. J. 126:837-850(1972).
CC
     -! - SUBCELLULAR LOCATION: Secreted.
CC
     -!- ALTERNATIVE PRODUCTS:
CC
        Event=Alternative splicing; Named isoforms=2;
CC
        Name=Secreted:
CC
          IsoId=P01868-1; Sequence=Displayed;
CC
          Note=May be the major isoform;
        Name=Membrane-bound;
CC
CC
          IsoId=P01869-1; Sequence=External;
     CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
    use by non-profit institutions as long as its content is in no way
CC
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
     DR
    EMBL; V00793; CAA24172.1; -.
    EMBL; V00793; CAA24173.1; -.
DR
    EMBL; V00793; CAA24174.1; -.
DR
    EMBL; V00793; CAA24175.1; -.
DR
    EMBL; V00795; CAA24176.1; -.
DR
DR
    PIR; A02159; G1MS.
    PDB; 1IGC; 03-JUN-95.
DR
    GlycoSuiteDB; P01868; -.
DR
    MGD; MGI:96446; Igh-4.
DR
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003597; Ig c1.
DR
    InterPro; IPR003006; Ig_MHC.
DR
    Pfam; PF00047; ig; 3.
DR
    SMART; SM00407; IGc1; 2.
DR
    PROSITE; PS50835; IG LIKE; 3.
DR
    PROSITE; PS00290; IG MHC; 1.
KW
    Immunoglobulin domain; Immunoglobulin C region; Glycoprotein;
    Alternative splicing; 3D-structure.
KW
FT
    NON TER
                1
                       1
FT
    DOMAIN
                1
                       97
                                CH1.
FT
    DOMAIN
                98
                      110
                               HINGE.
               111
                                              DOMAIN
ÊΤ
                      217
                               CH2.
FT
    DOMAIN
               218
                      324
                               CH3.
FT
    DISULFID
               27
                      82
FT
    DISULFID
               102
                      102
                               INTERCHAIN (WITH A LIGHT CHAIN).
FT
    DISULFID
               104
                     104
                               INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
               107
                      107
                               INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
               109
                      109
                               INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
               138
                      198
FT
    CARBOHYD
               174
                      174
                               N-LINKED (GLCNAC. . .).
FT
                               /FTId=CAR 000055.
FT
    DISULFID
               244
                      302
FT
    MOD RES
               324
                      324
                               REMOVED POST-TRANSLATIONALLY.
FT
    CONFLICT
               276
                      276
                               N \rightarrow D (IN REF. 3).
FT
    CONFLICT
               278
                      278
                               N \rightarrow D (IN REF. 3).
              324 AA; 35704 MW; A338812F3D1F2C93 CRC64;
SO
    SEQUENCE
 Query Match
                       66.0%; Score 817.5; DB 1; Length 324;
```

```
Best Local Similarity 62.5%; Pred. No. 1.5e-59;
 Matches 140; Conservative 44; Mismatches 35; Indels
                                                           5; Gaps
                                                                      2:
           7 CPP--CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE 64
QУ
             104 CKPCICTVPEV---SSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVE 160
Db
Qу
          65 VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGOP 124
             Db
         161 VHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRP 220
         125 REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS 184
QУ
             221 KAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMNTNGS 280
Db
         185 FFLYSKLTVDKSRWOOGNVFSCSVMHEALHNHYTOKSLSLSPGK 228
Qу
             Db
         281 YFVYSKLNVOKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK 324
RESULT 12
GC1M MOUSE
    GC1M MOUSE
                  STANDARD;
                               PRT;
                                      393 AA.
AC
    P01869;
DT
    21-JUL-1986 (Rel. 01, Created)
DT
    01-AUG-1991 (Rel. 19, Last sequence update)
    15-SEP-2003 (Rel. 42, Last annotation update)
DT
    Ig gamma-1 chain C region, membrane-bound form.
DE
OS
    Mus musculus (Mouse).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
    [1]
RP
    SEQUENCE FROM N.A.
RX
    MEDLINE=80045036; PubMed=115593;
RΑ
    Honjo T., Obata M., Yamawaki-Kataoka Y., Kataoka T., Kawakami T.,
RA
    Takahashi N., Mano Y.;
RT
    "Cloning and complete nucleotide sequence of mouse immunoglobulin
RT
    gamma 1 chain gene.";
RL
    Cell 18:559-568(1979).
RN.
    [2]
RP
    SEQUENCE OF 323-393 FROM N.A.
RX
    MEDLINE=82197626; PubMed=6804950;
    Tyler B.M., Cowman A.F., Gerondakis S.D., Adams J.M., Bernard O.;
RA
    "mRNA for surface immunoglobulin gamma chains encodes a highly
RT
RT
    conserved transmembrane sequence and a 28-residue intracellular
RT
    domain.";
RL
    Proc. Natl. Acad. Sci. U.S.A. 79:2008-2012(1982).
RN
RP
    SEQUENCE OF 323-366 FROM N.A.
RX
    MEDLINE=82115295; PubMed=6799207;
RA
    Rogers J., Choi E., Souza L., Carter C., Word C.J., Kuehl M.,
RA
    Eisenberg D., Wall R.;
RT
    "Gene segments encoding transmembrane carboxyl termini of
RT
    immunoqlobulin gamma chains.";
RL
    Cell 26:19-27(1981).
RN
    [4]
```

```
SEQUENCE OF 1-44 FROM N.A.
RX
     MEDLINE=82222190; PubMed=6283537;
RA
     Yamawaki-Kataoka Y., Nakai S., Miyata T., Honjo T.;
RT
     "Nucleotide sequences of gene segments encoding membrane domains of
     immunoglobulin gamma chains.";
RT
RL
     Proc. Natl. Acad. Sci. U.S.A. 79:2623-2627(1982).
CC
     -!- ALTERNATIVE PRODUCTS:
CC
         Event=Alternative splicing; Named isoforms=2;
CC
         Name=Membrane-bound;
CC
          IsoId=P01869-1; Sequence=Displayed;
CC
         Name=Secretéd;
          IsoId=P01868-1; Sequence=External;
CC
CC
          Note=May be the major isoform;
CC
     ------
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
     use by non-profit institutions as long as its content is in no way
CC
CC
     modified and this statement is not removed. Usage by and for commercial
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
CC
     or send an email to license@isb-sib.ch).
CC
     EMBL; V00793; CAA24172.1; -.
DR
     EMBL; V00793; CAA24173.1; -.
DR
DR
     EMBL; V00793; CAA24174.1; -.
     PIR; B02159; G1MSM.
DR
     PDB; 15C8; 23-MAR-99.
DR
     PDB; 1AE6; 18-MAR-98.
DR
     PDB; 1CL7; 12-JAN-00.
DR
     PDB; 1F11; 06-FEB-01.
DR
     PDB; 1F58; 29-DEC-99.
DR
     PDB; 1KC5; 24-JUL-02.
DR
     PDB; 1KCR; 11-MAY-02.
DR
     PDB; 25C8; 09-JUL-99.
DR
     MGD; MGI:96446; Igh-4.
     InterPro; IPR007110; Ig-like.
DR
     InterPro; IPR003597; Ig_c1.
DR
DR
     InterPro; IPR003006; Ig MHC.
DR
     Pfam; PF00047; ig; 3.
DR
     SMART; SM00407; IGc1; 2.
DR
     PROSITE; PS50835; IG_LIKE; 3.
DR
     PROSITE; PS00290; IG MHC; 1.
KW
     Immunoglobulin domain; Immunoglobulin C region; Glycoprotein;
KW
     Alternative splicing; Transmembrane; 3D-structure.
FT
     NON TER
                  1
                         1
FT
     DOMAIN
                        97
                  1
                                 CH1.
FT
     DOMAIN
                 98
                       110
                                 HINGE.
FT
     DOMAIN
                111
                       217
                                 CH2.
FT
     DOMAIN
                218
                       324
                                 CH3.
FT
     DISULFID
                 27
                       82
FT
     DISULFID
                102
                       102
                                 INTERCHAIN (WITH A LIGHT CHAIN).
FT
     DISULFID
                104
                       104
                                 INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
                107
                       107
                                 INTERCHAIN (WITH A HEAVY CHAIN).
FT
     DISULFID
                109
                       109
                                 INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
                138
                       198
FT
     CARBOHYD
                174
                       174
                                 N-LINKED (GLCNAC. . .).
FT
    DISULFID
                244
                       302
```

RP

```
FT
    DOMAIN
              358
                     393
                             CYTOPLASMIC (POTENTIAL).
SO
    SEQUENCE
             393 AA; 43386 MW; 4CC88343B7A1CE27 CRC64;
                      65.6%; Score 812.5; DB 1; Length 393;
  Ouery Match
 Best Local Similarity 62.3%; Pred. No. 4.9e-59;
 Matches 139; Conservative 44; Mismatches 35; Indels
                                                        5; Gaps
          7 CPP--CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE 64
Qу
            Db '
        104 CKPCICTVPEV---SSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVOFSWFVDDVE 160
         65 VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP 124
Qу
            Db
        161 VHTAOTOPREEOFNSTFRSVSELPIMHODWLNGKEFKCRVNSAAFPAPIEKTISKTKGRP 220
        125 REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOPENNYKTTPPVLDSDGS 184
QУ
            221 KAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMNTNGS 280
Db
Qу
        185 FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 227
            Db
        281 YFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPG 323
RESULT 13
GCC RAT
    GCC RAT
ID
                 STANDARD;
                              PRT;
                                    329 AA.
    P20762;
AC
DT
    01-FEB-1991 (Rel. 17, Created)
    01-FEB-1991 (Rel. 17, Last sequence update)
DT
DT
    15-JUL-1999 (Rel. 38, Last annotation update)
DE
    Ig gamma-2C chain C region.
OS
    Rattus norvegicus (Rat).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
ΟX
    NCBI TaxID=10116;
RN
    [1]
RP
    SEQUENCE FROM N.A.
RX
    MEDLINE=88166903; PubMed=3127222;
RA
    Brueggemann M., Delmastro-Galfre P., Waldmann H., Calabi F.;
ŔТ
    "Sequence of a rat immunoglobulin gamma 2c heavy chain constant
RT
    region cDNA: extensive homology to mouse gamma 3.";
RL
    Eur. J. Immunol. 18:317-319(1988).
    ------
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
    use by non-profit institutions as long as its content is in no way
CC
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
                           -----
CC
    EMBL; X07189; CAA30169.1; -.
DR
DR
    PIR; S00847; S00847.
DR
    HSSP; P01842; 7FAB.
DR
    InterPro; IPR007110; Iq-like.
```

POTENTIAL.

FT

TRANSMEM

340 357

```
DR
    InterPro; IPR003597; Ig cl.
DR
    InterPro; IPR003006; Iq MHC.
DR
    Pfam; PF00047; ig; 2.
DR
    SMART; SM00407; IGc1; 2.
    PROSITE; PS50835; IG LIKE; 3.
DR
    PROSITE; PS00290; IG MHC; 1.
DR
KW
    Immunoglobulin domain; Immunoglobulin C region.
    NON TER
FT
                 1
                       1
FT
    DOMAIN
                 1
                      97
                               CH1.
FT
    DOMAIN
                98
                     113
                               HINGE.
FT
    DOMAIN
               114
                     222
                               CH2.
FT
    DOMAIN
               223
                     329
                               CH3.
FT
    DISULFID
               15
                      15
                               INTERCHAIN (WITH A LIGHT CHAIN).
FT
    DISULFID
                27
                      82
FT
    DISULFID
               111
                     111
                               INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
               113
                     113
                               INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
               143
                     203
FT
    DISULFID
              249
                     307
SO
    SEOUENCE
              329 AA; 36571 MW; 5FCD7B7933850773 CRC64;
  Query Match
                       65.4%; Score 809.5; DB 1; Length 329;
  Best Local Similarity
                       63.8%; Pred. No. 6.9e-59;
  Matches 143; Conservative 41; Mismatches
                                            37; Indels
                                                           3; Gaps
                                                                      1;
Qу
           8 PP---CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE 64
             Db
         106 PPTDICSCDDNLGRPSVFIFPPKPKDILMITLTPKVTCVVVDVSEEEPDVQFSWFVDNVR 165
          65 VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP 124
Qу
             Db
         166 VFTAQTQPHEEQLNGTFRVVSTLHIOHODWMSGKEFKCKVNNKDLPSPIEKTISKPRGKA 225
Qу
         125 REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS 184
             Db
         226 RTPQVYTIPPPREQMSKNKVSLTCMVTSFYPASISVEWERNGELEQDYKNTLPVLDSDES 285
Qу
         185 FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 228
             Db
         286 YFLYSKLSVDTDSWMRGDIYTCSVVHEALHNHHTQKNLSRSPGK 329
RESULT 14
GCAA MOUSE
ID
    GCAA MOUSE
                  STANDARD;
                               PRT;
                                      330 AA.
AC
    P01863;
    21-JUL-1986 (Rel. 01, Created)
DT
DΤ
    21-JUL-1986 (Rel. 01, Last sequence update)
DT
    15-SEP-2003 (Rel. 42, Last annotation update)
DΕ
    Ig gamma-2A chain C region, A allele.
OS
    Mus musculus (Mouse).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
    [1]
RP
    SEQUENCE FROM N.A.
RX
    MEDLINE=81076554; PubMed=6777755;
RA
    Sikorav J.-L., Auffray C., Rougeon F.;
```

```
RT
     "Structure of the constant and 3' untranslated regions of the murine
RT
     Balb/c gamma 2a heavy chain messenger RNA.";
RL
     Nucleic Acids Res. 8:3143-3155(1980).
RN
     [2]
     SEQUENCE FROM N.A.
RP
     MEDLINE=81198976; PubMed=6262729;
RX
     Yamawaki-Kataoka Y., Miyata T., Honjo T.;
RA
RT
     "The complete nucleotide sequence of mouse immunoglobin gamma 2a gene
RT
     and evolution of heavy chain genes: further evidence for intervening
RT
     sequence-mediated domain transfer.";
RL
     Nucleic Acids Res. 9:1365-1381(1981).
RN
RΡ
     SEQUENCE FROM N.A.
RX
     MEDLINE=81223894; PubMed=6787604;
     Ollo R., Auffray C., Morchamps C., Rougeon F.;
RA
RT
     "Comparison of mouse immunoglobulin gamma 2a and gamma 2b chain genes
     suggests that exons can be exchanged between genes in a multigenic
RT
RT
     family.";
RL
     Proc. Natl. Acad. Sci. U.S.A. 78:2442-2446(1981).
RN
RP
     MYELOMA PROTEIN MOPC 173.
RX
     MEDLINE=74175517; PubMed=4831970;
RA
     Bourgois A., Fougereau M., Rocca-Serra J.;
RT
     "Determination of the primary structure of a mouse IgG2a
RT
     immunoglobulin:amino-acid sequence of the Fc fragment. Implications
RT
     for the evolution of immunoglobulin structure and function.";
RL
     Eur. J. Biochem. 43:423-435(1974).
RN
     [5]
RP
     DISULFIDE BONDS.
RX
     MEDLINE=73056887; PubMed=4565406;
RA
     de Preval C., Fougereau M.;
RT
     "Determination of the primary structure of a mouse gamma G2a
RT
     immunoglobulin. Identification of the disulfide bridges.";
RL
     Eur. J. Biochem. 30:452-462(1972).
CC
     -!- SIMILARITY: Contains 3 immunoglobulin-like domains.
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC.
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
CC
     or send an email to license@isb-sib.ch).
CC
     DR
     EMBL; V00798; CAA24178.1; -.
DR
     PIR; A02152; G2MSA.
DR
     PDB; 1E4W; 12-JUL-01.
DR
     PDB; 1E4X; 12-JUL-01.
DR
     PDB; 1MNU; 06-MAY-99.
DR
    InterPro; IPR007110; Ig-like.
DR
    InterPro; IPR003597; Ig_c1.
DR
    InterPro; IPR003006; Ig MHC.
    Pfam; PF00047; ig; 2.
DR
DR
    SMART; SM00407; IGc1; 2.
    PROSITE; PS50835; IG_LIKE; 3.
DR
    PROSITE; PS00290; IG MHC; 1.
DR
    Immunoglobulin domain; Immunoglobulin C region; 3D-structure; Repeat.
KW
```

```
FΤ
    DOMAIN
                 6
                       98
                               IG-LIKE 1.
FT
    DOMAIN
                121
                      220
                               IG-LIKE 2.
FT
    DOMAIN
                229
                      325
                               IG-LIKE 3.
FT
    DISULFID
                15
                      15
                               INTERCHAIN (WITH A LIGHT CHAIN).
FT
    DISULFID
                 27
                       82
FT
    DISULFID
                107
                      107
                               INTERCHAIN (WITH A HEAVY CHAIN).
FΤ
                               INTERCHAIN (WITH A HEAVY CHAIN).
    DISULFID
                110
                      110
FT
    DISULFID
                112
                      112
                               INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
                144
                      204
FT
    DISULFID
               250
                      308
FT
    MOD RES
               330
                      330
                               REMOVED POST-TRANSLATIONALLY.
SO
    SEOUENCE
               330 AA; 36389 MW; B84361C5445A6864 CRC64;
 Query Match
                        65.3%; Score 809; DB 1; Length 330;
 Best Local Similarity 65.2%; Pred. No. 7.6e-59;
 Matches 146; Conservative 30; Mismatches 46; Indels
                                                                Gaps
                                                                       1;
           7 CPP--CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE 64
Ov
             Db
         107 CPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVOISWFVNNVE 166
QУ
          65 VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGOP 124
                     167 VHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSV 226
Db
Qу
         125 REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS 184
             227 RAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGS 286
Db
Qу
         185 FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKSLSLSPGK 228
             :|:|||| | :| | :| :||||:|| | | :|||
Db
         287 YFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK 330
RESULT 15
GCAM MOUSE
ID
    GCAM MOUSE
                  STANDARD;
                                PRT;
                                       399 AA.
AC
    P01865;
DT
    21-JUL-1986 (Rel. 01, Created)
    01-AUG-1991 (Rel. 19, Last sequence update)
DT
DT
    15-SEP-2003 (Rel. 42, Last annotation update)
DE
    Ig gamma-2A chain C region, membrane-bound form.
OS
    Mus musculus (Mouse).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
    [1]
RΡ
    SEQUENCE FROM N.A.
RX
    MEDLINE=82222190; PubMed=6283537;
    Yamawaki-Kataoka Y., Nakai S., Miyata T., Honjo T.;
RA
    "Nucleotide sequences of gene segments encoding membrane domains of
RT
RT
    immunoglobulin gamma chains.";
    Proc. Natl. Acad. Sci. U.S.A. 79:2623-2627(1982).
RL
CC
    -!- ALTERNATIVE PRODUCTS:
CC
        Event=Alternative splicing; Named isoforms=2;
CC
        Name=Membrane-bound;
```

FT

NON TER

1

1

```
CC
          IsoId=P01865-1; Sequence=Displayed;
CC
        Name=Secreted:
CC
         IsoId=P01864-1; Sequence=External;
CC
         Note=Probably the major isoform;
    -!- SIMILARITY: Contains 3 immunoglobulin-like domains.
CC
    ______
CC
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
    ------
DR
    EMBL; J00471; AAB59661.1; ALT INIT.
DR
    PIR; A02154; G2MSAM.
DR
    PDB; 1KB5; 08-APR-98.
DR
    PDB; 1YEE; 15-OCT-97.
DR
    MGD; MGI:96443; Igh-1.
DR
    InterPro; IPR007110; Ig-like.
    InterPro; IPR003597; Ig_c1.
DR
DR
    InterPro; IPR003006; Ig_MHC.
DR
    Pfam; PF00047; ig; 2.
DR
    SMART; SM00407; IGc1; 2.
    PROSITE; PS50835; IG LIKE; 3.
DR
    PROSITE; PS00290; IG MHC; 1.
KW
    Immunoglobulin domain; Immunoglobulin C region; Glycoprotein;
KW
    Transmembrane; Alternative splicing; 3D-structure; Repeat.
FT
    NON TER
                1
                       1
FT
    DOMAIN
                6
                      98
                              IG-LIKE 1.
FT
    DOMAIN
               121
                     220
                              IG-LIKE 2.
FT
    DOMAIN
               229
                   325
                              IG-LIKE 3.
FT
    DISULFID
               15
                     15
                              INTERCHAIN (WITH A LIGHT CHAIN).
FT
               27
    DISULFID
                      82
             107 107
110 110
FT
    DISULFID
                              INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
                              INTERCHAIN (WITH A HEAVY CHAIN).
FT
                   112
    DISULFID
             112
                              INTERCHAIN (WITH A HEAVY CHAIN).
FT
    DISULFID
              144
                   204
FT
    DISULFID
              250
                   308
FT
    TRANSMEM
              346
                     363
                              POTENTIAL.
                   399
FT
    DOMAIN
              . 364
                             - CYTOPLASMIC (POTENTIAL).
FT
                    180
    CARBOHYD
              180
                             N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ
    SEQUENCE
              399 AA; 44020 MW; 4C38138BFAED3FF0 CRC64;
 Query Match
                       64.9%; Score 804; DB 1; Length 399;
 Best Local Similarity 65.0%; Pred. No. 2.5e-58;
 Matches 145; Conservative 30; Mismatches 46; Indels
                                                                     1:
Qу
          7 CPP--CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE 64
                 Db
         107 CPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVE 166
Qу
         65 VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP 124
            Db
        167 VHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSV 226
Qу
        125 REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS 184
```

Db	227	: :      :   :             :  :
Qy .		FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 227 : :      :   :   :
Db		YFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPG 329

Search completed: January 16, 2004, 09:36:59 Job time: 18 secs